<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Traditional Chinese herbal medicine for vascular dementia - Chan, ESY - 2018 | Cochrane Library</title> <meta content="Traditional Chinese herbal medicine for vascular dementia - Chan, ESY - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010284.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Traditional Chinese herbal medicine for vascular dementia - Chan, ESY - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010284.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010284.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Traditional Chinese herbal medicine for vascular dementia" name="citation_title"/> <meta content="Edwin SY Chan" name="citation_author"/> <meta content="Singapore Clinical Research Institute" name="citation_author_institution"/> <meta content="edwin.chan@scri.edu.sg" name="citation_author_email"/> <meta content="Dianne T Bautista" name="citation_author"/> <meta content="Singapore Clinical Research Insitute" name="citation_author_institution"/> <meta content="Yanan Zhu" name="citation_author"/> <meta content="A*STAR" name="citation_author_institution"/> <meta content="Yong You" name="citation_author"/> <meta content="First Affiliated Hospital of Nanhua University" name="citation_author_institution"/> <meta content="Jian Ting Long" name="citation_author"/> <meta content="First Affiliated Hospital of Nanhua University" name="citation_author_institution"/> <meta content="Wenyun Li" name="citation_author"/> <meta content="Jinan University" name="citation_author_institution"/> <meta content="Christopher Chen" name="citation_author"/> <meta content="Yong Loo Lin School of Medicine, National University of Singapore" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010284.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/12/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010284.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010284.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010284.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Dementia, Vascular [drug therapy]; *Drugs, Chinese Herbal [therapeutic use]; *Medicine, Chinese Traditional; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010284.pub2&amp;doi=10.1002/14651858.CD010284.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010284\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010284\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","th","ms","ja","pl","zh_HANT","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010284.pub2",title:"Traditional Chinese herbal medicine for vascular dementia",firstPublishedDate:"Dec 6, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010284.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010284.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010284.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010284.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010284.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010284.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010284.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010284.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010284.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010284.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7597 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010284.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/appendices#CD010284-sec-0140"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/table_n/CD010284StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/table_n/CD010284StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Traditional Chinese herbal medicine for vascular dementia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Edwin SY Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0003">Dianne T Bautista</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0004">Yanan Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0005">Yong You</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0006">Jian Ting Long</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0007">Wenyun Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information#CD010284-cr-0008">Christopher Chen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information/en#CD010284-sec-0152">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 December 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010284.pub2">https://doi.org/10.1002/14651858.CD010284.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010284-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010284-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010284-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010284-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD010284-abs-0003">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010284-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010284-abs-0001" lang="en"> <section id="CD010284-sec-0001"> <h3 class="title" id="CD010284-sec-0001">Background</h3> <p>Traditional Chinese herbal medicine (TCHM) is widely used for treating vascular dementia (VaD) in China. Recent studies of a number of TCHMs have demonstrated in vitro biological activity and therapeutic effects in animals, but the published clinical evidence has not been systematically appraised. </p> </section> <section id="CD010284-sec-0002"> <h3 class="title" id="CD010284-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of TCHMs listed in either the <i>Chinese Pharmacopoeia</i> (CP) or the <i>Chinese National Essential Drug List</i> (NEDL) that are used to treat VaD. A secondary aim was to identify promising TCHMs for further clinical research. </p> </section> <section id="CD010284-sec-0003"> <h3 class="title" id="CD010284-sec-0003">Search methods</h3> <p>We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register (on 14 March 2018) and also several Chinese biomedical databases: the Chinese Biological Medicine Database (January 1979 to May 2015), Wanfang database (January 1998 to May 2015), Chongqing VIP Information Co. Ltd or Weipu (January 1998 to May 2015) and the Chinese National Knowledge Infrastructure (January 1979 to May 2015). </p> </section> <section id="CD010284-sec-0004"> <h3 class="title" id="CD010284-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of TCHMs compared to placebo, to Western medicine (WM) or to routine therapy for VaD risk factors. Eligible participants were men and women aged 18 years and above, diagnosed with VaD by any of the following four criteria: (1) <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) versions III, III‐R, IV, IV‐TR; (2) <i>National Institute of Neurological Disorders and Stroke</i> (NINDS‐AIREN); (3) <i>International Classification of Diseases</i> 9 or 10; (4) the Hachinski or the Modified Hachinski Ischaemic Score. We required the use of an imaging technique to differentiate VaD from other dementias. We excluded (1) trials with participants diagnosed with mixed dementia or those that did not use an imaging technique to ascertain VaD; (2) trials of NEDL‐listed Gingko biloba or Huperzine A as experimental interventions, to avoid duplication of existing Cochrane Reviews; (3) trials using acupuncture alone as the experimental intervention; (4) trials using another CP‐ or NEDL‐listed TCHM (except for Huperzine A and Gingko which are popular in Western practice) as the control intervention; and (5) trials using purely non‐pharmacological interventions as the control intervention unless explicitly described as 'routine therapy for VaD risk factors'. </p> </section> <section id="CD010284-sec-0005"> <h3 class="title" id="CD010284-sec-0005">Data collection and analysis</h3> <p>We assessed the risks of bias using the Cochrane 'Risk of bias' tool and adapted the Outcome Reporting Bias in Trials (ORBIT) classification system for outcome reporting bias. We assessed TCHM effects on five clinically important outcomes: cognition, global performance, safety, activities of daily living and behaviour and summarised the effects using mean differences for continuous outcomes and risk ratios or risk differences for binary outcomes. We stratified the studies into those that estimated the TCHM versus 'no treatment' effect and those that estimated the TCHM versus the WM effect, with further stratification by the specific TCHM tested or by one of the four modes of action. We pooled using a random‐effects model. Due to substantial clinical and design heterogeneity, we did not estimate an 'overall TCHM effect'. </p> </section> <section id="CD010284-sec-0006"> <h3 class="title" id="CD010284-sec-0006">Main results</h3> <p>We only found studies (47 studies, 3581 participants) for 18 of the 29 eligible TCHMs as defined by our inclusion criteria. All were superiority trials conducted in China between 1997 and 2013, with most employing a two‐arm parallel design with sample sizes ranging from 26 to 240 and a median treatment duration of 12 weeks (range: 2 to 24 weeks). </p> <p>We found that reporting and trial methodology were generally poor; in particular, there was a lack of information on randomisation, an absence of blinding of participants and outcome assessors and incomplete reporting of adverse events (AEs). None of the 30 trials published from 2007 onwards adopted the CONSORT recommendations for reporting RCTs of herbal interventions. </p> <p>We found seven TCHMs which each had potentially large benefits in studies estimating the TCHM versus 'no treatment' effect and in studies estimating the TCHM versus the WM effect. Two TCHMs (NaoXinTong and TongXinLuo) were common to both groups. Three of these TCHMs – Nao XinTong, NaoMaiTai and TongXinLuo – had the strongest evidence to justify further research. Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor. </p> </section> <section id="CD010284-sec-0007"> <h3 class="title" id="CD010284-sec-0007">Authors' conclusions</h3> <p>We found moderate‐ to very low‐quality evidence of benefit and harm of TCHMs for VaD. Methodological inadequacies need to be addressed by better conducted and reported trials. We identified NaoMaiTai, NaoXinTong and TongXinLuo as warranting special research priority. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010284-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010284-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010284-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010284-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010284-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010284-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010284-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010284-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010284-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD010284-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010284-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010284-abs-0014">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010284-abs-0005" lang="en"> <h3>Traditional Chinese herbal medicine for vascular dementia</h3> <p><b>Background</b> </p> <p>Vascular dementia is a common form of dementia which is caused by problems with the blood supply to the brain. Some but not all people with vascular dementia have had strokes. There are no Western medicines licensed to treat vascular dementia. Traditional Chinese herbal medicines (TCHMs) are often used to treat it in China. </p> <p><b>Review question</b> </p> <p>We wanted to find out whether any TCHMs were effective treatments for vascular dementia and whether they had any harmful effects. We also wanted to identify promising TCHMs for further research. </p> <p><b>What we did</b> </p> <p>We searched for randomised controlled trials (RCTs) which had studied the use of any TCHM listed in either the <i>Chinese Pharmacopoeia</i> (CP) or the <i>Chinese National Essential Drug List</i> (NEDL) for the treatment of vascular dementia. In these studies, participants should have been randomly assigned to either a group given the TCHM or to a comparison (control) group that did not get the TCHM, but may have been given a placebo (dummy pill), a Western medicine or standard medical treatment to reduce the risk of strokes. </p> <p><b>What we found</b> </p> <p>We included 47 trials with 3581 participants of 18 TCHMs in this review. All were conducted in mainland China between 1997 and 2013 with participant numbers ranging from 26 to 240 and an average study duration of 12 weeks. There were significant problems with the methods in many of the trials, particularly with how participants were allocated to treatments, how outcomes were measured and how thoroughly harmful effects were monitored. For these and other reasons, we rated the overall quality of the evidence as variable, ranging from moderate to very low. This means that we are uncertain, and often very uncertain, about the accuracy of the results. </p> <p>Despite these reservations, we found seven TCHMs which each had potentially large benefits in studies comparing TCHMs to no treatment or Western Medicine. Three of these – Nao XinTong, NaoMaiTai and TongXinLuo – had the strongest evidence to justify further research. We found that the risk of harmful effects was at least 5% higher than the risk for participants in the control group for NaoMaiTai and TongXinLuo, but the quality of this evidence was poor. </p> <p><b>Conclusion</b> </p> <p>We think further research of some TCHMs for vascular dementia is justified, but it is important that the quality of trial conduct and reporting be improved by adhering to published best‐practice standards. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010284-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010284-sec-0132"></div> <h3 class="title" id="CD010284-sec-0133">Implications for practice</h3> <section id="CD010284-sec-0133"> <p>There are no available licensed treatments for vascular dementia (VaD). Due to the poor methodology of the included trials, this review found only moderate to very weak evidence to support the routine use of any traditional Chinese herbal medicines (TCHMs), whether as monotherapy or as adjunctive therapy to Western medicine (WM) or to routine therapy (RT), or both, for the treatment of people with VaD. Of the 18 TCHMs, we considered NMT (a neuroprotectant) and NXT (an antithrombotic) to be the best supported by the current evidence base for clinical practice. </p> <p>We have moderate confidence that NMT (four studies) clinically significantly improves MMSE cognition compared to WM. Three of the four studies reported little difference in adverse event (AE) risks between groups, and in the single study which reported a much increased risk of AEs in the NMT group, these were all mild elevations of liver biochemical tests. However this must be viewed against the results of the corresponding comparison of NMT versus 'no treatment' which is based on a single study. If NMT is indeed efficacious, we would expect that effect to be even more evident in the 'no treatment' control group studies. In fact the cognition effects (MMSE and HDS) are both less than the effect compared to WM. Given this inconsistency, we are therefore quite uncertain about the magnitude of cognition improvement of NMT. </p> <p>We also have moderate confidence that NXT (six studies) clinically significantly improves MMSE cognition compared to WM. We also have moderate confidence that there is improvement in other efficacy measures such as global performance and ADL and that there is no increased risk of AEs. In the corresponding 'no treatment' studies (three studies), the effect on MMSE cognition and ADL is as expected better, but the global performance is slightly worse. </p> </section> <h3 class="title" id="CD010284-sec-0134">Implications for research</h3> <section id="CD010284-sec-0134"> <section id="CD010284-sec-0135"> <h5 class="title">1. Potential TCHMs for future research</h5> <p>The active component(s) in most TCHM formulae and the underlying mechanism of action remain unidentified. More detailed mechanistic studies using modern scientific methodology and approaches are needed to elucidate the therapeutic potential of TCHM for VaD. Well‐designed animal studies and RCTs are also required to validate the physiological and pathological roles of these agents in the treatment of people with VaD. </p> <p>Despite the study limitations in design and execution, we identify NMT and NXT as having relatively stronger evidence of efficacy, based on the number of trials and consistency of effects across outcomes. </p> <p>Adequately‐designed RCTs are needed to establish the consistency of the beneficial effect seen for SFT (an anti‐inflammatory), TXL (neuroprotectant) across cognition, global performance, daily function, behaviour and the balance of harms and benefits. Since SFT is an intravenous injection and therefore unsuitable for long‐term use in people with dementia, further research on TXL in addition to NMT and NXT would appear to be more sensible. </p> </section> <section id="CD010284-sec-0136"> <h5 class="title">2. Design of RCTs of TCHMs for VaD</h5> <p><i>2.1 Evaluation of therapeutic efficacy</i> </p> <p>Follow‐up for efficacy should be for at least one year. Improvement of symptoms must be assessed in three domains: cognition as measured by objective tests (cognitive end point), instrumental activities of daily living (functional end point), and overall clinical response, as evaluated by global performance (or global assessment of change). Efficacy end points should be specified for each of these domains. The co‐primary end point approach is generally preferred as it promotes the clinical interpretability of any cognitive and functional gains that may be seen, so that two primary end points representing the cognitive and functional domains are used. When function is prioritised over the global domain, the latter should still be evaluated as a secondary end point. In mild to moderate VaD where it is difficult to establish symptomatic improvement in function (due to lack of symptoms), one would choose the cognitive and global as co‐primary end points. In advanced stages of VaD where cognitive deficiencies co‐occur with marked functional impairments, stabilising or improving the ADL may be a more important end point. In severe dementia where improvement in cognitive performance is less likely, using the functional and global domains as co‐primary end points may be more appropriate. </p> <p>The study should be powered to demonstrate statistically significant differences in each of the co‐primary end points. If both are shown to be statistically significant, then an assessment of the overall clinical benefit in each participant should be made. This could be summarised by the proportion of participants who achieved a clinically meaningful benefit. For instance, a claim of short‐term overall treatment benefit could define 'responders' as participants who at six months achieved a prespecified level of improvement in cognition without deterioration in the other two domains. Proposals for the minimal clinically important difference (MCID) in cognition and behaviour are given in <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> and <a href="./references#CD010284-bbs2-0160" title="QaseemA , SnowV , CrossJTJr . Current pharmacologic treatment of dementia: a clinical practice guideline from the American Academy of Family Physicians. Annals of Internal Medicine2008;148(5):370‐8. ">Qaseem 2008</a>. </p> <p>Neuropsychiatric and behavioural symptoms may be considered as secondary end points, as behavioural problems (e.g. agitation and aggression) have a significant impact on patients and their caregivers. These symptoms should be measured using specific and validated scales. </p> <p>Investigators may require multiple instruments to evaluate the efficacy of TCMHs for two reasons: first, there is currently no instrument shown in the literature to possess the desired properties of validity, reproducibility, sensitivity to change and user‐friendliness. Thus the choice of instruments remains open, so long as investigators explain the rationale for their use; second, people with dementia are poor observers and reporters of their own symptoms, particularly in moderate to severe dementia. Caregiver evaluations should therefore be part of the assessment. It would be desirable for each domain (cognition, function, clinical response) to be evaluated by a different assessor who should be blinded to treatment allocation. </p> <p><i>2.2 Evaluation of safety</i> </p> <p>Safety assessment should be conducted regularly at intervals determined by the expected rapidity of action of the TCHM test drug and the trial duration. After the treatment period, participants should be followed up for possible AEs related to withdrawal of treatment for a period appropriate for the TCHM test drug. </p> <p>All AEs should be fully documented with separate analysis of serious AEs, i.e. those AEs leading to dropouts and mortality. The documentation should facilitate the precise estimation of the (total and organ‐class‐specific) AE incidence rate by treatment arm. This entails a minimum report of the number of participants experiencing AEs, the type and frequency of AE episodes, and the total follow‐up time by treatment arm. Clinical observations should be supplemented by appropriate laboratory tests and electrophysiological recordings. Special attention must also be paid to differences in age groups (e.g. younger, old and very old) when reporting AEs. Depending on the TCHM's mechanism of action and target site, specific neurological AEs (e.g. cerebrovascular events, extrapyramidal symptoms, disorientation, further impairment of gait), psychiatric AEs (e.g. hallucinations, signs and symptoms of affective or psychotic disorders and neuro‐behavioural abnormalities including agitation or aggressive behaviour) or cardiovascular AEs (e.g. orthostatic hypotension, induction of arrhythmias or increased risk of myocardial infarction) might also be expected. </p> <p>AEs associated with combination therapy, e.g. TCHM plus WM or TCHM plus RT where RT involves components of WM should also be assessed to shed light on the drug‐drug interaction of particular combinations of TCHMs and WMs. </p> <p><i>2.3 Design of treatment arms</i> </p> <p>The viability of long‐term placebo‐controlled studies may be questioned on ethical grounds due to the availability of approved symptomatic treatments. However, different dementia trials have shown important differences between placebo participants, and given that improvement without treatment is possible, the preferred design option is still a three‐arm parallel design comparing the following arms: (TCHM versus WM versus placebo) or (TCHM plus WM) versus (WM plus placebo<sub>1</sub>) versus (placebo<sub>1</sub> + placebo<sub>2</sub>), with the placebo or double‐placebo for assay sensitivity. </p> </section> <section id="CD010284-sec-0137"> <h5 class="title">3. Other recommendations</h5> <p>Prospective registration of the trial protocol (in, for example, the Chinese Clinical Trials Registry) and adherence to the CONSORT standard for the reporting of the results of RCTs on herbal interventions would be highly desirable. </p> <p>Adherence to best practices for designing RCTs for investigating TCHMs, such as those proposed by <a href="./references#CD010284-bbs2-0132" title="FlowerA , WittC , LiuJP , Ulrich‐MerzenichG , YuH , LewithG . Guidelines for randomised controlled trials investigating Chinese herbal medicine. Journal of Ethnopharmacology2012;140(3):550‐4. [DOI: 10.1016/j.jep.2011.12.017] ">Flower 2012</a>. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010284-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010284-sec-0029"></div> <div class="table" id="CD010284-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FuFangDanShen compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FFDS compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> FFDS<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><a href="#CD010284-tbl-0011">Table 1</a><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FFDS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ FFDS ranged from −0.83 to −0.52</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3 higher<br/> (0.39 lower to 6.39 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a, b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog<br/> assessed with: ADAS‐Cog<br/> Scale from: 0 to 70 (lower score better outcome) </p> <p>follow‐up: mean 24 weeks</p> <p>MD of change score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐ADAS‐Cog ‐ FFDS ranged from 0.22 to 2.80</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.34 lower<br/> (6.23 lower to 2.46 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>321<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0005" title="">Analysis 1.3</a> (subgroup 1.3.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more)<br/> follow‐up: mean 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD 0.02<br/> (−0.05 to 0.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>322<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.2) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version<br/> Scale from: 14 to 56 (lower score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from −0.55 to 1.13</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.33 lower<br/> (5.60 lower to 0.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Non‐overlapping 95% CIs, with high I<sup>2</sup> exceeding 75%.<br/> <sup>b</sup>95% CI is wide and not statistically significant.<br/> <sup>c</sup>Average control group risk of the included studies.<br/> <sup>d</sup>Point estimates differ in direction of effect. <br/> <sup>e</sup>Lowest control group risk of the included studies.<br/> <sup>f</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FuFangHaiShe compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FFHS compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> FFHS<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FFHS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow up: mean 24 weeks<sup>a</sup> </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ FFHS ranged from 4.20 to 4.62</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.42 higher<br/> (0.21 higher to 2.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (AEs) (1 or more)<br/> follow‐up: mean 24 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RD 0.00<br/> (‐0.05 to 0.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>b, e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.3) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)</p> <p>follow‐up: mean 24 weeks<sup>a</sup> </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from −10.70 to −2.25</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.3 lower<br/> (4.98 lower to 0.39 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Follow‐up only reported by <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>.<br/> <sup>b</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria to be high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>c</sup>The 95% CI overlaps the threshold for a clinically significant difference.<br/> <sup>d</sup>Average control group risk of the included studies.<br/> <sup>e</sup>The effect is not statistically significant. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NaoXinTong compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NXT compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> NXT<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NXT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 8 weeks to 12 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 1.9 to 3.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.29 higher<br/> (2.66 higher to 5.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0004" title="">Analysis 1.2</a> (subgroup 1.2.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global performance (improved) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0006" title="">Analysis 1.4</a> (subgroup 1.4.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (AEs) (one or more events) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.5) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow up: mean 12 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from ‐4.7 to ‐4.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.18 lower<br/> (7.02 lower to 5.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.5) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>RT:</b> routine therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria to be high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Non‐overlapping 95% CIs, with high I<sup>2</sup> exceeding 75%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">YinDanXingNaoTong compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>YDXNT compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> YDXNT<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with YDXNT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ YDXNT ranged from 3.98 to 4.07</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.61 higher<br/> (0.74 higher to 2.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0004" title="">Analysis 1.2</a> (subgroup 1.2.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not‐ measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (AEs) (1 or more events)<br/> follow‐up: mean 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RD 0.00<br/> (−0.05 to 0.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>138<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.7) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (−1 to 1) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in ADL ranged from −25.59 to −2.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.59 lower<br/> (2.09 lower to 1.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria] to be high or unclear RoB.<br/> <sup>b</sup>The 95% CI overlaps the threshold for a clinically significant difference.<br/> <sup>c</sup>Average control group risk of the included studies.<br/> <sup>d</sup>95% CI is wide and not statistically significant. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">FuFangHaiShe compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FFHS compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> FFHS<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FFHS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 12 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 2.57 to 4.20</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.78 higher<br/> (3.05 lower to 4.60 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0017" title="">Analysis 3.3</a> (subgroup 3.3.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>AE (1 or more events)<br/> follow‐up: range 12 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RD −0.04<br/> (−0.26 to 0.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.2) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: range 12 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from −10.7 to −4.29</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.35 higher<br/> (4.86 lower to 7.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Direction of the two treatment effects differ and the I<sup>2</sup> is large (&gt; 80%).<br/> <sup>c</sup>The 95% CI is wide and is not statistically significant.<br/> <sup>d</sup>Average control group risk of the included studies.<br/> <sup>e</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">NaoMaiTai compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NMT compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> NMT<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NMT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 12 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 2.87 to 4.24</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.08 higher<br/> (2.27 higher to 3.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0017" title="">Analysis 3.3</a> (subgroup 3.3.2) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more events)</p> <p>follow‐up: mean 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD 0.02<br/> (−0.03 to 0.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>277<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.4) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52.2 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies,we judged most of the RoB criteria as unclear or low RoB. But we judged the blinding of participants criteria as High RoB and as the outcome is calculated from participant‐reported information we judge the overall study limitation to be serious.<br/> <sup>b</sup>Lowest control group risk of the included studies.<br/> <sup>c</sup>In all studies, we rated most of the RoB criteria as high or unclear. <br/> <sup>d</sup>95% CI is wide and not statistically significant. <br/> <sup>e</sup>Very different point estimates and moderately high I<sup>2</sup>.<br/> <sup>f</sup>Median control group risk of the included studies. <br/> <sup>g</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">NaoXinTong compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NXT compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> NXT<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NXT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 8 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 1.58 to 6.89</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.26 higher<br/> (1.50 higher to 3.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS<br/> assessed with: HDS </p> <p>Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 12 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐HDS ‐ NXT ranged from 2.45 to 3.33</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.80 higher<br/> (0.31 higher to 3.30 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Global performance (improved)</p> <p>follow‐up: range 12 weeks to 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.43<br/> (1.15 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>168<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD010284-fig-0018" title="">Analysis 3.4</a> (subgroup 3.4.4) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>548 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>783 per 1000<br/> (630 to 975) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/> (656 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more events)</p> <p>follow‐up: range 8 weeks to 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD −0.00<br/> (−0.03 to 0.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>515<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.5) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: range 8 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in ADL ranged from −6.5 to 0.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.72 lower<br/> (5.85 lower to 3.58 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.4) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>RD:</b> Risk difference; <b>RT:</b> routine therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Very different point estimates, barely overlapping 95% CIs and high I<sup>2</sup> exceeding 75%.<br/> <sup>c</sup>Average control group risk of the included studies.<br/> <sup>d</sup>In all studies, most of the RoB criteria were judged as high or unclear RoB. <br/> <sup>e</sup>Median control group risk of the included studies.<br/> <sup>f</sup>Lowest control group risk of the included studies.<br/> <sup>g</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">QingKaiLing compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>QKL compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> QKL<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with QKL</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐MMSE ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.7) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS<br/> assessed with: HDS<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 4 weeks to 8 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐HDS ‐ QKL ranged from 2.38 to 3.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.77 higher<br/> (1.11 higher to 4.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (AEs) (one or more events) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activities of Daily Living (ADL) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RT:</b> routine therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Very different point estimates and moderately high I<sup>2</sup> exceeding 50%. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">ShenFuTang compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SFT compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> SFT<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SFT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 3 weeks to 4 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ SFT ranged from 0.88 to 1.98</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.63 higher<br/> (1.02 higher to 6.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.9) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events (AEs) (1 or more events)<br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RD −0.01<br/> (−0.05 to 0.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>166<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.8) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: range 3 weeks to 4 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in ADL ranged from −3.9 to −0.68</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10.16 lower<br/> (16.61 lower to 3.71 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.7) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria as unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Non‐overlapping 95% CIs, with high I<sup>2</sup> exceeding 75%.<br/> <sup>c</sup>The 95% CI overlaps the threshold for a clinically significant difference and is wide.<br/> <sup>d</sup>Average control group risk of the included studies.<br/> <sup>e</sup>95% CI is wide and not statistically significant. <br/> <sup>f</sup>Highest control group risk of the included studies.<br/> <sup>g</sup>Very different point estimates, barely overlapping 95% CIs and high I‐square exceeding 75%.<br/> <sup>h</sup>95% CI is wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010284-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">TongXingLuo compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>TXL compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> TXL<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with TXL</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 1.97 to 2.56</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.58 higher<br/> (1.54 higher to 3.62 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.10) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global performance (improved)<br/> follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.26<br/> (1.00 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010284-fig-0018" title="">Analysis 3.4</a> (subgroup 3.4.7) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>544 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1000<br/> (544 to 871) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more)<br/> follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD −0.16<br/> (−042 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>180<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (40 to 205) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000<br/> (69 to 359) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (99 to 513) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activities of Daily Living (ADL) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0021" title="">Analysis 3.7</a> (subgroup 3.7.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> risk difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria as unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Average control group risk of the included studies.<br/> <sup>c</sup>Lower limit of 95% CI for the RR is 1.<br/> <sup>d</sup>Lowest control group risk of the included studies.<br/> <sup>e</sup>95% CI is wide and not statistically significant.<br/> <sup>f</sup>Median control group risk of the included studies. <br/> <sup>g</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010284-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010284-sec-0030"></div> <section id="CD010284-sec-0031"> <h3 class="title" id="CD010284-sec-0031">Description of the condition</h3> <p>Vascular dementia (VaD) is recognised as the second most common type of dementia after Alzheimer's disease (<a href="./references#CD010284-bbs2-0145" title="KalariaRN , MaestreGE , ArizagaR , FriedlandRP , GalaskoD , HallK , et al. World Federation of Neurology Dementia Research Group. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurology2008;7(9):812‐26. ">Kalaria 2008</a>) and represents 15% to 20% of all dementia cases (<a href="./references#CD010284-bbs2-0156" title="O’BrienJT , ThomasA . Vascular dementia. Lancet2015;386(10004):1698‐706. [DOI: 10.1016/S0140‐6736(15)00463‐8] ">O’Brien 2015</a>; <a href="./references#CD010284-bbs2-0164" title="Roman , GC . Facts, myths and controversies in vascular dementia. Journal of Neurological Sciences2004;226(1‐2):49‐52. ">Roman 2004</a>). It is a clinical syndrome that includes a wide range of cognitive dysfunctions resulting from hypoxic brain tissue death caused by reduced perfusion from diseased brain blood vessels. The predominant underlying pathology is an ischaemic stroke (cortical and subcortical) event, although other events, such as a haemorrhagic stroke and subarachnoid bleeding, can also lead to vascular dementia. The two main VaD subtypes are a) cortical vascular dementia or multi‐infarct dementia, and b) subcortical ischaemic vascular dementia or small vessel dementia (<a href="./references#CD010284-bbs2-0131" title="ErkinjunttiT , GauthierS . The concept of vascular cognitive impairment. Front Neurology and Neurosciences2009;24:79‐85. ">Erkinjuntti 2009</a>). </p> <p>Although symptoms may be most obvious soon after a major stroke, there is wide variation depending on the acuteness and severity of damage to the blood vessels and the part of the brain affected. Symptoms may include confusion, disorientation, difficulty in concentration, speaking or understanding speech, forgetfulness, incontinence, physical weakness or paralysis, vision loss, aggression, delusions, depression, epileptic seizures, hallucinations, restlessness and wandering (<a href="./references#CD010284-bbs2-0118" title="AlagiakrishnanK , MasakiK . Vascular Dementia Clinical Presentation. emedicine.medscape.com/article/292105‐clinical#a0216 (accessed 25 October 2018). ">Alagiakrishnan 2018</a>). The clinical course can manifest as a gradual worsening or a stepwise decline, with symptoms remaining at a stable level followed by an abrupt deterioration. </p> <p>The risk factors for vascular dementia are those associated with progressive damage to the brain vasculature, such as atrial fibrillation, diabetes, high blood cholesterol, obesity, sedentary lifestyle and smoking. Currently, there is no effective disease‐modifying therapy, hence emphasis is focused on symptomatic improvement and the prevention of further damage to the brain vasculature (<a href="./references#CD010284-bbs2-0151" title="McVeighC , PassmoreP . Vascular dementia: prevention and treatment. Clinical Interventions in Aging2006;1(3):229‐35. ">McVeigh 2006</a>). Vascular dementia is considered to be clinically and pathologically distinct from Alzheimer's dementia, Lewy body dementia, or frontotemporal dementia. However, many patients may also have concurrent Alzheimer's or other types of dementia (mixed dementia). </p> </section> <section id="CD010284-sec-0032"> <h3 class="title" id="CD010284-sec-0032">Description of the intervention</h3> <p>By 'traditional Chinese herbal medicine' (TCHM) we mean the collection of herbal medicines used according to traditional Chinese medicine (TCM) theory<i><b>,</b> </i> an ancient holistic system of healing based on the notion of harmony and balance, and employing ideas of moderation and prevention. The theories and concepts of prevention, diagnosis and treatment of illness in TCM rely on a holistic approach towards the individual, and disturbances are treated on the physical, emotional, mental, spiritual, and environmental levels simultaneously (<a href="./references#CD010284-bbs2-0169" title="World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. apps.who.int/iris/bitstream/handle/10665/66783/WHO_EDM_TRM_2000.1.pdf;jsessionid=729E57C6EFF0CF24E8F4E65DF8C968D8?sequence=1 (accessed 25 October 2018). ">WHO 2000</a>). In contemporary TCM practice, the prescription of herbal medicine depends on making the correct TCM 'zheng' (syndrome) diagnosis (<a href="./references#CD010284-bbs2-0167" title="WangTF , DongJ . What is “zheng” in traditional Chinese medicine?. Journal of Traditional Medical Sciences2017;4:14‐15. ">Wang 2017</a>) through the complementary methodologies of 'bian bing' (identification of the disease) which is most similar to Western medicine diagnosis and disease classification, and 'bian zheng' (identification of the syndrome) (<a href="./references#CD010284-bbs2-0133" title="FiermanD . Understanding and Applying Differential Diagnosis (ZhenDuan): The Heart of TCM Clinical Methodology. www.acupuncturetoday.com/mpacms/at/article.php?id=31280&amp;no_paginate=true&amp;no_b=true (accessed 23 Apr 2018). ">Frierman 2006</a>). The syndromic diagnosis is crucial because the goal is to personalise the treatment to the person's syndrome (zheng) rather than just to the disease (bing) (<a href="./references#CD010284-bbs2-0157" title="PanSY , ChenSB , DongHG , YuZL , DongJC , LongZX , et al. New perspectives on Chinese herbal medicine (zhong‐yao) research and development. Evidence‐Based Complimentary and Alternative Medicine2011; Vol. 2011:403709. ">Pan 2010</a>). In spirit, this is identical to the current Western medicine concept of 'personalised medicine', the difference being that TCM has always had this personalised focus and the syndromic diagnosis is based on correlated signs and symptoms derived largely from history‐taking and physical examination, using the TCM methods of 'wang' (visual inspection), 'wen'(second pronunciation tone) (listening and smelling), 'wen'(fourth pronunciation tone) (inquiry) and 'qie' (pulse taking and palpation) and not by employing the methods of modern molecular medicine (<a href="./references#CD010284-bbs2-0178" title="ZhouXZ , LiYB , PengYH , HuJQ , ZhangRS , HeLY , et al. Clinical phenotype network: the underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine. Frontiers in Medicine2014;8(3):337‐46. [DOI: 10.1007/s11684‐014‐0349‐8] ">Zhou 2014</a>). Additional details on TCHM and TCM are provided in <a href="./appendices#CD010284-sec-0141">Appendix 1</a>. </p> <p>This review adopts the definitions of herbs, herbal materials, herbal preparations, finished herbal products and herbal medicines as stated in the General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine (<a href="./references#CD010284-bbs2-0169" title="World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. apps.who.int/iris/bitstream/handle/10665/66783/WHO_EDM_TRM_2000.1.pdf;jsessionid=729E57C6EFF0CF24E8F4E65DF8C968D8?sequence=1 (accessed 25 October 2018). ">WHO 2000</a>) (see <a href="./appendices#CD010284-sec-0148">Appendix 2</a>).The TCHMs eligible for this review are 'finished herbal products', not herbs or crude plant material (e.g. leaves, flowers, fruits, seeds, stems wood, roots, rhizomes, other plant parts which may be entire, fragmented or powdered), nor herbal materials (fresh juices, gums, fixed oils, essential oils, resins or dry powders from herbs processed by various procedures such as steaming, roasting, stir‐baking with honey, alcoholic beverages or other materials). Finished herbal products are made from herbal preparations which may include comminuted or powdered herbal materials, or extracts, tinctures and fatty oils of herbal materials. These herbal preparations are produced by extraction, fractionation, purification, concentration, or other physical or biological processes including steeping or heating herbal materials in alcoholic beverages or in other materials. Finished herbal products may contain excipients of animal or mineral origin in addition to active plant ingredients. However, finished products to which chemically defined active substances have been added (e.g. synthetic compounds or isolated constituents, or both, from herbal materials) are not considered to be 'herbal'. Although most TCHMs are of plant origin, occasionally minerals, shells or animal products are also a part of the formulations, but they are not regarded as key active components. </p> <p>Of almost 100 TCHMs used to treat vascular dementia in China, we have only reviewed those recognised in the <i>Pharmacopoeia of the People's Republic of China</i> (<a href="./references#CD010284-bbs2-0127" title="Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China 2010. 9th Edition. Vol. I, II, III, Chinese Pharmacopoeia Commission, August 2011. ">ChP 2010</a><i>)</i> or the <i>National Essential Drug List of the People's Republic of China</i> (<a href="./references#CD010284-bbs2-0153" title="StateFood , DrugAdministration . National Essential Drug List of the People's Republic of China. app1.sfda.gov.cn/datasearch/face3/base.jsp (accessed 7 Nov 2012). ">NEDL 2009</a>)<i>.</i> The <i>Pharmacopoeia of the People's Republic of China</i> or <i>Chinese Pharmacopoeia</i> (CP) is an official and authoritative compendium of drugs, assembled by the Pharmacopoeia Commission of the Chinese Ministry of Public Health. As a national legal source, the CP details the minimum standards to be met by all drug and TCM companies throughout development, manufacturing, distribution, use, and management (<a href="./references#CD010284-bbs2-0177" title="Zhong‐zhiQ , DanY , Yan‐zeL , YongP . Pharmacopoeia of the People’s Republic of China (2010 Edition): a milestone in development of China’s healthcare. Chinese Herbal Medicines2010;2(2):157‐60. ">Zhong‐zi 2010</a>). The <i>National Essential Drug List of the People's Republic of China</i> (NEDL) includes drugs in the country's basic health insurance catalogue with a higher reimbursement percentage; these essential drugs are sold at government‐controlled prices. The NEDL encompasses treatments for at least 60% of the most common illnesses in China and is updated every three years. The CP or NEDL is the most scientifically standardised TCHM formulary because of the requirements for standardisation of components and the manufacturing processes. </p> </section> <section id="CD010284-sec-0033"> <h3 class="title" id="CD010284-sec-0033">How the intervention might work</h3> <section id="CD010284-sec-0034"> <h4 class="title">Traditional Chinese herbal medicines for memory enhancement</h4> <p>A variety of mechanisms have been targeted in the treatment of cognitive disorders. These include (1) modulation of the cholinergic system through the inhibition of acetylcholinesterase (AChE) or direct stimulation of muscarinic and nicotinic receptors; (2) neuroprotection against glutamate‐induced overstimulation of N‐methyl D‐aspartate (NMDA) receptors; and (3) anti‐inflammatory, antioxidant and oestrogenic activities. Among several plants reputed to enhance cognitive function in TCM, including those TCHMs covered in this review, only a few have been investigated in depth to ascertain the pharmacological basis for their use: </p> <p>(1) <i>Evodia ruticarpa</i> (<i>E. ruticarpa)</i> (Juss.) ('Wu zhu yu'). Four compounds, namely, dehydroevodiamine, evodiamine, rutaecarpine and synephrine and an ethanol extract were demonstrated to be anti‐inflammatory in vitro. The alkaloid rutaecarpine was reported to inhibit cyclo‐oxygenase‐2 (COX‐2) activity in vitro and be anti‐inflammatory in vivo<i>;</i> evodiamine was shown to inhibit COX‐2 induction and NF‐κB activation and NF‐κB‐regulated gene expression; dehydroevodiamine resulted in increased cerebral blood flow in vivo and may have a neuroprotective action as it inhibited glutamate uptake and release in vitro. </p> <p>(2) <i>Gingko biloba</i>. The active components are primarily flavonoids and terpenoids. The potential mechanisms of action are a combination of increasing blood flow by dilating blood vessels (<a href="./references#CD010284-bbs2-0146" title="KoltringerP , EberO , KlimaG , RothlauerW , WakonigP , LangstegerW , et al. Microcirculation in parenteral Ginkgo biloba extract therapy [Die mikrozirkulation unter parenteraler Ginkgo‐biloba‐extrakt‐therapie]. Wiener Klinische Wochenschrift1989;101(6):198‐200. ">Koltringer 1989</a>), interfering with platelet activation and hence blood clotting, changing in nerve cell metabolism (<a href="./references#CD010284-bbs2-0128" title="DeFeudisFV . Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. Editions Scientifiques. Trends in Pharmacological Sciences. Paris: Elsevier, 1991:78‐84. ">DeFeudis 1991</a>) and protecting cell membranes from free radical attack (<a href="./references#CD010284-bbs2-0158" title="PincemailJ , DupuisM , NasrC , HansP , Haag‐BerrurierM , AntonR , et al. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia1989;45(8):708‐12. [PUBMED: 2547645] ">Pincemail 1989</a>). </p> <p>(3) <i>Ginseng</i> . Ginsenosides Rg3(S) and Rg5/Rk1 from <i>Ginseng</i>, a popular invigorant in China, have been shown to significantly reverse the memory dysfunction induced by ethanol or scopolamine (<a href="./references#CD010284-bbs2-0123" title="BaoHY , ZhangJ , YeoSJ , MyungCS , KimHM , KimJM , et al. Memory‐enhancing and neuroprotective effects of selected ginsenosides. Archives of Pharmacal Research2005;28(3):335‐42. ">Bao 2005</a>). In addition, ginsenosides Rg1, Rg3, and RE were demonstrated to significantly reduce the amount of β‐amyloid detected in brains of animals after a single oral dose (<a href="./references#CD010284-bbs2-0125" title="ChenF , EckmanEA , EckmanCB . Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. Federation of American Societies for Experimental Biology2006;20(8):1269‐71. ">Chen 2006</a>). A possible mechanism of action may be through improving systemic glucose metabolism (<a href="./references#CD010284-bbs2-0159" title="PrabhakarPK , DobleM . Mechanism of action of natural products used in the treatment of diabetes mellitus. Chinese Journal of Integrated Medicine2011;17(8):563‐74. [DOI: 10.1007/s11655‐011‐0810‐3] ">Prabhakar 2011</a>). </p> <p>(4) <i>Huperzia serrata</i> (Thunb.) Trevis. ('Qian Ceng Ta<i>'</i> ). <i>Huperzine A</i> (<i>hupA</i> ) is a single‐component quinolizidine‐related alkaloid isolated from <i>Huperzia serrata</i> and is a reversible, potent and selective AChE inhibitor. <i>HupA</i> also possesses antioxidation and anti‐apoptosis neuroprotective effects (<a href="./references#CD010284-bbs2-0166" title="WangR , YanH , TangXC . Progress in huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica2006;27(1):1‐26. ">Wang 2006</a>; <a href="./references#CD010284-bbs2-0174" title="ZhangHY , TangXC . Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends in Pharmacological Sciences2006;27(12):619‐25. ">Zhang 2006</a>). </p> <p>(5) <i>Polygala tenuifolia</i> (<i>P. tenuifolia)</i> (Willd.) ('Yuan zhi'). Extracts from the root showed neuroprotective action against glutamate and amyloid precursor protein and dose‐dependent inhibition of AChE activity in vitro. Some cinnamic acid derivatives have apparent cholinergic activity since extracts of sinapic acid escalated choline acetyltransferase (ChAT) activity in the frontal cortex in brain‐lesioned rats. Tenuigenin extract inhibited β‐amyloid secretion through β‐secretase inhibition in vitro. Other compounds with in vitro effects include saponins, with the aglycone presenegenin (onjisaponins A, B, E, F and G), which raised NGF levels in astrocyte cultures. Onjisaponin F also induced the ChAT messenger ribonucleic acid level in rat basal forebrain cells. </p> <p>(6) <i>Salvia miltiorhiza</i> (<i>S. miltiorhiza)</i> (Bunge) ('Dan Shen<i>'</i>). Extracts from the root have been shown to modulate the action of some neuropeptides involved in cerebral ischaemia such as vasoactive intestinal peptide and somatostatin. Several compounds such as tanshinone IIb have demonstrated antioxidant effects. Other compounds seem to influence the action of substance P, which is linked to ischaemic neuronal damage and which is also reduced in the brains of people with Alzheimer's disease. Tanshinones were also shown to be anti‐inflammatory in vivo and were active against 5‐lipoxygenase (LOX) in vitro. In addition to anti‐inflammation in vivo, tanshinone I inhibited phospholipase A<sub>2</sub> and prostaglandin (PG) E<sub>2</sub> formation in vitro but did not affect COX‐2 activity or expression. Other reported activities of <i>S. miltiorhiza</i> extracts are the inhibition of neuronal cell death by inhibition of presynaptic glutamate release (crude extract), protection against β‐amyloid‐induced neuropathological changes in the hippocampus in vivo (tanshinones) and AChE inhibitory activity (diterpenoids) (<a href="./references#CD010284-bbs2-0141" title="HowesMJ , HoughtonP . Traditional medicine for memory enhancement. In: RamawatKG editor(s). Herbal Drugs: Ethnomedicine to Modern Medicine. Berlin Heidelberg: Springer‐Verlag, 2009:239‐91. ">Howes 2009</a>). </p> </section> <section id="CD010284-sec-0035"> <h4 class="title">Traditional Chinese herbal medicines (TCHMs) for stroke prevention</h4> <p>In people with vascular disease, stroke prevention is a main goal of therapy. Neuroprotection by TCHMs is hypothesised to be mediated through antioxidative, anti‐inflammatory and anti‐glutamatergic mechanisms, but it is difficult to be precise since the herbs contain many active compounds with disparate mechanisms of action. </p> </section> </section> <section id="CD010284-sec-0036"> <h3 class="title" id="CD010284-sec-0036">Why it is important to do this review</h3> <p>Reviews of TCHMs for vascular dementia are scant, despite their widespread use in China and the increasing demand for TCHMs in the West in recent years. In China, almost 100 TCHMs are used to treat vascular disease (<a href="./references#CD010284-bbs2-0142" title="HuangWM . 中国老年病秘方全书. 1st Edition. Scientific and Technical Documentation Press, 2004. ">Huang 2004</a>), with the most frequently reported being <i>shichangpu</i> (<a href="./references#CD010284-bbs2-0176" title="ZhangH , HanT , ZhangL , YuCH , WanDG , RahmanK , et al. Effects of tenuifolin extracted from radix polygalae on learning and memory: a behavioral and biochemical study on aged and amnesic mice. Phytomedicine2008;15(8):587‐94. ">Zhang 2008b</a>), <i>yuanzhi</i> (<a href="./references#CD010284-bbs2-0147" title="LeeB , ChoiY , KimH , KimSY , HahmDH , LeeHJ , et al. Protective effects of methanol extract of Acori graminei rhizome and Uncariae Ramulus et Uncus on ischaemia‐induced neuronal death and cognitive impairments in the rat. Life Sciences2003;74(4):435‐50. ">Lee 2003</a>), extracts of danshen (<a href="./references#CD010284-bbs2-0155" title="NomuraY , ArimaT , NambaT , HattoriM , KadotaS . Ameliorating effects of dan‐shen and its major ingredient calcium/magnesium lithospermate B on cognitive deficiencies in senescence‐accelerated mouse. Nippon Yakurigaku Zasshi1997;110:142‐7. ">Nomura 1997</a>), safflower (<a href="./references#CD010284-bbs2-0143" title="HuangJL , FuST , JiangYY , CaoYB , GuoML , WangY , et al. Protective effects of Nicotiflorin on reducing memory of dysfunction, energy metabolism failure and oxidative stress in multi‐infarct dementia model rats. Pharmacology, Biochemestry and Behaviour2007;86(4):741‐8. ">Huang 2007</a>), ginseng (<a href="./references#CD010284-bbs2-0148" title="LimJH , WenTC , MatsudaS , TanakaJ , MaedaN , PengH , et al. Protection of ischaemic hippocampal neurons by ginsenoside Rbl, a main ingredient of ginseng root. Neuroscience Research1997;28(3):191‐200. ">Lim 1997</a>) and <i>danggui‐shayao</i> (<a href="./references#CD010284-bbs2-0149" title="LuMC . Danggui shaoyao san improves colchicine‐induced learning acquisition impairment in rats. Acta Pharamcologica Sinica2001;22(12):1149‐53. ">Lu 2001</a>). Although there have been several systematic reviews on specific TCHMs (<a href="./references#CD010284-bbs2-0124" title="BirksJ , Grimley EvansJ . Gingko biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD003120.pub3] ">Birks 2009</a>; <a href="./references#CD010284-bbs2-0138" title="HaoZ , LiuM , LiuZ , LuD . Huperzine A for vascular dementia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007365.pub2] ">Hao 2009</a>; <a href="./references#CD010284-bbs2-0170" title="WuT , LiQ , YuanZ . Yizhi capsule for vascular dementia. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005382.pub2] ">Wu 2007</a>), no review has systematically assessed the evidence for clinical benefit and safety of most of the commonly‐used TCHMs for vascular dementia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010284-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010284-sec-0037"></div> <p> <ol id="CD010284-list-0001"> <li> <p>To evaluate the efficacy and safety of TCHMs listed in either the <i>Chinese Pharmacopoeia</i> (CP) or the <i>Chinese National Essential Drug List</i> (NEDL) that are used to treat VaD. </p> </li> <li> <p>To identify promising TCHMs for further clinical research.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010284-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010284-sec-0038"></div> <section id="CD010284-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010284-sec-0040"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs). We defined a study as a RCT if the allocation of participants to the comparison groups was described as randomised (including terms such as 'randomly', 'random' or 'randomisation') and if we considered the description of the randomisation method to be valid. If no further description of the method was provided, we still included the study but appraised it as being at unclear risk of bias for the random sequence generation (selection bias) domain. </p> </section> <section id="CD010284-sec-0041"> <h4 class="title">Types of participants</h4> <p>Men and women aged 18 years and older, diagnosed with vascular dementia (VaD) by any one of the following criteria: (1) <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) versions III, III‐R, IV, IV‐TR (<a href="./references#CD010284-bbs2-0119" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980. ">APA 1980</a>; <a href="./references#CD010284-bbs2-0120" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD010284-bbs2-0121" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>); (2) <i>National Institute of Neurological Disorders and Stroke</i> (NINDS‐AIREN) (<a href="./references#CD010284-bbs2-0163" title="RomanGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology1993;43(2):250‐60. ">Roman 1993</a>); (3) <i>International Classification of Diseases</i> 9 or 10 (<a href="./references#CD010284-bbs2-0168" title="World Health Organization. International Classification of Diseases (ICD‐10). Classification of Mental and Behavioural Disorders. www.who.int/classifications/icd/en/bluebook.pdf (accessed 29 Oct 2012). ">WHO 1992</a>); (4) the Hachinski Ischaemic Score (<a href="./references#CD010284-bbs2-0137" title="HachinskiVC , IliffLD , ZilhkaE , Du BoulayGH , McAllisterVL , MarshallJ , et al. Cerebral blood flow in dementia. Archives of Neurology1975;32(9):632‐7. ">Hachinski 1975</a>) or the Modified Hachinski Ischaemic Score (<a href="./references#CD010284-bbs2-0165" title="RosenWG , TerryRD , FuldPA , KatzmanR , PeckA . Pathological verification of Ischaemic Score in differentiation of dementias. Annals of Neurology1980;7(5):486‐8. ">Rosen 1980</a>). We also required a consensus about the presence of cerebrovascular disease (CVD) and a link between CVD and the onset of dementia. CVD was demonstrated by the presence of multiple infarcts or extensive white matter change. We required the use of an imaging technique to establish the subtype‐specific diagnosis of dementia, particularly to differentiate vascular dementia from other dementias such as Alzheimer's disease (presence of cortical and subcortical infarcts, lacunes and extensive white matter lesions). Examples of acceptable imaging techniques were (1) structural neuroimaging (computed tomography (CT) or magnetic resonance imaging (MRI)); (2) functional imaging (single photon emission computed tomography or positron emission tomography); or (3) other neuroimaging techniques (such as functional MRI, magnetic resonance spectroscopy, diffusion‐weighted magnetic resonance). We excluded people diagnosed with mixed dementia or studies that did not use an imaging technique/brain scan to establish a subtype‐specific diagnosis of dementia. </p> </section> <section id="CD010284-sec-0042"> <h4 class="title">Types of interventions</h4> <section id="CD010284-sec-0043"> <h5 class="title">Experimental interventions</h5> <p>Eligible TCHMs must have been listed in the <i>Chinese Pharmacopoeia</i> (CP) (<a href="./references#CD010284-bbs2-0126" title="National Pharmacopeia Committee. Chinese Pharmacopeia. Pharmacopeia of the People's Republic of China. Chemical Industry Press, 2005. ">ChP 2005</a>; <a href="./references#CD010284-bbs2-0127" title="Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China 2010. 9th Edition. Vol. I, II, III, Chinese Pharmacopoeia Commission, August 2011. ">ChP 2010</a>) or the <i>National Essential Drug List</i> (<a href="./references#CD010284-bbs2-0153" title="StateFood , DrugAdministration . National Essential Drug List of the People's Republic of China. app1.sfda.gov.cn/datasearch/face3/base.jsp (accessed 7 Nov 2012). ">NEDL 2009</a>) of the People's Republic of China. We describe the included TCHMs in <a href="#CD010284-tbl-0011">Table 1</a>, together with a description of their components. We provide the scientific names of the herbal components in <a href="#CD010284-tbl-0012">Table 2</a>. </p> <div class="table" id="CD010284-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Traditional Chinese herbal medicines (TCHMs) to treat vascular dementia in the Chinese Pharmacopeia or National Essential Drug List </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abbreviation (Name)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary Mode of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Herbal components<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐herbal components</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CWJ (CiWuJia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CiWuiJia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CXQ<sup>a</sup>(ChuanXiongQin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChuanXiong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DS (DanShen)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanShen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DZHS<sup>a</sup> (DengZhanHuaSu, Breviscapine) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DengZhanXiXin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DZXX<sup>a</sup> (DengZhanXiXin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DengZhanXiXin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FFDS<sup>a</sup> (FuFangDanShen) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian, <b>DanShen</b> , <b>SanQi</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FFHS<sup>a</sup> (FuFangHaiShe) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiChangPu, <b>YuanZhi</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HaiShe (sea snake), HaiShen (sea cucumber)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GGS<sup>a</sup> (GeGenSu) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GeGen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HQ<sup>a</sup> (HuangQi) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuangQi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HTZZ (HuaTuoZaiZao)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian, ChuanXiong, WuZhuYu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KNS (KangNaoShuai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao, DanShen, DangShen, GeGen, GouQi, HeShouWu, HuangQi, HuangQin, JuHua, MaiMenDong, Ren Shen, ShanYao, ShiChangPu, ShuDiHuang, SuanZaoRen, XiangFu, YuanZhi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fushen (Porea fungus sclerotium), LongGuFen (powdered animal bones)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LM (LeMai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiShao, <b>ChuanXiong</b> , DanShen, <b>HongHua</b>, MuXiang, ShanZha, XiangFu </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MLN (MaiLuoNing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JinYinHua, <b>NiuXi</b> , <b>ShiHu</b>, XuanShen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>a</sup> (NaoAn) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian, <b>ChuanXiong</b> , DangGui, <b>HongHua</b>, Ren Shen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NMT<sup>a</sup> (NaoMaiTai) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanShen, DangGui, GeGen, HeShouWu, HongHua, JiXueTeng, JuHua, <b>Ren Shen</b> , SanQi, ShanZha, <b>ShiChangPu</b>, ZhiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiJueMing (abalone shell)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NXT<sup>a</sup> (NaoXinTong) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiShao, ChuanXiong, DanShen, <b>DangGui</b> , GuiZhi, HongHua, <b>HuangQi</b> , JiXueTeng, <b>MoYao</b> , NiuXi, <b>RuXiang</b>, SangZhi, ShuiZhi, TaoRen, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DiLong (earthworm), QuanXie (scorpion)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QKL<sup>a</sup> (QingKaiLing) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diaphoretic and antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BanLanGen, HuangQin, <b>JinYinHua</b>, ZhiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NiuHuang (cattle gallstone), ShuiNiuJiao (water buffalo horn), ZhenZhuMu (mother of pearl, nacre) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RML<sup>a</sup> (RuanMaiLing) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao, ChuanXiong, DanShen, DangGui, GouQi, HeShouWu, HuaiNiuXi, HuangQi, ShuDiHuang, Ren Shen, WuWeiZi, YinYangHuo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SM (ShenMai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MaiMenDong, <b>RenShen</b>, WuWeiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFT<sup>a</sup> (ShenFuTang) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FuZi</b> , <b>Ren Shen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SQFZ (ShenQiFuZheng)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DangShen</b> , <b>HuangQi</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TJTT (TaiJiTongTian)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiZhi, BoHe, ChaYe, ChiShao, <b>ChuanXiong</b>, FangFeng, GanCao, JuHua, QiangHuo, TianMa, XiXin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXL<sup>a</sup> (TongXinLuo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RenShen</b>, TanXiang </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChanTui (cicada moult), QuanXie (scorpion), ShuiZhi (leech), TuBieChong (wingless cockroach), WuGong (centipede) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XNJ (XingNaoJing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diaphoretic and antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BingPian</b>, YuJin, ZhiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SheXiang (navel gland secretions of musk deer),</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XNZZ<sup>a</sup> (XingNaoZaiZao) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiFuZi, BaiShu, <b>BingPian</b> , ChiShao, ChuanXiong, DaHuang, DanNanXing, DangGui, GeGen, GouQi, HeShouWu, HongHua, HuangQi, JueMingZi, <b>RenShen</b> , SanQi, <b>ShiChangPu</b>, TaoRen, TianMa, XiXin, YinYangHuo, ZeXie, ZhuYaZao </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DiLong (earthworm), JiangCan (silkworm), ZhenZhu (pearl)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XST (XueSaiTong)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SanQi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YDXNT<sup>a</sup> (YinDanXinNaoTong) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AiPian, DaSuan, <b>DanShen</b> , DengZhanXiXin, JiaoGuLan, SanQi, ShanZha, <b>YinXingYe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YXQN<sup>a</sup> (YangXueQingNao) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao, ChuanXiong, DangGui, GouTeng, JiXueTeng, JueMingZi, ShuDiHuang, XiXin, XiaKuCao, YanHuSuo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZhenZhuMu (mother of pearl, nacre)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZZW<sup>a</sup> (25 Wei ZhenZhuWan) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CaoGuo, <b>DingXiang</b> , JiangXiang, <b>RouDouKou</b>, TanXiang, YuGanZi, ZangHongHua </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NiuHuang (cattle gallstone), ShiHuiHua (limestone powder) ShuiNiuJiao (water buffalo horn), ZhenZhu (pearl) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The 18 TCHMS that were evaluated in the 47 included studies.<br/> <sup>b</sup>Scientific name, common name and part of plant used are given in <a href="#CD010284-tbl-0012">Table 2</a>. In TCHMs which contain a mixture of herbal components, those in <b>bold</b> are the major active herb/s according to TCM theory. </p> </div> </div> <div class="table" id="CD010284-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scientific names of Traditional Chinese herbal medicine (TCHM) components in Table 1</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Herbal components (English common name(s)) [Mandarin]; Plant part used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scientific name (1) from www.plantlist.org; (2) from www.eflora.cn)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major active components (where known)<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AiPian (Borneol crystal, Ngai camphor) [ 艾片 ]; leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Blumea balsamifera</i> (L.) DC. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiFuZi (Giant Typhonium) [ 白附子 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Typhonium giganteum</i> Engl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao (White Peony) [ 白芍 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Paeonia lactiflora</i> Pall. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monoterpene glycosides e.g. paeoniflorin (&gt; 1.25%), ox‐paeonoflorin, benzoylpaeoniflorin, albiflorin R1, paeoniflorigenone, paeonilactones (A ‐ C) etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShu (White Atractylodes) [ 白术 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1)<i>Atractylodes japonica</i> (Koidz. ex Kitam.) Kitag.; (2) Atractylodes macrocephala Koidz </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils e.g. α and β‐humulene, β‐elemol, atraction etc.</p> <p>Lactones e.g. atractylenolides I ‐ IV, atractylenolactam, beishulenolide A, etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiZhi (Dahurian Angelica) [ 白芷 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Angelica dahurica</i> (Hoffm.) Benth. &amp; Hook.f. ex Franch. &amp; Sav. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BanLanGen (Dyers Woad) [ 板蓝根 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Isatis tinctoria</i> L.; Isatis indigotica Fortune </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian (Borneol flake) [ 冰片 ]; resin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dryobalanops aromatica</i> C.F.Gaertn, <i>Blumea balsamifera</i> (L.) DC. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BoHe (Field Mint, Mentha) [ 薄荷 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Mentha canadensis</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CaoGuo (Grass fruit, Tsaoko) [ 草果 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Amomum tsao‐ko</i> Crevost &amp; Lemarié </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChaYe (Tea leaves) [ 茶叶 ]; leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Camellia sinensis</i> (L.) Kuntze </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiShao (Red Peony) [ 赤芍 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Paeonia lactiflora</i> Pall. or <i>Paeonia veitchii</i> Lynch. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChuanXiong (Szechuan Lovage) [ 川芎 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Ligusticum striatum</i> DC.; (2) Ligusticum chuanxiong Hort. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CiWuJia (Manyprickle acanthopanax, Siberian Ginseng) [ 刺五加 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Eleutherococcus senticosus</i> (Rupr. &amp; Maxim.) Maxim.; (2) Acanthopanax senticosus (Rupr. et Maxim.) Harms </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DaHuang (Sorrel rhubarb) [ 大簧 ]; root and rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Rheum palmatum</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahoursaquinone glycosides, tannins and analogues</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DaSuan (Garlic) [ 大蒜 ]; bulb</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Allium sativum</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanNanXing (Jack‐in‐the‐Pulpit, Bile Arisaema) [ 胆南星 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Arisaema heterophyllum</i> Blume </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanShen (Red Sage, Salvia) [ 丹参 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Salvia miltiorhiza</i> Bunge, <i>Salvia miltiorhiza</i> var. <i>charbonnelii</i> (H. Lév.) C.Y. Wu </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanshinones: I, IIA, IIB, V, VI, cryptotanshinone, isotanshinones III, isocrptotanshinones I‐III etc. </p> <p>Acids: salvianolic acids A ‐ G, rosmarinic acid, lithospermic acid caffeic acid, isoferulic acid etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DangGui (Chinese Angelica) [ 当归 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Angelica sinensis</i> (Oliv.) Diels </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils: ligustilid, angelicone, n‐butylidene phthalide, carvacrol</p> <p>Acids: freulic acid, batanedioic acid, nicotinic acid, vanillic acid etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DangShen (Pilose Asiabell, Codonopsis) [ 党参 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Codonopsis pilosula</i> (Franch.) Nannf. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DengZhanXiXin (Erigerontis) [ 灯盏细辛 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Erigeron breviscapus</i> (Vaniot) Hand.‐Mazz. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flavonoids: scutellarin, apigenin‐β‐glucoside</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DingXiang (Clove) [ 丁香 ]; flower bud</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Syzygium aromaticum</i> (L.) Merr. &amp; L.M.Perry, <i>Eugenia caryophyllata</i> Thunb.; </p> <p>(2) Syringa oblata Lindl<i>.</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FangFeng (Ledebouriella, Divaricate Saposhnikovia) [ 防风 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Saposhnikovia divaricata</i> (Turcz.) Schischk. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FuZi (Common Monkshood, Aconite) [ 附子 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Aconitum carmichaelii</i> Debeaux </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GanCao (Ural licorice) [ 甘草 ]; rhizome and root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Glycyrrhiza uralensis</i> Fisch. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flavones: liquiritin, neoliquiritin, isoliquiritin, isoliquiritigenin.</p> <p>Glucuronic acid, glycyrrhetinic acid, glycrrhizin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GeGen (Kudzu root) [ 葛根 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Pueraria thunbergiana</i> (Siebold &amp; Zucc.) Benth.<i>,Pueraria lobata</i> (Willd.) Ohwi </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isolavones: puerarin (&gt; 2.4%), daidzein, daidzin etc.</p> <p>Saponins: sophoradiol, cantoniensistriol, soyasapogenols A ‐ B etc</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GouQi (Chinese Wofberry) [ 枸杞 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lycium chinense</i> Mill. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lycium barbarum (Lb) conjugates: LbGp1‐5</p> <p>Lb polysaccharides: LbP1a‐1,2,2a,3a‐1,3a‐2,3 etc.</p> <p>Alkaloids: betain</p> <p>Carotenoids: zeaxanthin, cryptosxanthin, zeaxanthin diplamitate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GouTeng (Gambir vine) [ 钩藤 ]; vine and branch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Uncaria rhynchophylla</i> (Miq.) Miq. ex Havil.,<i>Uncaria hirsuta</i> Havil.,<i>Uncaria sinensis</i> (Oliv.) Havil. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GuiZhi (Cassia, Cinnamon) [ 桂枝 ]; branch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cinnamomum cassia</i> (L.) J.Presl </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HeShouWu (Fleeceflower) [ 何首乌 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Polygonum multiflorum</i> Thunb.; (2) Fallopia multiflora (Thunb.) Harald. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anthraquinones: emodin, chrysophanol, physcion, rhein etc.</p> <p>Stilbenes: resveratrol, piceid, tetrahyroxystilbene glucoside etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HongHua (Safflower) [ 红花 ]; flower</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Carthamus tinctorius</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>31</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuaiNiuXi (Twotooth Achyranthes vine) [ 懷牛膝 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Achyranthes bidentata</i> Blume </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuangQi (Astragalus, Membranous Milkvetch) [ 黄芪 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Astragalus propinquus</i> Schischkin, <i>Astragalus mongholicus</i> Bunge; (2) Astragalus membranaceus (Fisch.) Bunge </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glucans: AG‐1 and 2 and heteroglycans 1 and 2.</p> <p>Polysaccharides: D‐glucose, D‐galactose, L‐araban.</p> <p>Flavonoids: dimercapto‐methoxyisoflavones, catycosin, kumatakenin, fomononetin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>33</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuangQin (Bailkal Skullcap) [ 黄芩 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Scutellaria baicalensis</i> Georgi </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>34</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JiangXiang (Dalbergia, Odoriferous Rosewood) [ 降香 ]; heartwood</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dalbergia odorifera</i> T.C.Chen </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JiaoGuLan (Fiveleaf Gynostemma) [ 绞股蓝 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gynostemma pentaphyllum</i> (Thunb.) Makino </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JinYinHua (Honeysuckle), [ 金银花 ]; flower</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lonicera japonica</i> Thunb. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorogenic acid and flavone derivatives</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JiXueTeng (Millettia vine, Spatholobus) [ 鸡血藤 ]; stem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Spatholobus suberectus</i> Dunn, <i>Millettia dielsiana</i> Harms </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flavonoids: formononetin, ononin, prunetin etc.</p> <p>Triterpenes: friedelinol, friedelin</p> <p>Sterol and glycosides: β‐sitosterol, daucosterol, anthemisol etc.</p> <p>Anthraquinones: aloe‐emodin, emodin‐3‐methyl‐ether</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JueMingZi (Cassia) [ 决明子 ]; seeds</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Senna tora</i> (L.) Roxb., <i>Senna obtusifolia</i> (L.) H.S.Irwin &amp; Barneby; (2) Cassia tora L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JuHua (Chrysanthemum) [ 菊花 ]; flower</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Chrysanthemum morifolium</i> Ramat.; <i>Chrysanthemum morifolium</i> Ramat.t.Dulce. var. <i>sinense</i> (Sabine) Makino </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils: borneol, chrysanthemon, camphor etc.</p> <p>Flavones: apigenin, acacetin, cosmosin, quercetin, luteolin etc.</p> <p>Sesquiterpenes: chrysanthediol‐A, chrysanthediacetates B ‐ C.</p> <p>Triterpenes: taraxasterol, faradiol, maniladiol etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MaiMenDong (Dwarf Lilyturf, Ophiopogon tuber) [ 麦门冬 ]; tuber</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ophiopogon japonicus</i> (Thunb.) Ker Gawl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MoYaoZi (Myrrh) [ 没药 ]; resin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Commiphora myrrha</i> (Nees) Engl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>42</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MuXiang (Common Aucklandia, Costus root) [ 木香 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Saussurea costus</i> (Falc.) Lipsch or <i>Dolomiaea souliei</i> (Franch.) C.Shih; Aucklandia costus Falc. or </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NiuXi (Twotooth Achryanthes root) [ 牛膝 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Achyranthes bidentata</i> Blume </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QiangHuo (Incised Notopterygium root) [ 羌活 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Notopterygium incisum</i> K.C.Ting ex H.T.Chang </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RenShen (Asian ginseng, Red Ginseng) [ 人参 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Panax ginseng</i> C.A.Mey. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saponins: ginsenosides Rg1, Rg2, Rc, Rd, Re, Rf, Rb1, Rb2, Rb0 etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RouDouKou (Nutmeg) [ 肉豆蔻 ], seed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Myristica fragrans</i> Houtt. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RuXiang (Franckincense) [ 乳香 ]; resin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Boswellia sacra</i> Flueck.; (2) Boswellia carteri Birdw. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SanQi (Notoginseng, Pseudoginseng) [ 三七 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Panax notoginseng</i> (Burkill) F.H.Chen; (2) Panax pseudo‐ginseng Wall. var. notoginseng (Burkill) Hoo &amp; Tseng </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saponins: notoginsenosides A ‐ E, G ‐ N, U, etc. ginsenosides Rb1, Rb2, Rd, Re etc.</p> <p>Favonosides and others: quercetin, sanchian A, denicichine, daucosterol, panaxydol etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>48</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SangZhi (Mulberry twig) [ 桑枝 ]; branch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Morus alba</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>49</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShanYao (Chinese Yam, Common Yam) [ 山药 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dioscorea oppositifolia</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mucopolysaccharides, diosgenin, allantoin, batatasin i, saponins, dopamine etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShanZha (Hawthorn) [ 山楂 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Crataegus pinnatifida</i> Bunge </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>51</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiChangPu (Grassleaf Sweetflag) [ 石菖蒲 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Acorus gramineus</i> Sol.; <i>Acorus gramineus</i> Soland. var. <i>crassispadix</i> Lingelsh. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>52</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiHu (Dendrobium) [ 石斛 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dendrobium nobile</i> Lindl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShuDiHuang (Chinese Foxglove, Rehmannia) [ 熟地黄 ]; rootzanh</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Rehmannia glutinosa</i> (Gaertn.) DC. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acteoside (&gt; 0.02%), sterols, glycosides and polysaccharides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SuanZaoRen (Sour jujube, Spiney date) [ 酸枣仁 ]; seed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ziziphus jujuba</i> var. <i>spinosa</i> (Bunge) Hu ex H.F.Chow </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>55</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TanXiang (Sandalwood) [ 檀香 ]; heartwood</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Santalum album</i> L. (Santalaceae) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>56</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TaoRen (Peach) [ 桃仁 ]; seeds</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Prunis persica (L.) Stokes;</i> Amygdalus persica L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>57</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TianMa (Tall Gastrodia) [ 天麻 ]; tuber</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gastrodia elata</i> Bl. (Orchidaceae) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrodin (&gt; 0.2%), gastrodioside, vanillal alcohol, vanilline etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>58</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WuWeiZi (Chinese Magnoliavine, Schisandra) [ 五味子 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Schisandra chinensis</i> (Turcz.) Baill </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils: sesquicarene, bisabolene, cahmigrene, ylangene.</p> <p>Organic acids: citric, malic, tartaric, succinic acids</p> <p>Lignans: schisandrin and derivatives, gomisins and derivatives</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>59</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WuZhuYu (Medicinal Evodia) [ 吴茱萸 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Evodia ruticarpa</i> (Juss.) Benth. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiaKuCao (Prunella, Selfheal Spike) [ 夏枯草 ]; spike or whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Prunella vulgaris</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>61</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiangFu (Nutgrass Galingale) [ 香附 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyperus rotundus</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiXin (Chinese/Manchurian Wildginger) [ 细辛 ], rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bei Xi Xin : <i>Asiarum heterothropoides</i> Fr. Schmidt/<i>Asarum heterotropoides</i> f. <i>mandshuricum</i> (Maxim.) Kitag. </p> <p>Hua Xi Xin : <i>Asarum sieboldii</i> Miq. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XuanShen (Ningpo Figwort) [ 玄参 ], root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Scrophularia ningpoensis</i> Hemsl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YanHuSuo (Corydalis) [ 延胡索 ], rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Corydalis yanhusuo</i> (Y.H.Chou &amp; Chun C.Hsu) W.T.Wang ex Z.Y.Su &amp; C.Y.Wu </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>65</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YinXingYe (Gingko, Ginkgo) [ 銀杏叶 ], leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ginkgo biloba</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YinYangHuo (Longspur Epimedium) [ 淫羊藿 ], leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Epimedium grandiflorum</i> C.Morren; (2) Epimedium brevicornu Maxim. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>67</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuGanZi (Emblic Leafflower) [ 于甘子 ], fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Phyllanthus emblica</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>68</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuJin (Common turmeric) [ 郁金 ], root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Curcuma longa</i> L.; (2) Curcuma aromatica Salisb. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuanZhi (Chinese Senega, Thinleaf Milkwort) [ 元志 ], root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Polygala tenuifolia</i> Willd., (2) Polygala sibirica L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZangHongHua (Saffron) [ 藏红花 ] ; stigma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Crocus sativus</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>71</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZeXie (Oriental Waterplantain) [ 泽泻 ], rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Alisma plantago‐aquatica</i> subsp. <i>orientale</i> (Sam.) Sam. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZhiZi (Cape Jasmine, Gardenia) [ 栀子 ], fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gardenia jasminoides</i> J.Ellis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZhuYaZao (Chinese Honeylocust) [ 猪牙皂 ], pod and seed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gleditsia sinensis</i> Lam. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Sources of information: (1) <a href="http://www.plantlist.org" target="_blank">www.plantlist.org</a> and (2) <a href="http://www.eflora.cn" target="_blank">www.eflora.cn</a> (Flora of China,中国植物志). Only one scientific name is given unless the two sources differ.<br/> <sup>b</sup>Source of information: (1) <a href="http://www.shen-nong.com" target="_blank">www.shen‐nong.com</a> and (2) TM‐MC database at <a href="http://informatics.kiom.re.kr/compound" target="_blank">informatics.kiom.re.kr/compound</a> </p> </div> </div> </section> <section id="CD010284-sec-0044"> <h5 class="title">Control interventions</h5> <p>Eligible comparators for estimating the 'TCHM effect' were placebo and conventional pharmacological interventions ('Western' medicine (WM)). </p> <p>A placebo TCHM was the preferred representation of the 'no treatment' comparator, as it serves to blind participants and study personnel. However, we anticipated that it might not be used consistently, especially in studies where there were co‐interventions common to both treatment arms. For example, studies estimating the effect of TCHM versus 'no treatment' that enrolled participants also taking WM (in both groups), should ideally have randomised participants to either (TCHM with WM) or (placebo TCHM with WM). However we expected that some studies would not have used a placebo in the control arm, i.e. (TCHM with WM) versus (WM alone). </p> <p>We use the terms 'conventional' and 'Western' interchangeably to describe a type of intervention distinct from TCHM interventions. Such interventions could include AChE inhibitors (e.g. donepezil, galantamine, rivastigmine) or anti‐dementia drugs (e.g. memantine), psychostimulants and nootropics (e.g. citicoline, piracetam), peripheral vasodilators (e.g. hydergine), selective calcium channel blockers with mainly vascular effects (e.g. nimodipine), vasoprotective capillary stabilising agents (e.g. troxerutin), anti‐inflammatory agents (non‐steroidal anti‐inflammatory drugs (NSAIDS), e.g. indomethacin), antioxidants (Vitamin E), Vitamin B12, folate (folacin, folic acid) and other compounds (e.g. almitrine, cerebroprotein hydrolysate). </p> </section> <section id="CD010284-sec-0045"> <h5 class="title">Interventions common to all study arms</h5> <p>In addition to the experimental and control interventions, we accepted other interventions common to all treatment groups such as WM, placebo and routine therapy (RT) for control of cerebrovascular risk factors. RT would typically be pharmacologic agents such as antihypertensives, anti‐diabetics, antiplatelets, lipid‐lowering drugs and blood flow‐improving drugs (e.g. pentoxifylline, propentofylline). We also accepted non‐pharmacologic agents when they were clearly described by the authors as being used for such a purpose. </p> </section> <section id="CD010284-sec-0046"> <h5 class="title">Types of group comparisons eligible for meta‐analysis</h5> <p>We recognised several distinct types of experimental‐control group comparisons in our review: </p> <p> <div class="table" id="CD010284-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Experimental group interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control group interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect being estimated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM versus No treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM versus No treatment (in presence of WM)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM versus No treatment (in presence of RT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM versus No treatment (in presence of WM and RT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM versus WM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM versus WM (in presence of RT)</p> </td> </tr> </tbody> </table> </div> </p> <p>These in turn we further categorised into two major groups: (1) comparisons estimating the TCHM versus the 'no treatment' effect; and (2) comparisons estimating the TCHM versus the WM effect. </p> <p>For all three‐arm trials, we performed pairwise comparisons categorised according to the classification above, taking care not to double‐count a common comparator group in any subsequent meta‐analysis. </p> </section> <section id="CD010284-sec-0047"> <h5 class="title">Excluded interventions and comparisons</h5> <p>We considered the use of other pharmacological interventions as an exclusion criterion on a case‐by‐case basis. We excluded comparisons of a single or combination of TCHMs versus a single or combination of non‐pharmacological interventions, unless the non‐pharmacological comparator was explicitly described as a form of standard care. Examples of non‐pharmacological interventions used were exercise/physical therapy, psychological interventions (e.g. cognitive stimulation, memory/cognitive training, creative arts therapy, music therapy, light therapy, and relaxation, etc.), behavioural interventions, educational interventions, medical or nursing care interventions or interventions involving working with caregivers. </p> <p>We also excluded the following:</p> <p> <ol id="CD010284-list-0002"> <li> <p>Trials of NEDL‐listed Gingko biloba or Huperzine A as experimental interventions for vascular dementia. This avoided duplication of existing Cochrane Reviews (<a href="./references#CD010284-bbs2-0124" title="BirksJ , Grimley EvansJ . Gingko biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD003120.pub3] ">Birks 2009</a>; <a href="./references#CD010284-bbs2-0138" title="HaoZ , LiuM , LiuZ , LuD . Huperzine A for vascular dementia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007365.pub2] ">Hao 2009</a>). </p> </li> <li> <p>Trials using another CP‐ or NEDL‐listed TCHM as control interventions. This comparison is not relevant to the main question. Huperzine A and Gingko biloba were the exceptions to this rule, as they are popular in Western practice. </p> </li> <li> <p>Trials using acupuncture therapy alone as the experimental intervention. While acupuncture is a component of TCM, it is not a herbal preparation. However, we included trials that used acupuncture therapy as a common co‐intervention. </p> </li> <li> <p>Trials using purely non‐pharmacological interventions in the control, unless explicitly described as 'routine therapy for vascular dementia risk factors' by the study authors. </p> </li> </ol> </p> </section> </section> <section id="CD010284-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>Our choice of outcomes was based on those relevant to the attainment of recommended therapeutic goals in dementia care, namely "maintenance of function including cognitive functions, management of behaviours that challenge and reduction of comorbid emotional disorders" (Dementia NICE‐SCIE Guidelines 2007, <a href="./references#CD010284-bbs2-0154" title="National Institute for Clinical Excellence, Social Care Institute for Excellence. Dementia ‐ Supporting people with dementia and their carers in health and social care. NICE Clinical Guidelines, No. 42 (www.nice.org.uk/guidance/CG42) (accessed 29 Oct 2012). ">NICE‐SCIE 2006</a>). </p> <section id="CD010284-sec-0049"> <h5 class="title">Primary outcomes</h5> <section id="CD010284-sec-0050"> <h6 class="title">Cognition</h6> <p>We reported general cognitive function if it was measured by scales such as: Mini‐Mental State Examination (MMSE), Hasegawa Dementia Scale (HDS), Alzheimer's Disease Assessement Scale‐cognitive subscale (ADAS‐Cog), Cognitive Capacity Screening Examination (CCSE), Wechsler Adult Intelligence Scale (WAIS‐R), and the Clock Drawing Test (CDT). </p> </section> <section id="CD010284-sec-0051"> <h6 class="title">Global performance</h6> <p>We reported the clinical impression of global improvement if it was measured by scales such as: the Clinical Global Impression (CGI), Global Deterioration Scale (GDS), Sandoz Clinical Assessment ‐ Geriatric (SCAG), Blessed Dementia Rating Scale (Blessed‐D), and the Gottfies‐Brane‐Steen Scale (GBS) or any other standardised and validated scales. </p> </section> <section id="CD010284-sec-0052"> <h6 class="title">Safety</h6> <p>We reported safety as the occurrence of treatment‐emergent adverse events (AEs) (including study dropouts because of AEs), and the types of adverse events. </p> </section> </section> <section id="CD010284-sec-0053"> <h5 class="title">Secondary outcomes</h5> <section id="CD010284-sec-0054"> <h6 class="title">Activities of daily living</h6> <p>Daily functioning and degree of dependence on caregivers was reported if measured by scales such as: Activities of Daily Living (ADL), Activities of Daily Living Checklist (ADL‐C), Barthel ADL Index (BI), the Disability Assessment for Dementia (DAD), the Instrumental Activities of Daily Living (IADL) or other standardised and validated scales. </p> </section> <section id="CD010284-sec-0055"> <h6 class="title">Behaviour</h6> <p>Non‐cognitive behavioural and psychological symptoms or neuropsychiatric symptoms was reported if measured by scales such as: Blessed‐Roth Behaviour Scale (BBS), Neuropsychiatric Inventory (NPI), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE‐AD) or other standardised and validated scales. </p> </section> </section> </section> </section> <section id="CD010284-sec-0056"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010284-sec-0057"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>), the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register, on 14 March 2018. </p> <p>ALOIS is maintained by the Information Specialists of the Cochrane Dementia and Cognitive Improvement Group and contains studies in the areas of dementia (prevention and treatment), mild cognitive impairment and cognitive improvement. The studies are identified from:   </p> <p> <ol id="CD010284-list-0003"> <li> <p>Monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO and LILACS </p> </li> <li> <p>Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others) </p> </li> <li> <p>Quarterly search of the Cochrane Library’s Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses </p> </li> </ol> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the ‘Methods used in reviews’ section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>We performed additional searches in many of the sources listed above, to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. The search strategies used are described in <a href="./appendices#CD010284-sec-0149">Appendix 3</a>. The most recent search was carried out in March 2018. </p> <p>Five review authors (YY, LL, JTL, WL, YZ) also independently identified trials through searches of the China Biological Medicine Database (CBM) (1979 to 2013), Wanfang Database (Wanfang) (1998 to 2013), Chongqing VIP Information Co., Ltd (Weipu) (1989 to 2013) and the China National Knowledge Infrastructure (CNKI) (1979 to February 2013) in December 2013. In May 2015 two review authors (WL, YZ) searched these four databases again to find potential new studies. The search strategies used are described in <a href="./appendices#CD010284-sec-0150">Appendix 4</a>. </p> </section> <section id="CD010284-sec-0058"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD010284-list-0004"> <li> <p>We searched the bibliographies of all relevant articles for further studies. After de‐duplication, there were no further articles to assess. </p> </li> <li> <p>We handsearched the Journal of Traditional Chinese Medicine, English edition (1981 through Feb 2013) and the Journal of Chinese Medicine (2005 to February 2013). The most recent search was on 26 October 2017, which retrieved no new results. The previous search (May 2015) had produced no results. </p> </li> </ol> </p> </section> </section> <section id="CD010284-sec-0059"> <h3 class="title" id="CD010284-sec-0059">Data collection and analysis</h3> <section id="CD010284-sec-0060"> <h4 class="title">Selection of studies</h4> <p>YY, YZ, JTL and WL reviewed the titles and abstracts of publications accessed from the Chinese electronic databases, to eliminate patently irrelevant reports. YZ and DB did the same for English titles and abstracts. We retrieved full‐text reports of titles or abstracts, or both. </p> <p>Review authors in Chinese (YY, YZ, JTL) and English (YZ, DB) articles then checked the full text for conformity with eligibility criteria and corresponded with the primary authors to clarify study eligibility as the need arose. The review authors discussed and decided on study inclusion by consensus and proceeded to data collection. </p> </section> <section id="CD010284-sec-0061"> <h4 class="title">Data extraction and management</h4> <p>DB, YZ, YY and WL independently extracted data on characteristics of included studies using a structured form. This included study design, hospital level for trials conducted in China (1, 2a, 2b, 3a, 3b), participants, diagnostic criteria, study size, interventions, when from the onset of stroke diagnosis was the treatment started, treatment duration, assessment period/s and outcome measures (<a href="./references#CD010284-bbs2-0171" title="WuT , LiY , BianZ , LiuG , MoherD . Randomized trials published in some Chinese journals: how many are randomized?. Trials2009;10:46. ">Wu 2009</a>). </p> <p>DB, YZ, YY, and WL independently extracted numerical results of primary and secondary outcomes using a structured form. We resolved discrepancies by examining the original papers and by discussion. </p> <p>We entered all extracted information into the Review Manager 5 software (<a href="./references#CD010284-bbs2-0162" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">Revman 2014</a>). </p> </section> <section id="CD010284-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>DB, YZ, and YY jointly assessed the risks of bias according to the methodology provided in the <i>Cochrane Handbook for Systematic Review of Interventions</i> (<a href="./references#CD010284-bbs2-0139" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We appraised and recorded the following domains in a structured form: adequacy of sequence generation; adequacy of allocation concealment; adequacy of blinding of participant, caregivers, and outcome assessors; completeness of follow‐up or appropriate treatment of incomplete data; complete outcome reporting; and other biases such as baseline balance. For a given outcome, we took the overall risk of bias judgement across the domains as the worst of the set of judgements. We resolved disagreements by referring to the original reports and by discussion with a fourth party (EC or CC). </p> </section> <section id="CD010284-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010284-sec-0064"> <h5 class="title">Continuous outcomes</h5> <p>We analysed cognition, ADL and behaviour as continuous outcomes. Where possible the group summaries were the mean change scores, i.e. mean of the (post‐treatment score minus the baseline score). We estimated the treatment effect by the mean difference (MD) of the change scores, or in situations where different scales were used we reported the standardised mean difference (SMD). The interpretation of the direction of the effect is dependent on the specific scale being used and is tabulated in <a href="#CD010284-sec-0095">Effects of interventions</a>. </p> </section> <section id="CD010284-sec-0065"> <h5 class="title">Dichotomous outcomes</h5> <p>We analysed global performance as a binary outcome ('improved' versus 'not improved'). The group summaries were the respective risks of improved global performance and we estimated the treatment effect by the risk ratio (RR). A RR greater than one favoured the TCHM group. </p> <p>We analysed safety (AE occurrence) as a binary outcome ('occurrence of one or more treatment‐emergent AEs' versus 'no treatment‐emergent AE'). The group summaries were the respective risks of one or more treatment‐emergent AEs and we estimated the treatment effect by the risk ratio (RR) or a risk difference (RD) when the RR was not estimable. A RR greater than one favoured the control group. </p> </section> </section> <section id="CD010284-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>All included studies used the standard parallel‐arm RCT design with the participant as the unit of analysis. </p> </section> <section id="CD010284-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We intended to contact the investigators of studies for missing information, which was predominantly in the reporting of methods (e.g. randomisation details) and safety outcomes (e.g. incidence and type of adverse events by treatment arm). However only seven of 50 studies with missing information provided a corresponding author with an email address. We contacted all seven authors by email but did not receive any response. For the other 43 studies with no corresponding author, we searched the Internet for official (institutional) contact details of the first author only. The search produced a low yield: one email address (that was no longer valid at the time of contact), 23 departmental (telephone) main lines and 19 general hospital main lines, either from official hospital websites or non‐official websites that were located using the search engines 'Google' (<a href="http://www.google.com" target="_blank">www.google.com</a>) and 'Baidu' (<a href="http://www.baidu.com" target="_blank">www.baidu.com</a>), a Chinese search engine. Due to the non‐specificity of contact information, we did not pursue additional attempts to contact by telephone. </p> <p>In view of this limitation, when there were missing details on methods (e.g. randomisation) we made a judgement of unclear risk of bias. For missing outcomes we described the status of reporting for each and, where possible, performed a meta‐analysis including only studies without missing data. We discuss the implications of missingness in our synthesis. </p> </section> <section id="CD010284-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity of study characteristics and treatment estimates (statistical heterogeneity). Judging by the review's scope and eligibility criteria, we expected significant clinical and design heterogeneity. We assessed important differences from the <a href="./references#CD010284-sec-0164" title="">Characteristics of included studies</a> table, examining the nature and pharmacological action of the TCHM interventions, the variation in the implementations of the interventions (strength, mode of administration, time of treatment initiation relative to stroke onset, duration of treatment, choice of comparators), the participant mix (diagnosis, diagnostic criteria, study setting, baseline severity) and differences in the rigour of trial design and conduct (randomisation, allocation concealment, blinded assessment, reliable measurement of outcomes). </p> <p>Where meta‐analysis was feasible we assessed and quantified heterogeneity of the treatment effect estimates within subgroups using the I<sup>2</sup>statistic. </p> </section> <section id="CD010284-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>For each of the five review outcomes (cognition, global performance, AEs, ADL, behaviour), we described the reporting status ‐ outcomes either (fully reported/partially reported/not reported but mentioned in Methods/not assessed) in a format adapted from <a href="./references#CD010284-bbs2-0130" title="DwanK , GambleC , Kolammunage‐DonaR , MohammadS , PowellC , WilliamsonP . Assessing the potential for outcome reporting bias in a review: a tutorial. Trials2010;11:52. ">Dwan 2010</a>, by comparing the outcomes mentioned in the Methods section with those reported in the Results section of the studies. We did not generate funnel plots because of the small number of studies in each clinically homogeneous group. </p> </section> <section id="CD010284-sec-0070"> <h4 class="title">Data synthesis</h4> <p>We created six strata according to the categorisation of the Experimental‐Control group combinations described below. Within each stratum we pooled effect sizes for two prespecified subgroups: by common TCHM interventions and by class of TCHM primary mode of action. We used a random‐effects model based on DerSimonian and Laird's method to calculate the pooled treatment effect (<a href="./references#CD010284-bbs2-0129" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We reported the precision of the treatment effects as 95% confidence intervals (95% CIs). We did not pool across subgroups. However we did pool across the strata nested within the larger TCHM versus 'no treatment' and TCHM versus WM strata. </p> <p> <div class="table" id="CD010284-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Experimental group</b> </p> <p><b>interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> <p><b>interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Strata categories</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM alone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>TCHM versus 'no treatment'</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(TCHM and WM) versus WM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(TCHM and RT) versus RT</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(TCHM,WM and RT) versus (WM and RT)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM alone versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TCHM versus WM</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCHM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(TCHM and RT) versus (WM and RT)</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We defined the following two types of subgroups:</p> <p> <ol id="CD010284-list-0005"> <li> <p>'Common TCHM intervention' subgroup ‐ the categories within this subgroup were the 18 eligible specific TCHMs. We performed this analysis to address the second review aim of identifying promising TCHM interventions for further research. </p> </li> <li> <p>'TCHM primary mode of action' subgroup ‐ the four categories within this subgroup were: </p> <ol id="CD010284-list-0006"> <li> <p>TCHMs for 'channel‐collateral stroke patients' or for treating exterior syndrome (diaphoretics) and dispersing internal heat (antipyretics). This mode of action is intimately linked to TCM theory and is least accessible to pharmacological research; </p> </li> <li> <p>Anti‐inflammatory TCHMs or those for relieving rheumatism (anti‐rheumatics);</p> </li> <li> <p>Anti‐thrombotic TCHMs used to unblock obstructed blood vessels and promote blood circulation;</p> </li> <li> <p>Neuroprotective TCHMs used to treat neurological symptoms and stroke sequelae such as spasm with high fever, dizziness, strong headaches, flushed face, sudden syncope and facial paralysis. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD010284-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>We anticipated that not all trials would report the standard error of the change score treatment effect<b>,</b> so we undertook sensitivity analyses to explore the impact of using different values of the correlation coefficient (ρ<sub>change score</sub>) to compute the standard deviation (SD) of the change score for continuous outcomes. We performed a meta‐analysis at ρ<sub>change score</sub> = 0.25, 0.50, and 0.75. </p> <section id="CD010284-sec-0073"> <h5 class="title">'Summary of fIndings' tables</h5> <p>We presented the quantity and quality of evidence in 'Summary of findings' tables for any TCHM that was evaluated in two or more studies in any of the comparison groups. We appraised five outcomes (cognition, global performance, safety, daily functioning, behaviour) as we considered them clinically important. We rated the quality of evidence for the treatment effect estimates as either high, moderate, low or very low, using the GRADE approach (<a href="./references#CD010284-bbs2-0122" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence.. Journal of Clinical Epidemiology2011;64(4):401‐6. ">Balshem 2011</a>). The rating expresses the level of confidence that the treatment estimate reflects the true effect, taking account of study limitations (GRADE risk of bias), imprecision, inconsistency, indirectness, and publication bias. The study limitations incorporated the study and outcome‐specific Cochrane overall 'Risk of bias' judgements aggregated across all studies that reported the outcome. Where possible, we judged clinical significance with reference to published threshold criteria. When there were no published criteria we judged a 'potentially large' benefit when the 95% CI lower bound for the MD of the HDS, ADAS‐Cog and ADL outcomes was 2.0 or more, and for the global performance outcome the 95% CI lower bound of the RR needed to be 1.5 or more. We judged imprecision by whether the relevant lower or upper bound of the 95% CI crossed the threshold of statistical or clinical significance. We judged inconsistency qualitatively by consistency of effect direction (consistently favouring treatment or control) and the magnitude of the I<sup>2</sup>. We prepared the 'Summary of findings' (SoF) tables using the online GRADEpro Guideline Development Tool (<a href="https://gradepro.org" target="_blank">gradepro.org</a>; <a href="./references#CD010284-bbs2-0136" title="EvidencePrime . GRADEpro GDT: GRADEpro GUideline Development Tool [Software]. McMaster University, 2015. ">GRADEproGDT 2015</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010284-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010284-sec-0074"></div> <section id="CD010284-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD010284-sec-0076"> <h4 class="title">Results of the search</h4> <p>Four review authors (YY, JTL, YZ, WL) searched the Chinese databases individually by using a common set of key search terms: we retrieved 88 full‐text articles out of 6875 hits in CNKI; 45 full‐text articles out of 1935 hits in CBM; 20 full‐text articles out of 1141 hits in Weipu; 19 full‐text articles out of 1230 hits in Wanfang in December 2013. Two review authors (WL, YZ) searched the Chinese databases again in May 2015, retrieving eight full‐text articles out of 220 hits in CNKI; six full‐text articles out of 145 hits in CBM; seven full‐text articles out of 226 hits in Weipu; three full‐text articles out of 115 hits in Wanfang. The Cochrane CRG searched the ALOIS database and found 139 hits, none of which were eligible. We did not find any potentially relevant studies from handsearching in the Journal of Traditional Chinese Medicine or the Journal of Chinese Medicine. After removing duplicates, we retrieved 117 full‐text articles (<a href="#CD010284-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010284-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010284-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p> Study flow diagram.</p> </div> </div> </div> <p>Forty‐seven studies (3581 participants) of 18 TCHMs satisfied the eligibility criteria ‐ ChuanXiongQin (CXQ), DengZhanHuaSu (DZHS), DengZhanXiXin (DZXX), FuFangDanShen (FFDS), FuFangHaiShe (FFHS), GeGenSu (GGS), combination HuangQi (HQ) and FFDS, NaoAn (NA), NaoMaiTai (NMT), NaoXinTong (NXT), QingKaiLing (QKL), RuanMaiLing (RML), ShenFuTang (SFT), TongXinLuo (TXL), XinNaoZaiZao (XNZZ), YinDanXingNaoTong (YDXNT), YangXueQingNao (YXQN), 25 Wei ZhenZhuWan (ZZW). All studies evaluated the TCHM effect (as monotherapy or as adjunctive therapy to WM, RT or WM and RT) in a superiority trial using one or a combination of the following as a control: placebo, conventional WM or routine therapy for VaD risk factors. We did not find any eligible studies for 11 TCHMs (CiWuJia, DanShen, HuaTuoZaiZao, KangNaoShuai, LeMai, MaiLuoNing, ShenMai, ShenQiFuZheng, TaiJiTongTian, XinNaoJing, XueSaiTong). </p> </section> <section id="CD010284-sec-0077"> <h4 class="title">Included studies</h4> <section id="CD010284-sec-0078"> <h5 class="title">Study design and settings</h5> <p>All trials were conducted in China between 1997 and 2013. Forty‐seven studies reported randomly allocating participants to treatment groups. Sample sizes were generally small, ranging from 26 to 240 with a median of 68. </p> <p> <div class="table" id="CD010284-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of treatment arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>References</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Two</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Three</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>Hospitals in China are classified into three levels, with level 3a or 3b having the highest capability. A recent study reported that the adequacy of randomisation in studies that claimed to be RCTs was related to the hospital level (<a href="./references#CD010284-bbs2-0171" title="WuT , LiY , BianZ , LiuG , MoherD . Randomized trials published in some Chinese journals: how many are randomized?. Trials2009;10:46. ">Wu 2009</a>). Information on hospital levels is provided by the Hospital Quality Monitoring System (<a href="http://www.hqms.org.cn" target="_blank">www.hqms.org.cn</a>). </p> <p> <div class="table" id="CD010284-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital setting of study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>References</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health Centre or clinic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCM Hospital</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐TCM Hospital (Level II)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐TCM Hospital (Level III)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐TCM Hospital (unknown level)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>;<a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>Only two studies reported funding sources: one was funded by the government (<a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>) and the other was sponsored by a pharmaceutical company (<a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>). A summary of the characteristics of included studies can be found in <a href="./references#CD010284-sec-0164" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD010284-sec-0079"> <h5 class="title">Participants</h5> <p>Vascular dementia was diagnosed according to one or a combination of the following criteria: DSM (versions III, III‐R, IV, IV‐R), ICD‐10, NINDS‐AIREN and Hachinski Ischaemic Score. The proportion of men across the studies ranged from 45% to 88%, with a median age of approximately 67 years (range 43 to 96 years). </p> <p>The onset of treatment from stroke diagnosis varied significantly from one to 360 months, with a median of 27 months based on 31 studies (<a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a>). </p> <p>Treatment duration was relatively short, between 2 to 24 weeks with a median of 12 weeks. Nine studies had treatment durations lasting from two weeks to four weeks. Final assessments occurred at the end of the treatment period in all 47 studies, with a median duration of 12 weeks and a range from two weeks to six months. None of the studies followed participants up for as long as a year. </p> <p> <div class="table" id="CD010284-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>References</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>From 2 to 4 weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>More than 4 to 12 weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>More than 12 to 24 weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0080"> <h5 class="title">Interventions and comparator groups</h5> <p>There was substantial clinical heterogeneity among studies in the composition of both the experimental TCHM and the control interventions, as well as the use or non‐use of a common co‐intervention such as WM, RT or a combination of WM and RT. The relevant pairwise comparisons from the three three‐arm studies are included in the following summaries of the clinical heterogeneity: </p> <p> <ol id="CD010284-list-0007"> <li> <p>Clinical heterogeneity of the experimental group TCHM Interventions</p> <ol id="CD010284-list-0008"> <li> <p>We found eligible studies for 18 out of the 29 eligible TCHM formulations (<a href="#CD010284-tbl-0011">Table 1</a>). Four TCHMs accounted for half of the included studies and more than half of the number of participants: NXT (12 studies, 926 participants), NMT (six studies, 420 participants), SFT (four studies, 323 participants) and TXL (three studies, 240 participants). </p> </li> <li> <p>The herbal composition ranged from single herbs to 26‐herb mixtures with four‐ to five‐herb mixtures being the most common. We identified 73 types of herbs (<a href="#CD010284-tbl-0012">Table 2</a>). The eight most frequently used, in descending order, were ChuanXiong, DanShen, RenShen, DangGui, BingPian, HongHua, HuangQi and SanQi. There were also 18 non‐herbal components (<a href="#CD010284-tbl-0011">Table 1</a>). </p> </li> <li> <p>The four primary modes of action (<a href="#CD010284-tbl-0011">Table 1</a>) were: diaphoretic/antipyretic (two TCHMs: QKL, XNJ), anti‐inflammatory (four TCHMs: CWJ, HQ, SFT, SQFZ), anti‐thrombotic (11 TCHMs: CXQ, DS, DZHS, FFDS, GGS, HTZZ, MLN, NXT, RML, XST and YDXNT) and neuroprotective (11 TCHMs: DZXX, FFHS, KNS, NA, NMT, SM, TJTT, TXL, XNZZ, YXQN and ZZW). </p> </li> </ol> </li> <li> <p>Clinical heterogeneity of the control group Interventions</p> <ol id="CD010284-list-0009"> <li> <p>The control group interventions were placebo, WM, RT or a combination of WM and RT.</p> </li> <li> <p>31 studies used single WM control therapies, five studies used combination WM therapy and nine studies used some form of RT control such as anti‐coagulants, anti‐hypertensives, anti‐inflammatories, electrolytes, hypoglycaemics, lipid‐lowering agents etc., but details were often poorly described. </p> </li> </ol> </li> </ol> </p> <p> <div class="table" id="CD010284-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>References</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single WM (31)</p> <p>1. Almitrine (Duxil)</p> <p>2. Aniracetam</p> <p>3. Cerebroprotein hydrolysate</p> <p>4. Citicoline</p> <p>5. Donepezil</p> <p>6. Ergoloid mesylates</p> <p>7. Huperzine A</p> <p>8. Nicergoline (Sermion)</p> <p>9. Nimodipine</p> <p>10. Oxiracetam</p> <p>11. Piracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> <p>1</p> <p>1</p> <p>4</p> <p>5</p> <p>3</p> <p>1</p> <p>1</p> <p>3</p> <p>1</p> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a> </p> <p><a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> <p><a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a> </p> <p><a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a> </p> <p><a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a> </p> <p><a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a> </p> <p><a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a> </p> <p><a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a> </p> <p><a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a> </p> <p><a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a> </p> <p><a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination WM (5)</p> <p>1. Almitrine, Nimodipine</p> <p>2. Citicoline, Piracetam</p> <p>3. Dihydroergotoxine mesylate, fluoxetine, nimodipine</p> <p>4. Piracetam, Troxerutin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> <p>1</p> <p>1</p> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a> </p> <p><a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> <p><a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> <p><a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT(9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>3. Clinical heterogeneity of experimental‐control group combinations</p> <p>Eighteen studies essentially estimated the TCHM versus 'no treatment' effect using four different comparator combinations: TCHM alone against placebo (4 studies), TCHM as an adjuvant to WM (11 studies), RT (1 study) and (WM with RT) (2 studies). </p> <p> <div class="table" id="CD010284-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Experimental group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCHM alone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCHM and WM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCHM and RT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCHM and WM and RT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM and RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>Thirty‐one studies essentially estimated the TCHM versus WM effect using two different comparator combinations ‐ TCHM alone against WM (25 studies) and (TCHM and RT) against (WM and RT) (six studies). </p> <p> <div class="table" id="CD010284-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Experimental group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM alone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM and RT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WM and RT (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0081"> <h5 class="title">Primary outcomes: cognition, global performance and safety</h5> <p>All 47 studies (3581 participants) assessed cognition using one or a combination of the following scales: MMSE (41 studies; 3227 participants), HDS (21 studies; 1544 participants), ADAS‐Cog (5 studies; 481 participants), CCSE (1 study; 26 participants) and CDT (1 study; 60 participants). </p> <p> <div class="table" id="CD010284-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADAS‐Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CCSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CDT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>32 studies (2267 participants) assessed global performance which was also called 'efficacy rate'. One study (26 participants) used the Sandoz Clinical Assessment‐Geriatric scale and one study (60 participants) used the Global Deterioration Scale. All other studies measured global performance on an ordinal scale based on different criteria: two studies (160 participants) used TCM criteria to define three response levels, 20 studies (1455 participants) used one or a combination of the MMSE‐, HDS‐ and ADL‐derived scores to define three or four response levels, and eight studies (566 participants) did not specify the criteria used to define the response levels. The three‐level ordinal responses were labelled 'very effective', 'effective' and 'no effect'; where a fourth level was recognised it was labelled either 'worsening', 'almost controlled' or 'almost normal'. </p> <p> <div class="table" id="CD010284-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global performance scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sandoz Clinical Assessment‐Geriatric scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global Deterioration Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCM‐based scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition or ADL‐based scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unspecified</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>Thirty‐two studies (2445 participants) explicitly reported collecting safety data but none reported the exact number of AE episodes. Twenty‐nine studies (2296 participants) reported the number of participants experiencing one or more AEs as well as the type of AEs. Two studies (123 participants) reported only the number experiencing one or more AEs without describing the AEs, and one study (26 participants) assessed safety based on electroencephalogram and regional cerebral blood flow measurements (<a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>). Fifteen studies (1208 participants) did not report AEs, neither the number of participants experiencing AEs nor the type and number of AEs. Two of these studies (167 participants) reported the presence of dropouts without specifying reasons (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>), and three studies (204 participants) drew a conclusion about the safety of the TCHM (<a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>). </p> <p> <div class="table" id="CD010284-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants experiencing one or more AEs and AE types</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants experiencing one or more AEs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0082"> <h5 class="title">Secondary outcomes: activities of daily living (ADL) and behaviour</h5> <p>Twenty‐eight studies (2297 participants) assessed daily function using one of the following scales: Activities of Daily Living (23 studies; 1868 participants), Instrumental Activities of Daily Living (2 studies; 203 participants), and the Functional Activities Questionnaire (3 studies; 226 participants). </p> <p> <div class="table" id="CD010284-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily functioning scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IADL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional Activities Questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>Only two studies (148 participants) assessed behaviour using the Blessed‐Roth Behavioural Scale (48 participants) (<a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>) and the Neuropsychiatirc Inventory (100 participants) (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>). </p> </section> </section> <section id="CD010284-sec-0083"> <h4 class="title">Excluded studies</h4> <p>We excluded 70 studies (<a href="./references#CD010284-bbs1-0002" title="">Excluded studies</a>): 37 evaluated an experimental TCHM intervention that was listed neither in the CP nor in the NEDL (<a href="./references#CD010284-bbs2-0048" title="CaiJ , DuJ , HuangJS , LinQC , ChenKY . Clinical observation of KangXin capsule on the influence of vascular dementia [康欣胶囊对血管性痴呆影响的临床观察]. Chinese Journal of Gerontology2003;23(8):482‐4. ">Caijing 2003</a>; <a href="./references#CD010284-bbs2-0049" title="CaiJ , DuJ , HuangJS , LinQC , ChenKY . Efficacy of Kangxin capsule on Homocysteine and β‐amyloid protein in vascular dementia patients [康欣胶囊对血管性痴呆患者血浆同型半胱氨酸及β‐淀粉样蛋白的影响]. Chinese Journal of Integrated Traditional and Western MedicineSeptember 2003;23(9):664‐7. ">Caijing 2003‐2</a>; <a href="./references#CD010284-bbs2-0051" title="ChangD , SteinerG , YeungA , DeBlasioF , PipingasA , ScholeyA , et al. Sailuotong (SLT), a standardised Chinese herbal medicine formula, enhances working memory in healthy adults: a pilot study. Conference: Integrative Medicine Research. 2015. ">Changdennis 2015</a>; <a href="./references#CD010284-bbs2-0052" title="ChenR , ChenZB , WangT , CaiMH , SuQJ . Impact of GuHong injection on cognitive function in patients of vascular dementia [谷红注射液对血管性痴呆患者智能的影响]. Chinese Journal of Clinical Healthcare2006;9(5):470‐1. ">Chenrong 2006</a>; <a href="./references#CD010284-bbs2-0053" title="DengPR , SuYJ . Clinical observation of ZhuYuTongMai capsule for the treatment of multi‐infarct dementia [逐瘀通脉胶囊治疗多梗死性痴呆的临床观察]. Guide of China Medicine2011;9(7):131‐2. ">Dengpinrui 2011</a>; <a href="./references#CD010284-bbs2-0054" title="DuGY , ZhuXC , ZhaoJJ , WangJ , TianJZ , LiuXF , et al. Clinical observation of TianZhi granule for the treatment of senile vascular dementia [天智颗粒治疗老年血管性痴呆临床观察]. China Journal of Chinese Materia Medica2003;28(1):73‐7. ">Duguiyou 2003</a>; <a href="./references#CD010284-bbs2-0056" title="GaoQ . Clinical study of ShuMaiYiNao capsule for the treatment of 58 cases of vascular dementia [疏脉益脑胶囊治疗血管性痴呆58例临床研究]. Journal of Gansu College of TCM2007;24(5):14‐6. ">Gaoqi 2007</a>; <a href="./references#CD010284-bbs2-0058" title="GuoL , FengHS . Efficacy of TianZhi Granule combined with Nunodipine in the treatment of vascular dementia [天智颗粒联合尼莫地平治疗老年血管性痴呆的临床疗效观察]. Medical InformationAugust 2009;22(8):4‐6. ">Guolei 2009</a>; <a href="./references#CD010284-bbs2-0059" title="GuoQ , CaoWZ , ZhaoH , ZhuYX , YangDD , ZhongS , et al. Effect of Sancaijiangtang on plasma nitric oxide and endothelin‐1 levels in patients with type 2 diabetes mellitus and vascular dementia: a single‐blind randomized controlled trial. Journal of Traditional Chinese Medicine2015;35(4):375‐80. ">Guoqiang 2015</a>; <a href="./references#CD010284-bbs2-0060" title="GuoZS , JinJ , JiaJX . Clinical observation of DanHong injection for the treatment of 42 cases of vascular dementia [丹红注射液治疗气滞血瘀型血管性痴呆42例疗效观察]. Chinese Journal of Practical Nervous Diseases2009;12(1):59‐61. ">Guozhisheng 2009</a>; <a href="./references#CD010284-bbs2-0061" title="HeJB , JinJ . Clinical research of ShenXiong glucose injection treating vascular dementia and influence on AVP [参芎葡萄糖注射液治疗血管性痴呆的疗效及对AVP的影响]. Chinese Journal of Experimental Traditional Medical Formulae2012;18(21):306‐10. ">Hejinbo 2012</a>; <a href="./references#CD010284-bbs2-0063" title="HeJ , ZangDJ , ZhaiJ . DanHong injection and Vinpocetine injection improve intelligence of vascular dementia patients in clinic [丹红注射液联合长春西汀对于老年血管性痴呆患者智能康复的临床研究]. Journal of Chengdu University of TCM2010;33(1):32‐4. ">Hejun 2010</a>; <a href="./references#CD010284-bbs2-0066" title="Jia Jianping (study leader). Phase 2 clinical trial of SaiLuoTong capsule for vascular dementia：A 26‐week, multicentre, randomized, double‐blind, placebo‐controlled trial with a 26‐week open‐label extension. www.chictr.org/en/proj/show.aspx?proj=6441 (first received 7 May 2014). [Trial registration: ChiCTR‐TRC‐14004613] ">Jiajianping 2014</a>; <a href="./references#CD010284-bbs2-0068" title="JiangHP , KuangSX . Early efficacy observation of NaoTong capsule for the treatment of vascular dementia [脑通胶囊治疗血管性痴呆早期疗效观察]. Journal of Emergency in Traditional Chinese Medicine2010;19(10):1669‐70,78. ">Jianghaipeng 2010</a>; <a href="./references#CD010284-bbs2-0071" title="LiSL . Clinical observation of TianZhi granule for the treatment of 62 cases of vascular dementia [天智颗粒治疗血管性痴呆62例临床观察]. Chinese Journal of Practical Nervous Diseases2011;14(13):35‐7. ">Lishilin 2011</a>; <a href="./references#CD010284-bbs2-0072" title="LiuGR . Efficacy observation on TianZhi granule for the treatment of mild and moderate vascular dementia [天智颗粒治疗轻度及中度血管性痴呆疗效观察]. Chinese Community Doctors2009;19:119. ">Liuguirong 2009</a>; <a href="./references#CD010284-bbs2-0075" title="LiuXF , DuJ , CaiJ , LiuXF , WangLL , XuGL , et al. Clinical observation of KangXin capsule for the treatment of vascular dementia [康欣胶囊治疗老年肾虚血瘀型血管性痴呆的临床观察]. Journal of Nanjing TCM University2007;23(3):148‐51. ">Liuxifei 2007</a>; <a href="./references#CD010284-bbs2-0076" title="LiWW , WangMC , YuPP , WangY . Observation on clinical effects of Oxiracetam capsule and SanQiTongShu capsule in treating vascular dementia [奥拉西坦联合三七通舒治疗血管性痴呆的临床疗效观察]. Western Journal of Traditional Chinese Medicine2013;26(2):81‐3. ">Liweiwei 2013</a>; <a href="./references#CD010284-bbs2-0077" title="LiY , DuXH , ZhaoXW . Clinical efficacy of ShuXueTong injection for vascular dementia [疏血通注射液治疗血管性痴呆的临床观察]. China Pharmacy2009;20(33):2620‐1. ">Liying 2009</a>; <a href="./references#CD010284-bbs2-0078" title="LiYH . Clinical observation of PeiYuanTongNao capsule for the treatment of vascular dementia [培元通脑胶囊治疗老年血管性痴呆的临床观察]. Seek Medical And Ask The Medicine2011;9(6):143,110. ">Liyuehua 2011</a>; <a href="./references#CD010284-bbs2-0084" title="QinFS , LiuXM . Clinical observation on DanHong injection for the treatment of 68 cases of vascular dementia [丹红注射液治疗血管性痴呆68例临床观察]. Chinese Journal of Modern Drug Application2009;3(11):141‐2. ">Qinfusheng 2009</a>; <a href="./references#CD010284-bbs2-0085" title="ShiDH , ZhangHT , ZhaoMY , HeL , SunQ , TanJW , et al. Clinical research of DanHong injection combined with piracetam on vascular dementia [丹红注射液联合吡拉西坦治疗血管性痴呆临床研究]. Clinical Journal of Medical Officers2011;39(1):43‐5. ">Shidehai 2011</a>; <a href="./references#CD010284-bbs2-0087" title="ShiHT . Efficacy observation on TianZhi granule for the treatment of vascular dementia [天智颗粒治疗血管性痴呆疗效观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(8):955‐6. ">Shihaiting 2011</a>; <a href="./references#CD010284-bbs2-0089" title="TaoGY . Clinical research on treatment of vascular dementia with Brain‐refreshing Pill [醒脑丸治疗血管性痴呆临床研究]. Journal of Shaanxi College of Traditional Chinese Medicine2004;27(1):5‐7. ">Taogenyu 2004</a>; <a href="./references#CD010284-bbs2-0090" title="WangDM , LiAM , YuanYG , WangL , YiRB , LinYJ , et al. Study of effect of treatment of vascular dementia on event related potential by Tzepao Sanpien pills [三鞭丸治疗血管性痴呆对事件相关电位影响的研究]. Journal of Chinese Clinical Medicine2003;4(7):30‐1. ">Wangdongming 2003</a>; <a href="./references#CD010284-bbs2-0097" title="WeiCH . Clinical observation on TianZhi granule for the treatment of vascular dementia [天智颗粒治疗血管性痴呆的临床观察]. Chinese Journal of Practical Nervous Diseases2013;16(16):83‐4. ">Weichunhua 2013</a>; <a href="./references#CD010284-bbs2-0098" title="WuTC , XuRQ . Clinical observation on HuanShaoDan for the treatment of 32 patients with vascular dementia [还少丹加减治疗血管性痴呆32例临床观察]. Hunan Journal of Traditional Chinese Medicine2012;28(5):43‐4. ">Wutianchen 2012</a>; <a href="./references#CD010284-bbs2-0103" title="YinJX , TianJZ , YangCZ , LiuH . A single‐blind controlled study of Jian Nao An( JNA) treatment of the syndrome of deficiency of the kidney and phlegm turbidness of vascular dementia [健脑安治疗血管性痴呆肾虚痰浊证的单盲对照研究]. Chinese Journal of Natural Medicine2000;2(4):212‐5. ">Yinjunxiang 2000</a>; <a href="./references#CD010284-bbs2-0105" title="ZhangCY , LiYP , LiMX , WangRL . Efficacy observation on TianMaSu for the treatment of vascular dementia [天麻素治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(8):1220‐1. ">Zhangchunyan 2009</a>; <a href="./references#CD010284-bbs2-0107" title="ZhangF , HeL , ZhuC , ZhuQF . HuanShaoDan for the treatment of 60 cases of vascular dementia [还少丹加减治疗血管性痴呆60例]. GuangMing Chinese Medicine2011;26(8):1591‐2. ">Zhangfeng 2011</a>; <a href="./references#CD010284-bbs2-0080" title="ZhangYL . The study of Jian Pi Yi Shen Hua Tan granules in cognitive impairment after acute cerebral infarction. clinicaltrials.gov/show/NCT02641886 (first received 30 December 2015). [NCT02641886] ">NCT02641886</a>; <a href="./references#CD010284-bbs2-0109" title="ZhangYL . An fMRI Study of the Efficacy and Safety of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction. clinicaltrials.gov2016; Vol. ClinicalTrials.gov Identifier: NCT02752867. ">Zhangyunling 2016</a>; <a href="./references#CD010284-bbs2-0111" title="ZhaoY . Clinical observation of DanHong injection treatment of vascular dementia [丹红注射液治疗血管性痴呆的临床观察]. Journal of China Traditional Chinese Medicine Information2010;2(10):113. ">Zhaoyan 2010</a>; <a href="./references#CD010284-bbs2-0113" title="ZhaoY , LiZX . HuanShaoDan for the treatment of 80 cases of vascular dementia [还少丹治疗肝肾亏虚型血管性痴呆80例]. Henan Traditional Chinese Medicine2010;30(4):380‐1. ">Zhaoyun 2010</a>; <a href="./references#CD010284-bbs2-0114" title="ZhuAH , TianJZ , ZhongJ , ShiJ . A clinical study on a randomized, double‐blind control of Tianzhi granules in treatment of the senile vascular dementia [天智颗粒治疗老年人血管性痴呆的随机双盲临床对照研究]. Chinese Journal of Gerontology2005;12:1435‐8. ">Zhuaihua 2005</a>; <a href="./references#CD010284-bbs2-0115" title="ZhuangHK , ChiYL , GaoHF . Clinical study of HuaZhuoQingNao decoction for vascular dementia [化浊清脑合剂治疗血管性痴呆临床研究]. Journal of Shandong University of TCM2007;31(1):28‐30. ">Zhuanghuikui 2007</a>; <a href="./references#CD010284-bbs2-0116" title="ZhuN , ZhuHS , LiuHY . Effect of Tianzhi granule combined oxiracetam on mild or moderate vascular dementia [天智颗粒联合奥拉西坦治疗轻中度血管性痴呆临床观察]. Chinese Journal of Practical Nervous Diseases2011;14(17):29‐31. ">Zhuning 2011</a>); 11 evaluated ineligible interventions (<a href="./references#CD010284-bbs2-0064" title="HouDR , ChenK , WangY , TianY , WanS , TangJC , et al. Efficacy and mechanism of Butylphthalide for the treatment of vascular dementia [丁苯酞治疗血管性痴呆的疗效和作用机制]. Journal of Southern Medical University2009;29(3):574‐5,8. ">Houderen 2009</a>; <a href="./references#CD010284-bbs2-0067" title="JiaJP , WeiCB , LiangJH , ZhouAH , ZuoXM , SongHQ , et al. The effects of DL‐3‐n‐butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: A multicentre, randomized, double‐blind, placebo‐controlled trial. Alzheimer's &amp; Dementia2016;12(2):89‐99. ">Jiajianping 2016</a>; <a href="./references#CD010284-bbs2-0073" title="LiuQ , WangX‐J , ZhangZ‐C , XueR , LiP , LiB . Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential. Neural Regeneration Research2016;11(3):460‐4. ">Liuq 2016</a>; <a href="./references#CD010284-bbs2-0074" title="LiuW . Clinical observation of Butylphthalide for the treatment of vascular dementia [丁苯酞治疗血管性痴呆临床观察]. Clinical Focus2009;24(17):1533‐4. ">Liuwei 2009</a>; <a href="./references#CD010284-bbs2-0086" title="ShiGX , LiuCZ , GuanW , WangZK , WangL , XiaoC . Effects of acupuncture on Chinese medicine syndromes of vascular dementia. Chinese Journal of Integrative Medicine2014;20(9):661‐6. ">Shiguangxia 2014</a>; <a href="./references#CD010284-bbs2-0091" title="WangG . Clinical study of YangXueQingNao granule and needing in treating vascular dementia [养血清脑颗粒配合针刺治疗血管性痴呆的临床研究]. Hebei Medicine2006;12(2):131‐3. ">Wangguang 2006</a>; <a href="./references#CD010284-bbs2-0093" title="WangLX , LiLH , LiuGH , MaZJ , MaYQ . Effect of XingNaoJing injection and hyperbaric oxygen on intelligence and apolipoprotein in treating vascular dementia [醒脑静注射液联合高压氧对血管性痴呆患者智能和载脂蛋白的影响]. Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care2000;7(3):158‐60. ">Wanglixin 2000</a>; <a href="./references#CD010284-bbs2-0095" title="WangYK , SunLP , ZhangM . Butylphthalide soft capsules joint donepezil treatment of vascular dementia in clinical efficacy [丁苯酞软胶囊联合多奈哌齐治疗血管性痴呆临床疗效观察]. Journal of Brain and Nervous Diseases2010;18(5):387‐90. ">Wangyankuo 2010</a>; <a href="./references#CD010284-bbs2-0099" title="XieYY . FuFangDanShen injection for the treatment of 15 cases of vascular dementia [复方丹参注射液治疗血管性痴呆15例]. Zhejiang Journal of Traditional Chinese Medicine1997;4:156. ">Xieyongyong 1996</a>; <a href="./references#CD010284-bbs2-0102" title="YangXL . Butylphthalide soft capsules and nimodipine treatment of vascular dementia after stroke effect assessment (Master Degree Thesis) [丁苯酞软胶囊与尼莫地平治疗卒中后血管性痴呆的疗效评价]. HeBei Medical University2008. ">Yangxiaoli 2011</a>; <a href="./references#CD010284-bbs2-0108" title="ZhangXH . Efficacy observation on Butylphthalide soft capsule combined with Donepezil for the treatment of vascular dementia [丁苯酞软胶囊联合多奈哌齐治疗血管性痴呆疗效观察]. Chinese Journal of Practical Nervous Diseases2013;16(3):70‐1. ">Zhangxuehong 2013</a>); nine failed to have eligible diagnostic criteria for vascular dementia, e.g. lack of imaging technique to establish the subtype‐specific diagnosis of dementia (<a href="./references#CD010284-bbs2-0050" title="CaoXB , GongL , DaiJ , KuangLH , LiuYF , SunYP , et al. Clinical study of Oxiracetam combined with LeMai capsule for the dialectical treatment of vascular dementia [奥拉西坦联合乐脉颗粒辨证治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2015;18(3):60‐1. ">Caoxiongbin2015</a>; <a href="./references#CD010284-bbs2-0069" title="LiGL . Clinical study on FuFangDanShen injection combined with HuangQi injection for the treatment of vascular dementia [复方丹参注射液与黄芪注射液联合治疗血管性痴呆临床研究]. Nei Mongol Journal of Traditional Chinese Medicine2013;32(19):33‐4. ">Liguolin2013</a>; <a href="./references#CD010284-bbs2-0070" title="LiH . Clinical study on FuFangDanShen injection combined with HuangQi injection for the treatment of vascular dementia [复方丹参注射液联合黄芪注射液治疗血管性痴呆临床研究]. China Health Industry2013;10(5):67. ">Lihong2013</a>; <a href="./references#CD010284-bbs2-0079" title="MaJM . The efficacy of ShenMai injection for patients with vascular dementia [参麦注射液治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(1):89. ">Majingmei 2006</a>; <a href="./references#CD010284-bbs2-0092" title="WangLX , LiuGH , YanRP , ZhengXL , LiLH . The treatment of XingNaoJing injection for 39 patients with vascular dementia [醒脑静治疗血管性痴呆39例临床分析]. Chinese Journal of Information on Traditional Chinese Medicine1999;6(5):54‐5. ">Wanglixin 1999</a>; <a href="./references#CD010284-bbs2-0094" title="WangSZ , ZhangYJ . XingNaoJing injection for 31 patients with dementia [醒脑静注射液治疗痴呆症31 例]. TCM Research2002;15(6):32. ">Wangsongzhen 2002</a>; <a href="./references#CD010284-bbs2-0104" title="YuFC , YuMQ , SongJC . The efficacy of HuaTuoZaiZao pill for age‐related dementia [华佗再造丸治疗老年期痴呆205例疗效观察]. Journal of Chinese Medicinal Materials1999;22(5):269‐70. ">Yufangchen 1999</a>; <a href="./references#CD010284-bbs2-0106" title="ZhangDD , YangYQ . MaiLuoNing injection for 64 patients with vascular dementia [脉络宁注射液治疗脑血管性痴呆64例]. Journal of PLA Junior College of Medicine1999;27(2):110‐2. ">Zhangdaodong 1999</a>; <a href="./references#CD010284-bbs2-0112" title="ZhaoYM , WuXS . Observation of MaiLuoNing for 36 patients with vascular dementia [脉络宁治疗血管性痴呆36例疗效观察]. Journal of Zheijiang College of TCM1994;18(6):19‐20. ">Zhaoyiming 1994</a>); five studies did not involve people with vascular dementia (<a href="./references#CD010284-bbs2-0055" title="FengJ , ZangM . Clinical study on LiuWeiDiHuangWan for the treatment of mild and moderate vascular cognitive impairment [六味地黄丸治疗轻中度血管性认知障碍的临床研究]. Clinical Journal of Traditional Chinese MedicineApril 2010;22(2):131‐2. ">Fengjiong 2010</a>; <a href="./references#CD010284-bbs2-0082" title="GaoY . Xingnaojing for Moderate‐to‐severe Acute Ischaemic Stroke (XMAS). clinicaltrials.gov/show/NCT02728180 (first received 5 April 2016). [NCT02728180] ">NCT02728180</a>; <a href="./references#CD010284-bbs2-0065" title="HuangLW , YuanJF , WuY , MaiLS , PanHZ . Mongolian milkvetch root injection for improving the cognitive disorder of chronic cerebral ischaemic patients [黄芪注射液改善慢性脑缺血患者认知功能障碍的效应]. Chinese Journal of Clinical Rehabilitation2006;10(43):34‐6. ">Huangliwu 2006</a>; <a href="./references#CD010284-bbs2-0083" title="MengJi . Enterprise stent implantation in the treatment of carotid artery stenosis with ischaemic stroke. clinicaltrials.gov/show/NCT02802072 (first received 16 June 2016). [NCT02802072] ">NCT02802072</a>; <a href="./references#CD010284-bbs2-0081" title="MaoS . Baduanjin exercise prevents post‐myocardial infarction left ventricular remodeling (BE‐PREMIER Trial). clinicaltrials.gov/show/NCT02693795 (first received 29 February 2016). [NCT02693795] ">NCT02693795</a>); four did not have an eligible comparison (<a href="./references#CD010284-bbs2-0057" title="GongXH , YangFM , HeXH , LiXS , ZhangJH , YuRL , et al. The efficacy of ShenQiFuZheng injection for vascular dementia [参芪扶正注射液治疗血管性痴呆的疗效观察]. Chinese Journal for Clinicians2004;32(6):37‐8. ">Gongxuhai 2004</a>; <a href="./references#CD010284-bbs2-0062" title="HeJ , CaiYY , WangHW , ZangDJ , TanXM . Danshen injection with cerebrolysin for vascular dementia [丹参联合脑神经生长素对血管性痴呆病人智能状况的改善]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseFebruary 2006;4(2):104‐5. ">Hejun 2006</a>; <a href="./references#CD010284-bbs2-0088" title="SunMB , ChenXZ . Effect of tetramethylpyrazine in improving cognitive function and content of arginine vasopressin in plasma and cerebrospinal fluid of patients with vascular dementia [川芎嗪对血管性痴呆患者认知功能及血浆和脑脊液中精氨酸加压素含量的提高效应]. Chinese Journal of Clinical Rehabilitation2005;9(24):194‐6. ">Sunmeibo 2005</a>; <a href="./references#CD010284-bbs2-0110" title="ZhangZP , GaoJF , DongSX , ZhangRK , WangYL , LiHS . Clinical observation on YangXueQingNao granule for the treatment of vascular dementia [养血清脑颗粒治疗血管性痴呆临床观察]. Clinical Journal of Clinical Rational Drug Use2014;7(11A):48‐9. ">Zhangzhipeng2014</a>), one was a duplicate report (Zhangzuodan 2007a), and three were not RCTs (<a href="./references#CD010284-bbs2-0096" title="WanJF , LuY , XuYY , LiuCC , ChangSJ , ZhouWD . Clinical effect of LeMai granule combined with Oxiracetam on treatment of vascular dementia [乐脉颗粒联合奥拉西坦治疗血管性痴呆疗效观察]. Chinese Journal of General Practice2012;10(1):31,82. ">Wanjifeng 2012</a>; <a href="./references#CD010284-bbs2-0100" title="XuDM , ZhangYL , MaXQ . Clinical efficacy observation on YangXueQingNao granule for the treatment of 60 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆60例疗效观察]. Chinese Journal of Practical Nervous Diseases2009;12(19):64. ">Xudongmei 2009</a>; <a href="./references#CD010284-bbs2-0101" title="XuHB , ChenH . Clinical observation of TongXinLuo capsule for vascular dementia [通心络胶囊联合氢麦角碱治疗血管性痴呆效果观察]. Medical Journal of Communications2007;21(4):390‐1. ">Xuhaibo 2007</a>). </p> </section> </section> <section id="CD010284-sec-0084"> <h3 class="title">Risk of bias in included studies</h3> <p>Incomplete reporting of methods and results complicated the 'Risk of bias' assessment. None of the 29 trials published in 2007 or later adopted the CONSORT reporting recommendations for randomised controlled trials of herbal interventions (<a href="./references#CD010284-bbs2-0134" title="GagnierJ , BoonH , RochonP , MoherD , BarnesJ , BombardierC , CONSORT group. Recommendations for the reporting of randomized controlled trials of herbal interventions: explanation and elaboration. Journal of Clinical Epidemiology2006;59(11):1134‐49. ">Gagnier 2006</a>). This is a modification of the 22‐item CONSORT checklist for standardised reporting of parallel‐group RCTs (<a href="./references#CD010284-bbs2-0152" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. Annals of Internal Medicine2001;134(8):657‐62. [PUBMED: 11154618] ">Moher 2001</a>), with particularly extensive elaboration of Item 4 which concerns the description of the intervention (i.e. herbal product name, plant part source, extraction characteristics, authentification, dosage regimen, quantitative mixture composition, chemical fingerprint, impurity assays, biochemical standardisation, required training and practice experience of practitioners). We provide a summary of the 'Risk of bias' (RoB) judgements for each study at the study and outcome level in <a href="#CD010284-fig-0002">Figure 2</a>. A blank cell in the figure indicates an RoB domain that was not appraised because that particular outcome was not reported. The last five columns in the figure are the overall (summary) RoB judgements across all domains for each of the five review outcomes. We added this to facilitate the GRADE RoB assessment of quality of evidence. </p> <div class="figure" id="CD010284-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010284-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010284-sec-0085"> <h4 class="title">Allocation</h4> <p>All 47 studies reported random allocation of interventions, but we judged only two as adequately randomised, i.e. low risk of bias in both sequence generation and allocation concealment. Seven studies partially reported randomisation procedures by mentioning the use of a table of random numbers, but with no information about allocation concealment we judged these as having low risk of bias in sequence generation and unclear risk in allocation concealment. Thirty‐eight studies did not provide information on randomisation procedures and we rated them at unclear risk of bias in both sequence generation and allocation concealment. </p> <p> <div class="table" id="CD010284-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk:</b> sequence generation and allocation concealment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk:</b> sequence generation </p> <p><b>Unclear risk:</b> allocation concealment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unclear risk:</b> sequence generation and allocation concealment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0086"> <h4 class="title">Blinding</h4> <p>We judged six studies as having a low risk of both performance and detection bias on account of a low or unclear risk of selection bias and use of placebos or identical forms of TCHM and control treatments. We judged all other studies as having high risk of performance or detection bias or both as a result of differences that we inferred from the form or delivery of the competing interventions, such as differences in preparation (tablet versus capsule) , colour of injectables, odour of treatments, the kind and quantity of medications (related to dosage), the frequency of administration (three versus two times a day) or the form of treatment (TCHM + RT versus RT only, etc.). </p> <p> <div class="table" id="CD010284-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk:</b> performance and detection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High risk:</b> </p> <p>‐ differences in preparation (tablet versus capsule)</p> <p>‐ colour of injectables</p> <p>‐ kind and dosage quantity</p> <p>‐ dosage frequency</p> <p>‐ form of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>5</p> <p>12</p> <p>3</p> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(<a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a> </p> <p><a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> <p><a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a> </p> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>, <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0087"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 29 studies to be at low risk. Twenty‐four of these (1751 participants) or 52.0% of included studies reported no losses to follow‐up. We deemed this to be plausible as the included trials were generally of short duration and the result was consistent with a previous systematic review on the quality of RCTs conducted in China which reported that the proportion of studies reporting zero losses to follow‐up was 53.7% (<a href="./references#CD010284-bbs2-0175" title="ZhangD , YinP , FreemantleN , JordanR , ZhongN , ChengK . An assessment of the quality of randomised controlled trials conducted in China. Trials2008;9(22):doi:10.1186/1745‐6215‐9‐22.. ">Zhang 2008a</a>). We judged the remaining five studies (346 participants) as probably having no losses to follow‐up because the trials were conducted within hospital premises (<a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>). We could not ascertain the adequacy of follow‐up for eight studies (642 participants), as investigators did not report the sample size at the end of trial (or the number of participants analysed), nor did they describe the completeness of follow‐up, so we judged these as having unclear risk of attrition bias. We found 10 studies (914 participants) that reported the incidence of dropouts. The median dropout rate was 4.4% (range: 1% to 13%). By treatment arm, the median and range of dropout rates were 5.3% (2% to 20%) in the TCHM group and 1.3% (&lt; 1% to 17%) in the control group. Some studies' dropout rates were in the vicinity of their respective adverse‐event rates (taken as the number of participants experiencing adverse events). Two studies explicitly reported the reasons for dropouts, citing perceived lack of drug efficacy (<a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>) and experience of AEs (<a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>). One study defined the conditions for dropout (experience of side effects, development of complications, unblinding of allocation status or withdrawal of consent) but did not give the distribution of the dropouts observed (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>). For these reasons, we judged these 10 studies as having a high risk of attrition bias. In these 10 studies where either an intention‐to‐treat (ITT) approach or sensitivity analyses (to assess the impact of missing data) was appropriate, only one study (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>) made an attempt by implementing an ITT primary analysis using a 'last observation carried forward' (LOCF) imputation method. </p> <p> <div class="table" id="CD010284-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unclear risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0088"> <h4 class="title">Selective reporting</h4> <p>Although all 47 included studies were conducted in China, none was registered in the Chinese Clinical Trials Register (<a href="http://www.chictr.org/en/about.aspx" target="_blank">www.chictr.org/en/about.aspx</a>), either prospectively or retrospectively. We provide a summary of the reporting status of the review outcomes for each study in <a href="#CD010284-tbl-0013">Table 3</a>. Only one study (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>) fully reported cognition, daily function, behaviour and global performance outcomes. Twenty‐nine studies fully reported safety outcomes. The proportion of studies judged as having a high risk of reporting bias was greatest for the safety outcome (48.9%, see <a href="#CD010284-fig-0002">Figure 2</a>). </p> <div class="table" id="CD010284-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Review outcome reporting status by study</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No.</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Review outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global performance</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADL</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Behaviour</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other trial outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDA<sup>a</sup>; GSH<sup>a</sup>; SOD<sup>a</sup>; GSH‐PX<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>whole blood viscosity<sup>a</sup>; plasma viscosity<sup>a</sup>; fibrinogen<sup>a</sup>; haematocrit<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS‐R<sup>a</sup>; </p> <p>brain CT scan<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BBS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; HDS<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>whole blood viscosity<sup>a</sup>; plasma viscosity<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hcy<sup>a</sup>; ET<sup>a</sup>; TXB<sub>2</sub><sup>a</sup>; TXA<sub>2</sub>/PGI<sub>2</sub><sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDL<sup>b</sup>; LDL<sup>b</sup>; CHO<sup>b</sup>; TG<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; HDS<sup>b</sup>; CCSE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAQ<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EEG<sup>b</sup>; rCBF<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P300 latency<sup>a</sup>; P300 amplitude<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological Function Defects Scale<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; ADAS‐Cog<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAQ<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>31</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DND<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>33</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup>; CDT<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS‐R<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>34</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSH<sup>a</sup>; TT<sub>3</sub><sup>a</sup>; TT<sub>4</sub><sup>a</sup>; FT<sub>3</sub><sup>a</sup>; FT<sub>4</sub><sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vs<sup>a</sup>; Vm<sup>a</sup>; PI<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDR<sup>a</sup>; P300 latency<sup>a</sup>; P300 amplitude<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P300 latency<sup>a</sup>; P300 amplitude<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological Function Defects Scale<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCD Vm<sup>a</sup>; TCD PI<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; HDS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>plasma viscosity<sup>a</sup>; fibrinogen<sup>a</sup>; whole blood viscosity<sup>a</sup>; haematocrit<sup>a</sup>; erythrocyte electrophoresis<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>42</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>maximum platelet aggregation rate<sup>a</sup>; whole blood viscosity<sup>a</sup>; plasma viscosity<sup>a</sup>; haematocrit<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>whole blood viscosity<sup>a</sup>; plasma contrast viscosity<sup>a</sup>; </p> <p>fibrinogen<sup>a</sup>; haematocrit<sup>a</sup>; erythrocyte sedimentation rate<sup>a</sup>; </p> <p>whole blood reduced viscosity<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAQ<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Results fully reported<br/> <sup>b</sup>Results partially reported<br/> <sup>c</sup>Mentioned in Methods section, but no results reported<br/> N/A: Not assessed </p> <p>ADAS‐Cog: Alzheimer’s Disease Assessment Scale‐cognitive subscale; ADL: Activities of Daily Living; BBS: Blessed‐Roth Behaviour Scale; CDR: clinical dementia rating; CHO:cholestrol; CT: Computed Tomography; DND: delayed neuronal death; ECG: electrocardiogram; EEG: electroencephalogram; ET: endothelin; FAQ: Functional Activities Questionnaire; FT<sub>3</sub>: free triiodothyronine; FT<sub>4</sub>: free thyroxine; GSH: glutathione; GSH‐PX: Glutathione peroxidase; Hcy: homocysteine; HDL: High‐density lipoprotein; HDS: Hasegawa Dementia Scale; HDS‐R: Hasegawa Dementia Scale‐revised; LDL: Low‐density lipoprotein; MDA: Malondialdehyde; MMSE: Mini‐Mental State Examination; NPI: Neuropsychiatric Inventory; PGI<sub>2</sub>: prostaglandin I<sub>2</sub>; PI: pulsatility index; rCBF: regional cerebral blood flow; SOD: Superoxide Dismutase; TCD: Transcranial Doppler; TG: Triglyceride; TSH: thyroid stimulating hormone; TT<sub>3</sub>: Total‐triiodothyronine; TT<sub>4</sub>: total thyroxine; TXA<sub>2</sub>: thromboxane A<sub>2</sub>; TXB<sub>2</sub>: thromboxane B<sub>2</sub>; Vm: mean velocity; Vs: systolic velocity; WMS: Wechsler memory scale; </p> </div> </div> <section id="CD010284-sec-0089"> <h5 class="title">General cognitive function</h5> <p>Forty‐two studies fully reported a cognition outcome. We judged the five studies that had incomplete reporting as having a high risk of reporting bias (<a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>). One of these studies analysed the MMSE categorically rather than continuously, without giving a rationale and without offering evidence supporting the validity of the cut‐offs used. We could therefore not rule out the possibility that the choice of cut‐offs was data‐driven (<a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-sec-0164" title="">Characteristics of included studies</a>). </p> </section> <section id="CD010284-sec-0090"> <h5 class="title">Global performance</h5> <p>In 32 studies that assessed global performance, 20 derived their global performance ratings from their MMSE, HDS or ADL scores by categorisation (e.g. 'very effective', 'effective' or 'no effect') or by calculating the percentage change from the baseline scores (<a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a>). To avoid duplication or double‐counting or both of information already extracted, we excluded these results and appraised the remaining 12 studies for selective reporting bias and for inclusion into the meta‐analysis (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>). All 12 studies reported the outcome completely so we judged them as having a low risk of selective reporting bias (<a href="#CD010284-fig-0002">Figure 2</a>). </p> </section> <section id="CD010284-sec-0091"> <h5 class="title">Safety</h5> <p>Twenty‐nine studies fully reported safety outcomes (<a href="#CD010284-tbl-0013">Table 3</a>). Three studies collected but partially or wholly failed to report safety assessments (<a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>) and 15 studies probably measured safety outcomes but did not mention or report them (<a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a>). We judged 13 studies as having a low risk of reporting bias (<a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>), 11 studies with unclear risk (<a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>) and 23 studies with high risk of reporting bias (<a href="#CD010284-fig-0002">Figure 2</a>); these included all 15 studies that we judged as having probably measured safety outcomes but failing to report them. </p> </section> <section id="CD010284-sec-0092"> <h5 class="title">ADL</h5> <p>Twenty‐five studies fully reported ADL (<a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>). Three studies clearly collected but only partially reported it (<a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>) and 20 studies did not report it at all. We judged 25 studies as low risk of reporting bias (<a href="#CD010284-fig-0002">Figure 2</a>), one as unclear (<a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>) and two as high risk of reporting bias (<a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>). </p> </section> <section id="CD010284-sec-0093"> <h5 class="title">Behaviour</h5> <p>One of two studies that assessed this outcome reported the results completely and we judged it to be at low risk (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>). The other study (<a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>) reported it partially, presenting and analysing the data categorically rather than continuously. They provided neither a rationale for this, nor the validity of the number of categories and thresholds used to define the categories. We judged it as having a high risk of reporting bias. </p> </section> </section> <section id="CD010284-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify other potential biases in 26 of 47 studies (<a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>). In 21 studies that we rated at unclear risk of other biases, 18 did not provide data to support their claims that experimental and control groups were prognostically similar at baseline (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a>). We required a supporting table or a section in the text showing baseline prognostic balance between groups, because 38 of the 47 studies did not explicitly describe their randomisation methods. Given that baseline imbalance could have occurred, we were also uncertain whether the study analysis methods were adequate, particularly where statistical adjustments by regression or stratification could have been merited in the primary or in a sensitivity analysis. </p> <p>In two of the three studies with unclear risk of other biases (<a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>), one participant (a completer) was excluded from the analysis without providing reasons. The impact of exclusion on the estimated effect size was not investigated. In the other study (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>), there was evidence of imbalance in cardiovascular risk factors between the intervention groups and the aggregation of disparate reasons (e.g. dropout due to safety reasons, unblinding, participant choice) in the report of the dropout rate was questionable. </p> <p>We noted another potential source of bias in the assessment of global performance wherein at least one of the MMSE, HDS or ADL scores was categorised in a somewhat arbitrary fashion. None of the trialists offered a rationale behind this operational definition of global performance; neither was the choice of the number of categories (three or four were common) nor the specific cut‐points used to define the categories supported with independent validation studies. However, since we did not analyse such derived global performance outcomes, this potential bias does not affect our conclusions about the effect on global performance. </p> </section> </section> <section id="CD010284-sec-0095"> <h3 class="title" id="CD010284-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD010284-tbl-0001"><b>Summary of findings for the main comparison</b> FuFangDanShen compared to 'no treatment'</a>; <a href="./full#CD010284-tbl-0002"><b>Summary of findings 2</b> FuFangHaiShe compared to 'no treatment'</a>; <a href="./full#CD010284-tbl-0003"><b>Summary of findings 3</b> NaoXinTong compared to 'no treatment'</a>; <a href="./full#CD010284-tbl-0004"><b>Summary of findings 4</b> YinDanXingNaoTong compared to 'no treatment'</a>; <a href="./full#CD010284-tbl-0005"><b>Summary of findings 5</b> FuFangHaiShe compared to Western medicine</a>; <a href="./full#CD010284-tbl-0006"><b>Summary of findings 6</b> NaoMaiTai compared to Western medicine</a>; <a href="./full#CD010284-tbl-0007"><b>Summary of findings 7</b> NaoXinTong compared to Western medicine</a>; <a href="./full#CD010284-tbl-0008"><b>Summary of findings 8</b> QingKaiLing compared to Western medicine</a>; <a href="./full#CD010284-tbl-0009"><b>Summary of findings 9</b> ShenFuTang compared to Western medicine</a>; <a href="./full#CD010284-tbl-0010"><b>Summary of findings 10</b> TongXingLuo compared to Western medicine</a> </p> <p>We report separate intervention effects for two categories of comparisons: (1) the effect of TCHM versus 'no treatment', and (2) the effect of TCHM versus WM. In each category, we report the five outcomes in the order: cognitive function, global performance, safety, daily function and behaviour. For each outcome, we first discuss the effects of the specific TCHMs followed by the effects of specific primary modes of action. We conclude with our confidence in the reported results. </p> <p>The following table summarises for the continuous outcomes the treatment effect estimator and the interpretation of the direction of change that favours the TCHM group: </p> <p> <div class="table" id="CD010284-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment effect estimator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Favours TCHM group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition‐MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (MD) of change score from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postive MD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition‐HDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD of change score from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postive MD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition‐ADAS‐Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD of change score from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative MD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition‐CDT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD of change score from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postive MD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Activities of Daily Living</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD or standardised mean difference (SMD) of change score from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative MD or SMD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Behaviour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD of change score from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative MD</p> </td> </tr> </tbody> </table> </div> </p> <section id="CD010284-sec-0096"> <h4 class="title">Effect of TCHM versus 'no treatment'</h4> <p>We summarise the pooled effects on each of the five outcomes for specific TCHMs that were evaluated in more than one study. We do not report pooled effects across TCHMs because of clinical heterogeneity in the interventions in both experimental and control groups. We did not conduct sensitivity analyses when there was no pooling. </p> <section id="CD010284-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD010284-sec-0098"> <h6 class="title">1. Cognition</h6> <p>All 18 studies assessed cognition, of which six used MMSE only (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>), three used HDS only (<a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>), four used both MMSE and HDS (<a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>), four used MMSE and ADAS‐Cog (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>) and one used HDS and CDT (<a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>). </p> </section> <section id="CD010284-sec-0099"> <h6 class="title">1.1 MMSE</h6> <p>Of the 14 studies using MMSE, two studies of one TCHM (NXT: <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>) did not report either a mean or a measure of dispersion and therefore did not contribute to the forest plots. The remaining 12 studies tested seven TCHMs (<a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a>); four were tested in more than one study ‐ FFDS, FFHS, NXT, YDXNT. All treatment effects favoured TCHM. Our judgement of a clinically significant effect was based on two reported minimally clinically important difference (MCID) thresholds: ≥ 1.4 points (<a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a>) and &gt; 3 points (<a href="./references#CD010284-bbs2-0160" title="QaseemA , SnowV , CrossJTJr . Current pharmacologic treatment of dementia: a clinical practice guideline from the American Academy of Family Physicians. Annals of Internal Medicine2008;148(5):370‐8. ">Qaseem 2008</a>). We summarise the results of the four TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0010"> <li> <p>FFDS may improve cognition compared to 'no treatment' (MD 3.00, 95% confidence interval (CI) −0.39 to 6.39, I<sup>2</sup> = 89%; 2 studies, 95 participants) with placebo in the control groups; low‐certainty evidence due to inconsistency and imprecision (<a href="./full#CD010284-tbl-0001">summary of findings Table for the main comparison</a>). The pooled point estimate was clinically significant but the 95% CI indicates that FFDS might make little or no difference. </p> </li> <li> <p>FFHS may slightly improve cognition compared to 'no treatment' (MD 1.42, 95% CI 0.21 to 2.63, I<sup>2</sup> = 0%; 2 studies, 110 participants) with WM (donepezil) in both treatment and control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0002">summary of findings Table 2</a>). The pooled point estimate was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, but the 95% CI indicates that FFHS might make little or no difference. </p> </li> </ul> <ul id="CD010284-list-0011"> <li> <p>NXT may improve cognition compared to 'no treatment' (MD 4.29, 95% CI 2.66 to 5.93, I<sup>2</sup> = 81%; 3 studies, 225 participants, with nimodipine (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>), nimodipine and RT (<a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>) and donepezil and RT (<a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>) in both treatment and control groups; low quality of evidence due to serious study limitations and inconsistency (<a href="./full#CD010284-tbl-0003">summary of findings Table 3</a>)). The pooled point estimate was clinically significant by both criteria, and was precise. </p> </li> <li> <p>YDXNT may slightly improve cognition compared to 'no treatment' (MD 1.61, 95% CI 0.74 to 2.48, I<sup>2</sup> = 8%; 2 studies, 139 participants, with nimodipine (<a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012)</a> and donepezil (<a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>) in both treatment and control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0004">summary of findings Table 4</a>)). The pooled point estimate was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, but the 95% CI indicates that YDXNT might make little or no difference. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the standard deviation (SD) of the change score did not change the magnitude of the effects, except for FFHS in which the pooled effect became non‐significant and hence imprecise (<a href="#CD010284-tbl-0014">Table 4</a>) . </p> <div class="table" id="CD010284-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis ‐ common TCHM ‐ vs no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.57 to 6.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.49 to 6.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.39 to 6.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.66 to 3.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.29 to 3.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 to 2.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53 to 5.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58 to 5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66 to 5.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>YDXNT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 to 2.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 to 2.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 to 2.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition_ADAS‐COG (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.1 to −2.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.14 to −2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.23 to −2.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADL (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.84 to −0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.89 to −0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.98 to −0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.66 to 0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.82 to 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.13 to 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.78 to −0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.09 to −1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.68 to −1.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>YDXNT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.34 to 0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.34 to 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.33 to 0.73</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </div> <p>Of the three TCHMs (CXQ, DZXX, NMT) tested in single studies, all had a high overall risk of bias. Only one (<a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>) had a large clinically significant effect in favour of TCHM: CXQ (MD 6.10, 95% CI 4.47 to 7.73; 91 participants; moderate‐certainty evidence). </p> <p>There were two primary modes of action:</p> <p> <ul id="CD010284-list-0012"> <li> <p>Anti‐thrombotic (MD 3.60, 95% CI 2.25 to 4.96, I<sup>2</sup> = 88%; 8 studies, 550 participants; <a href="./references#CD010284-fig-0009" title="">Analysis 2.1</a>). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All individual study effects favoured TCHM but they were inconsistent in magnitude. The pooled point estimate was clinically significant by both threshold criteria and also precise enough by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria but not by the <a href="./references#CD010284-bbs2-0160" title="QaseemA , SnowV , CrossJTJr . Current pharmacologic treatment of dementia: a clinical practice guideline from the American Academy of Family Physicians. Annals of Internal Medicine2008;148(5):370‐8. ">Qaseem 2008</a> criteria. </p> </li> <li> <p>Neuroprotective (MD 1.22, 95% CI 0.54 to 1.90, I<sup>2</sup> = 0%; 4 studies, 313 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The pooled point estimate was not clinically significant by either threshold criterion and it was also imprecise. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score did not change the magnitude of the effects (<a href="#CD010284-tbl-0015">Table 5</a>). </p> <div class="table" id="CD010284-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis ‐ primary mode of action ‐ vs no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.03 to 5.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.12 to 5.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.25 to 4.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 1.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 1.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 to 1.90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ HDS (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.18 to 6.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 to 5.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.83 to 5.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.30 to 5.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.32 to 5.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34 to 5.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ ADAS‐COG (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.10 to −2.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.14 to −2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.23 to −2.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.71 to −1.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.87 to −1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.95 to −1.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.87 to 1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.86 to 1.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.85 to 1.12</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </div> <p>In conclusion, we are very uncertain of the MMSE effect estimates, as the overall risk of bias was high in all 12 studies of the seven TCHMs and the GRADE quality of evidence was low. </p> </section> <section id="CD010284-sec-0100"> <h6 class="title">1.2 HDS</h6> <p>Of the eight studies using HDS, seven reported sufficient data and each tested a different TCHM (CXQ, GGS, NMT, NXT, TXL, YDXNT, ZZW; <a href="./references#CD010284-fig-0004" title="">Analysis 1.2</a>). One study did not report either a mean or a measure of dispersion and is therefore not included in the forest plot (NXT: <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>). </p> <p>All studies had a high overall risk of bias mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The treatment effects favoured TCHM but with high inconsistency (I<sup>2</sup> = 78%). </p> <p>There were two primary modes of action:</p> <p> <ul id="CD010284-list-0013"> <li> <p>Anti‐thrombotic (MD 4.29, 95% CI 2.83 to 5.76, I<sup>2</sup> = 67%; 4 studies, 298 participants; <a href="./references#CD010284-fig-0010" title="">Analysis 2.2</a>). The overall risk of bias was high in three of the four studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All individual study effects favoured TCHM but they were inconsistent in magnitude. The pooled point estimate was large and statistically significant. </p> </li> <li> <p>Neuroprotective (MD 4.15, 95% CI 2.34 to 5.96 I<sup>2</sup> = 88%; 3 studies, 188 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All individual study effects favoured TCHM but they were inconsistent in magnitude.The pooled point estimate was large and statistically significant. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score did not change the magnitude of the effects (<a href="#CD010284-tbl-0015">Table 5</a>). </p> <p>Of the seven TCHMs, four had potentially large effects in favour of TCHM, with the lower bound of the 95% CI for the MD greater than or equal to 2.0: CXQ (MD 5.40, 95% CI 3.91 to 6.89, <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>), NXT (MD 5.50, 95% CI 4.20 to 6.80, <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>), TXL (MD 4.12, 95% CI 3.28 to 4.96, <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>) and ZZW (MD 6.00, 95% CI 4.71 to 7.29, <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>). </p> <p>In conclusion, we are very uncertain of the HDS effect estimates as the overall risk of bias was high in six of the seven studies, and the evidence was sparse, with only one study for each specific TCHM. </p> </section> <section id="CD010284-sec-0101"> <h6 class="title">1.3 ADAS‐Cog</h6> <p>Four studies tested two TCHMS: FFDS (three studies) and FFHS (one study) using the ADAS‐Cog (<a href="./references#CD010284-fig-0005" title="">Analysis 1.3</a>). All treatment effects favoured TCHM but three of the four studies had a high overall risk of bias, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). We summarise the results of the FFDS studies below: </p> <p> <ul id="CD010284-list-0014"> <li> <p>FFDS probably improves cognition compared to 'no treatment' (MD −4.34, 95% CI −6.23 to −2.46, I<sup>2</sup> = 0%; 3 studies, 321 participants; moderate‐certainty evidence) with placebo in the control groups; low to moderate quality of evidence due to inconsistency and imprecision (<a href="./full#CD010284-tbl-0001">summary of findings Table for the main comparison</a>). The pooled point estimate was clinically significant. </p> </li> </ul> </p> <p>There were two primary modes of action ‐ anti‐thrombotic (FFDS) and neuroprotection (FFHS) (see <a href="./references#CD010284-fig-0011" title="">Analysis 2.3</a>). The anti‐thrombotic action had the same studies as summarised for FFDS above. </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score did not change the magnitude of the effects (<a href="#CD010284-tbl-0015">Table 5</a>). </p> <p>In conclusion, we are very uncertain of the ADAS‐Cog effect estimates, as the overall risk of bias was high in the single FFHS study and the GRADE quality of evidence was low in the FFDS studies. </p> </section> <section id="CD010284-sec-0102"> <h6 class="title">1.4 Other cognitive outcomes: CDT and CCSE</h6> <p>Only one study comparing TXL plus RT versus RT alone (<a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>) used CDT. The treatment effect favoured TCHM (MD 0.35, 95% CI 0.16 to 0.54) but we are uncertain of the effect as the overall risk of bias was high because of lack of blinding (<a href="#CD010284-fig-0002">Figure 2</a>). </p> </section> <section id="CD010284-sec-0103"> <h6 class="title">2. Global performance</h6> <p>Eleven studies reported global performance but nine of these studies derived it secondarily from the primary MMSE, HDS or ADL assessment (<a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>). We therefore did not analyse these results to avoid double‐counting. The remaining two studies assessed global performance using an ordinal scale: one used the single‐item Global Deterioration scale (<a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>) and the other classified global performance into three categories: 'very effective', 'effective', 'no effect (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>). We dichotomised global performance as 'improvement' (the event of interest) comprising those participants for whom the treatment was 'effective' or 'very effective', and 'no improvement' (non‐events) comprising those participants for whom the treatment had 'no effect' or caused a worsening of state. We eventually excluded <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> because it was not possible to map its GDS seven‐point Likert response format to our binary partition of 'improvement' without significant loss of information. The lowest GDS response, option 'one', representing the ideal outcome of 'no cognitive decline', did not distinguish between participants who improved (event) and those who neither experienced improvement nor worsened (non‐events). The remaining study (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-fig-0006" title="">Analysis 1.4</a>) compared the antithrombotic NXT plus nimodipine versus nimodipine alone. The effect favoured NXT (RR 1.23, 95% CI 1.04 to 1.45; <a href="./references#CD010284-fig-0012" title="">Analysis 2.4</a>) but we are uncertain of the effect as the overall risk of bias was high and the result imprecise. </p> </section> <section id="CD010284-sec-0104"> <h6 class="title">3. Adverse events</h6> <p>Eleven studies reported AEs for seven TCHMs (CXQ, FFDS, FFHS, NMT, NXT, TXL, YDXNT; <a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a>). The median proportion of participants experiencing AEs in these 11 studies was 7.5% (TCHM group: range 0% to 36.7%, control group: range 0% to 16.7%). We found the reporting of the type and frequency of AE episodes to be imprecise or inadequate or both. None of the studies tabulated AEs and the corresponding number of episodes by treatment arm. In addition, the types of AEs reported were not likely to be exhaustive, as studies in general did not describe the scope or regularity of safety assessments. Occurrences of mild and non‐serious AEs are particularly likely to be under‐reported in the studies that reported no "obvious" side effects without explaining what they meant by "obvious" (<a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>). </p> <p>Five studies may have had dropouts because of AEs. We confirmed AEs as the reason in one study: 8.8% (NXT) versus 12.5% (control group) (<a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>), and thought it to be highly likely in another study: 8.3% (FFDS) versus 16.7% (placebo) (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>). We could not rule out the possibility in the remaining studies (<a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013;</a><a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>). </p> <p>A risk ratio (RR) less than one or a risk difference (RD) less than zero indicates a lower chance of participants experiencing one or more AEs in the TCHM compared to the control groups. We summarise the results of the three TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0015"> <li> <p>FFDS may make little or no difference to the risk of AEs compared to 'no treatment' (RD 0.02, 95% CI −0.05 to 0.09, I<sup>2</sup> = 33%; 3 studies, 322 participants) with placebo in the control groups; low quality of evidence due to inconsistency and imprecision (<a href="./full#CD010284-tbl-0001">summary of findings Table for the main comparison</a>). </p> </li> <li> <p>FFHS may make little or no difference to the risk of AEs compared to 'no treatment' (RD 0.00, 95% CI −0.05 to 0.05, I<sup>2</sup> = 0%; 2 studies, 110 participants) with WM (donepezil) in both the treatment and control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0002">summary of findings Table 2</a>). </p> </li> </ul> <ul id="CD010284-list-0016"> <li> <p>YDXNT may make little or no difference to the risk of AEs compared to 'no treatment' (RD 0.00, 95% CI −0.05 to 0.05, I<sup>2</sup> = 0%; 2 studies, 138 participants) with nimodipine (<a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012)</a> and donepezil (<a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>) in both treatment and control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0004">summary of findings Table 4</a>). </p> </li> </ul> </p> <p>Of the four TCHMs tested only in single studies, all had a high overall risk of bias. One study reported no difference: CXQ (RD 0.00, 95% CI −0.04 to 0.04; 91 participants <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>), another reported a large and precise effect in favour of the control: TXL (RD 0.37, 95% CI 0.19 to 0.54, 60 participants <a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a>), the remaining two reported conflicting moderate but imprecise effects in favour of the control: NMT (RD 0.07, 95% CI −0.02 to 0.17; 80 participants <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>) and in favour of TCHM: NXT (RD −0.05, 95% CI −0.22 to 0.11; 62 participants <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>). </p> <p>There were two primary modes of action (<a href="./references#CD010284-fig-0013" title="">Analysis 2.5</a>) </p> <p> <ul id="CD010284-list-0017"> <li> <p>Anti‐thrombotic (RD 0.00, 95% CI −0.02 to 0.03, I<sup>2</sup> = 0%; 7 studies, 614 participants). The overall risk of bias was high in five studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Due to the small event rate, the pooled result was not precise enough to exclude net benefit or harm. </p> </li> <li> <p>Neuroprotective (RD 0.11, 95% CI −0.06 to 0.27, I<sup>2</sup> = 88%; 4 studies, 250 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>) and inconsistency. The pooled point estimate favoured the control arm, but was imprecise. </p> </li> </ul> </p> <p>In conclusion, we are uncertain about the safety effect estimates, as the overall risk of bias was high in nine of the 11 studies of the seven TCHMs, and the GRADE quality of evidence was low. </p> </section> </section> <section id="CD010284-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD010284-sec-0106"> <h6 class="title">4. Activities of daily living</h6> <p>Ten studies of six TCHMs reported daily functioning using what we suspected was a Chinese version of the Activities of Daily Living Questionnaire (<a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a>; <a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>; <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>; <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>; <a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a>), but no details were given. Four TCHMs were tested in more than one study (FFDS, FFHS, NXT, YDXNT). One other study did not report the mean and standard deviation (FFDS: <a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>) and we therefore do not include it in the forest plot. We summarise the results of the four TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0018"> <li> <p>FFDS probably slightly improves daily functioning compared to 'no treatment' (MD −2.33, 95% CI −5.60 to 0.94, I<sup>2</sup> = 59%; 2 studies, 95 participants; <a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a>) with placebo in the control groups; low quality of evidence due to inconsistency and imprecision (<a href="./full#CD010284-tbl-0001">summary of findings Table for the main comparison</a>). The pooled point estimate is of uncertain clinical significance, but the 95% CI indicates that FFDS might make little or no difference. </p> </li> <li> <p>FFHS may slightly improve daily functioning compared to 'no treatment' (MD −2.30, 95% CI −4.98 to 0.39, I<sup>2</sup> = 55%; 2 studies, 110 participants), WM (donepezil) in both treatment and control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0002">summary of findings Table 2</a>). The pooled point estimate is of uncertain clinical significance, but the 95% CI indicates that FFHS might make little or no difference. </p> </li> </ul> <ul id="CD010284-list-0019"> <li> <p>NXT probably improves daily functioning compared to 'no treatment' (MD −6.18, 95% CI −7.02 to −5.33, I<sup>2</sup> = 0%; 2 studies, 166 participants) with nimodipine (<a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a>), nimodipine plus RT ( <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>) in both treatment and control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0003">summary of findings Table 3</a>). The pooled point estimate favoured TCHM and was precise. </p> </li> <li> <p>YDXNT probably slightly improves daily functioning compared to 'no treatment' (MD −1.59, 95% CI −2.09 to −1.09, I<sup>2</sup> = 0%; 2 studies, 139 participants) with nimodipine (<a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012)</a> and donepezil (<a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a>) in both treatment and control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0004">summary of findings Table 4</a>). The pooled point estimate is of uncertain clinical significance, but the 95% CI indicates that YDXNT might make little or no difference. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score negligibly changed the magnitude of the effects (<a href="#CD010284-tbl-0014">Table 4</a>). </p> <p>Of the two TCHMs tested in single studies, both had a high overall risk of bias, and neither had potentially large effects, although both were statistically significant; one was in favour of the control (DZXX: <a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a>) and the other in favour of the TCHM (NMT: <a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a>). </p> <p>There were two primary modes of action:</p> <p> <ul id="CD010284-list-0020"> <li> <p>Anti‐thrombotic (MD −3.60, 95% CI −5.95 to −1.24, I<sup>2</sup> = 95%, 6 studies, 400 participants, <a href="./references#CD010284-fig-0014" title="">Analysis 2.6</a>). The overall risk of bias was high in five of the six studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>), all individual study effects favoured TCHM but were inconsistent in magnitude. </p> </li> <li> <p>Neuroprotective (MD −1.37, 95% CI −3.85 to 1.12, I<sup>2</sup> = 88%; 4 studies, 313 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The pooled point estimate favoured TCHM but the study effects were inconsistent. </p> </li> </ul> </p> <p>In conclusion, we are uncertain of the daily functioning effect estimates, as the overall risk of bias was high in nine of the 10 studies and the GRADE quality of evidence was low to moderate. </p> </section> <section id="CD010284-sec-0107"> <h6 class="title">5. Behaviour</h6> <p>No studies assessed changes in behaviour.</p> </section> </section> </section> <section id="CD010284-sec-0108"> <h4 class="title">Effect of TCHM versus Western medicine (WM)</h4> <p>We summarise the pooled effects for each of the five outcomes with specific TCHMs that were tested in more than one study. We do not report pooled effects across TCHMs because of clinical heterogeneity in the interventions in both experimental and control groups. We did not conduct sensitivity analyses when there was no pooling. </p> <section id="CD010284-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD010284-sec-0110"> <h6 class="title">1. Cognition</h6> <p>All 31 studies assessed cognition, of which 15 used MMSE only (<a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>; <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>; <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; <a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>), two used HDS only (<a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a>; <a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a>), 11 used both MMSE and HDS (<a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>; <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>), two used MMSE and ADAS‐Cog (<a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>), and one used MMSE, HDS and CCSE (<a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>). </p> </section> <section id="CD010284-sec-0111"> <h6 class="title">1.1 MMSE</h6> <p>Of the 29 studies using MMSE, four studies of three TCHMs (DZHS: <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; NMT: <a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>; NXT: <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>) did not report either a mean or a measure of dispersion and we therefore did not include them in the forest plot. The remaining 25 studies tested 12 TCHMs (<a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a>), five of them being tested in more than one study: FFHS, NMT, NXT, SFT, and TXL. All but one treatment effect favoured TCHM. our judgement of a clinically significant effect was based on two reported minimally clinically important difference (MCID) thresholds: ≥ 1.4 points (<a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a>) and &gt; 3 points (<a href="./references#CD010284-bbs2-0160" title="QaseemA , SnowV , CrossJTJr . Current pharmacologic treatment of dementia: a clinical practice guideline from the American Academy of Family Physicians. Annals of Internal Medicine2008;148(5):370‐8. ">Qaseem 2008</a>). We summarise the results of the five TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0021"> <li> <p>FFHS: we are very uncertain if FFHS improves cognition compared to WM (MD 0.78, 95% CI −3.05 to 4.60, I<sup>2</sup> = 89%; 2 studies, 143 participants) with piracetam (<a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>) and donepezil (<a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>) in the control groups; very low quality of evidence due to serious study limitations, inconsistency and imprecision (<a href="./full#CD010284-tbl-0005">summary of findings Table 5</a>). The pooled point estimate was not clinically significant by either the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> or the <a href="./references#CD010284-bbs2-0160" title="QaseemA , SnowV , CrossJTJr . Current pharmacologic treatment of dementia: a clinical practice guideline from the American Academy of Family Physicians. Annals of Internal Medicine2008;148(5):370‐8. ">Qaseem 2008</a> criteria. </p> </li> </ul> <ul id="CD010284-list-0022"> <li> <p>NMT probably improves cognition compared to WM (MD 3.08, 95% CI 2.27 to 3.89, I<sup>2</sup> = 0%; 4 studies, 289 participants) with sermion (<a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>), piracetam (<a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>), and cerebroprotein hydrolysate (<a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>) in the control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0006">summary of findings Table 6</a>). The pooled point estimate was clinically significant by both criteria, and was precise. </p> </li> <li> <p>NXTprobably slightly improves cognition compared to WM (MD 2.26, 95% CI 1.50 to 3.02, I<sup>2</sup> = 61%; 6 studies, 461 participants) with nimodipine (<a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>), duxil (<a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>), hydergine (<a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>), donepezil and RT (<a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>), oxiracetam (<a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>) and aniracetam ( <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>) in the control groups. <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a> also used RT in the TCHM group; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0007">summary of findings Table 7</a>). The pooled point estimate was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, and was precise. </p> </li> <li> <p>SFT: we are very uncertain if SFT improves cognition compared to WM (MD 3.63, 95% CI 1.02 to 6.25, I<sup>2</sup> = 96%; 4 studies, 323 participants) with citicoline and RT (<a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>); citicoline (<a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>) and piracetam (<a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>) in the control groups. <a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a> also used RT in the TCHM group; very low quality of evidence due to serious study limitations, inconsistency and imprecision (<a href="./full#CD010284-tbl-0009">summary of findings Table 9</a>). The pooled point estimate was clinically significant by both criteria but the 95% CI indicates that SFT might make little or no difference. </p> </li> <li> <p>TXL probably slightly improves cognition compared to WM (MD 2.58, 95% CI 1.54 to 3.62, I<sup>2</sup> = 0%; 2 studies, 180 participants) with piracetam (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>) and huperzine A (<a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>) in the control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0010">summary of findings Table 10</a>). The pooled point estimate was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, and was precise. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score did not change the magnitude of the effects (<a href="#CD010284-tbl-0016">Table 6</a>) . </p> <div class="table" id="CD010284-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ common TCHM ‐ vs WM</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.77 to 4.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.92 to 4.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.05 to 4.60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71 to 4.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96 to 4.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27 to 3.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 to 3.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 to 3.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 to 3.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 to 6.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 to 6.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 to 6.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 to 4.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 to 3.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 to 3.62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_HDS (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 to 3.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 to 3.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 to 3.30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QKL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 to 4.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 to 4.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 to 4.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.99 to 7.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.93 to 7.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.86 to 7.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.25 to −3.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.99 to −3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.85 to −3.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−16.88 to −4.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−16.75 to −3.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−16.61 to −3.71</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </div> <p>Of the seven TCHMs (DZHS, DZXX, NA, QKL, RML, XNZZ, YXQN) tested in single studies, two had large and precise clinically significant effects in favour of TCHM: DZXX (MD 4.19, 95% CI 3.13 to 5.25; 60 participants (<a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a>)), QKL (MD 3.05, 95% CI 2.09 to 4.01; 60 participants (<a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>)), but both studies' overall risk of bias was high. </p> <p>There were four primary modes of action, three with multiple studies (<a href="./references#CD010284-fig-0022" title="">Analysis 4.1</a>): </p> <p> <ul id="CD010284-list-0023"> <li> <p>Diaphoretic or antipyretic, or both (MD 3.05, 95% CI 2.09 to 4.01; 1 study, 60 participants (<a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>)). The overall risk of bias was high, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The study effect favoured TCHM and was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, and was precise. </p> </li> <li> <p>Anti‐inflammatory (MD 3.63, 95% CI 1.02 to 6.25, I<sup>2</sup> = 96%; 4 studies, 323 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Each study favoured TCHM, but they were inconsistent in magnitude. The pooled point estimate was clinically significant by both criteria, but was imprecise. </p> </li> <li> <p>Anti‐thrombotic (MD 2.19, 95% CI 1.53 to 2.85, I<sup>2</sup> = 56%; 8 studies, 589 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All study effects favoured TCHM but they were moderately inconsistent in magnitude. The pooled point estimate was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, and was precise. </p> </li> <li> <p>Neuroprotective (MD 2.47, 95% CI 1.77 to 3.17, I<sup>2</sup> = 66%; 12 studies, 840 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All but one individual study favoured TCHM but they were moderately inconsistent in magnitude. The pooled point estimate was clinically significant by the <a href="./references#CD010284-bbs2-0140" title="HowardR , PhillipsP , JohnsonT . Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a> criteria, and was precise. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score did not change the magnitude of the effects (<a href="#CD010284-tbl-0017">Table 7</a>). </p> <div class="table" id="CD010284-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analysis ‐ primary mode of action ‐ vs WM</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 to 6.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 to 6.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 to 6.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 to 2.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 to 2.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 to 2.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71 to 3.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 to 3.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.77 to 3.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ HDS (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diaphoretics and antipyretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 to 4.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 to 4.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 to 4.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 to 3.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 to 3.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 to 3.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ ADAS‐COG (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06 to 2.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08 to 2.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.11 to 2.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL (SMD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.36 to −0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.66 to −0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.35 to −0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.85 to −0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.01 to −0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.36 to −0.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.43 to −0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.43 to −0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.44 to −0.01</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </div> <p>In conclusion, we are very uncertain of the MMSE effect estimates, as the overall risk of bias was high in all 25 studies of the 12 TCHMs, and the GRADE quality of evidence ranged from moderate to very low. </p> </section> <section id="CD010284-sec-0112"> <h6 class="title">1.2 HDS</h6> <p>Eleven studies used HDS to test eight TCHMs (<a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a>), with two tested in multiple studies (NXT, QKL) and six single‐study comparisons (DZHS, HQ + DS, NMT, SFT, TXL, XNZZ). Three other studies reported neither an average nor a measure of dispersion (NXT: <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; DZHS: <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>) and we therefore did not include them in the forest plot. </p> <p>We summarise the results of the two TCHMs tested in more than one study below:</p> <p> <ul id="CD010284-list-0024"> <li> <p>NXT may slightly improve cognition compared to WM (MD 1.80, 95% CI 0.31 to 3.30, I<sup>2</sup> = 83%; 3 studies, 258 participants) with nimodipine (<a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>), hydergine (<a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>), and aniracetam (<a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>) in the control groups; low quality of evidence due to serious study limitations and inconsistency (<a href="./full#CD010284-tbl-0007">summary of findings Table 7</a>). The pooled estimate is of uncertain clinical significance and the 95% CI indicates that NXT might make little or no difference. </p> </li> <li> <p>QKL may slightly improve cognition compared to WM (MD 2.77, 95% CI 1.11 to 4.43, I<sup>2</sup> = 73%; 2 studies, 150 participants) with citicoline and RT (<a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>), citocoline and piracetam (<a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a>) in the control groups. <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a> also used RT in the TCHM group; low quality of evidence due to serious study limitations and inconsistency (<a href="./full#CD010284-tbl-0008">summary of findings Table 8</a>). The pooled estimate is of uncertain clinical significance and the 95% CI indicates that QKL might make little or no difference. </p> </li> </ul> </p> <p>Of the six TCHMs tested in single studies, two had potentially large effects in favour of TCHM, with the lower bound of the 95% CI for the MD greater than or equal to 2.0: NMT (MD 7.58, 95% CI 5.15 to 10.01, <a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a>; 60 participants), SFT (MD 2.43, 95% CI 2.11 to 2.75, <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; 100 participants), but their overall risk of bias was high. </p> <p>There were four primary modes of action, all with multiple studies (<a href="./references#CD010284-fig-0023" title="">Analysis 4.2</a>): </p> <p> <ul id="CD010284-list-0025"> <li> <p>Diaphoretic or antipyretic, or both: this is the same group of studies summarised for QKL above. </p> </li> <li> <p>Anti‐inflammatory (MD 2.44, 95% CI 2.13 to 2.74, I<sup>2</sup> = 0%; 2 studies, 200 participants). The overall risk of bias was high in both studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Each study favoured TCHM and they were consistent in magnitude. The pooled estimate was statistically significant and precise. </p> </li> <li> <p>Anti‐thrombotic (MD 1.99, 95% CI 0.89 to 3.08, I<sup>2</sup> = 73%; 5 studies, 426 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All study effects favoured TCHM but they were inconsistent in magnitude. The pooled estimate was statistically significant but imprecise. </p> </li> <li> <p>Neuroprotective (MD 4.21, 95% CI 1.55 to 6.87, I<sup>2</sup> = 85%; 3 studies, 188 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All study effects favoured TCHM but they were inconsistent in magnitude. The pooled point estimate was statistically significant but imprecise. </p> </li> </ul> </p> <p>The <a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a> study appears twice in <a href="./references#CD010284-fig-0023" title="">Analysis 4.2</a>, because a combination of two TCHMs were used one with anti‐inflammatory action (HQ) and the other with anti‐thrombotic action (DS). </p> <p>In conclusion, we are very uncertain of the HDS effect estimates, as the overall risk of bias was high in all 11 studies of the eight TCHMs, and the GRADE quality of evidence was low. </p> </section> <section id="CD010284-sec-0113"> <h6 class="title">1.3 ADAS‐Cog</h6> <p>Both TCHMs that used HDS to measure outcomes were tested in single studies (FFHS, NMT; <a href="./references#CD010284-fig-0017" title="">Analysis 3.3</a>). Both studies had a high overall risk of bias, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Treatment effects consistently favoured the control group. </p> <p>There was one primary mode of action (<a href="./references#CD010284-fig-0024" title="">Analysis 4.3</a>): </p> <p> <ul id="CD010284-list-0026"> <li> <p>Neuroprotective (MD 2.19, 95% CI 2.11 to 2.27, I<sup>2</sup> = 0%; 2 studies, 121 participants). Both studies had a high overall risk of bias, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Treatment effects consistently favoured the control group. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score did not change the magnitude of the effects (<a href="#CD010284-tbl-0017">Table 7</a>). </p> <p>In conclusion, we are very uncertain of the ADAS‐Cog effect estimates, as the overall risk of bias was high in both studies. </p> </section> <section id="CD010284-sec-0114"> <h6 class="title">1.4 Other cognitive outcomes</h6> <p>Only one study comparing DZHS versus hydergine used the CCSE (<a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>). However, the investigators did not report quantitative results (means and standard deviations), but only mentioned that the difference was not statistically significant at the 5% level. </p> </section> <section id="CD010284-sec-0115"> <h6 class="title">2. Global performance</h6> <p>Nineteen studies reported global performance but nine of them derived it secondarily from the primary MMSE, HDS or ADL assessment ( <a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>; <a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a>; <a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a>; <a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>; <a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a>; <a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a>; <a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a>; <a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a>). We therefore have not analysed these results, to avoid double‐counting. The remaining 10 studies of eight TCHMs (<a href="./references#CD010284-fig-0018" title="">Analysis 3.4</a>) assessed global performance using an ordinal scale: seven studies used three categories: 'very effective'' "effective', 'no effect' (<a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>; <a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>; <a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>), including one study that categorised the Sandoz Clinical Assessment‐Geriatric Scale (<a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a>). Three studies used four categories: 'very effective', 'effective', 'clinical control/almost normal', 'no effect or worsening' (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>). We dichotomised global performance into 'improvement' (the event of interest) and 'no improvement' (non‐events). 'Improvement' comprised those participants for whom the treatment was 'very effective', 'effective' or resulted in an 'almost normal' status, whilst 'no improvement' comprised those for whom the treatment had 'no effect' or caused a worsening of state. All treatment effects favoured TCHM. A risk ratio greater than one indicates a greater chance of improvement in global performance in the TCHM compared to the control group. We summarise the results of the two TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0027"> <li> <p>NXT probably slightly improves global performance compared to WM (RR 1.43, 95% CI 1.15 to 1.78, I<sup>2</sup> = 0%; 2 studies, 168 participants; <a href="./references#CD010284-fig-0018" title="">Analysis 3.4</a>) with duxil and nimodipine (<a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>) and aniracetam (<a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>) in the control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0007">summary of findings Table 7</a>). The 95% CI indicates that NXT might make little or no difference. </p> </li> </ul> <ul id="CD010284-list-0028"> <li> <p>TXL may make little or no difference to global performance compared to WM (RR 1.26, 95% CI 1.00 to 1.60, I<sup>2</sup> = 0%; 2 studies, 180 participants) with piracetam (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>) and huperzine A (<a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>) in the control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0010">summary of findings Table 10</a>). </p> </li> </ul> </p> <p>Of the six TCHMs tested in a single study, all had a high overall risk of bias and none had potentially large effects (lower bound of the 95% CI for the RR greater than or equal to 1.5) in favour of TCHM. </p> <p>There were three primary modes of action, two with multiple studies:</p> <p> <ul id="CD010284-list-0029"> <li> <p>Anti‐inflammatory (RR 1.45, 95% CI 1.07 to 1.97; 1 study, 100 participants; <a href="./references#CD010284-fig-0025" title="">Analysis 4.4</a>). The overall risk of bias was high and the result was not of clinical significance. </p> </li> <li> <p>Anti‐thrombotic (RR 1.37, 95% CI 1.03 to 1.81, I<sup>2</sup> = 68%; 4 studies, 254 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All individual study effects favoured TCHM but were inconsistent in magnitude. The pooled estimate was statistically significant but imprecise. </p> </li> <li> <p>Neuroprotective (RR 1.34, 95% CI 1.15 to 1.56, I<sup>2</sup> = 0%; 5 studies, 368 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All individual study effects favoured TCHM and were consistent in magnitude. The pooled estimate was statistically significant and precise. </p> </li> </ul> </p> <p>In conclusion, we are very uncertain about the global performance effect estimates as the overall risk of bias was high in all 10 studies of the eight TCHMs, and the GRADE quality of evidence was low. </p> </section> <section id="CD010284-sec-0116"> <h6 class="title">3. Adverse events</h6> <p>Twenty‐two studies reported AEs on 10 TCHMs (DZHS, FFHS, NA, NMT, NXT, QKL, RML, SFT, TXL, XNZZ; <a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a>). The median proportion of participants experiencing adverse events in these studies was 1.25% (range TCHM group: 0% to 30.6%; Control group: 0% to 45%). One study might have had dropouts because of AEs (<a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a>). </p> <p>A risk ratio less than one or a risk difference less than zero indicates a lower chance of participants experiencing one or more AEs in the TCHM compared to the control group. We summarise the results of the five TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0030"> <li> <p>FFHS: we are very uncertain if FFHS changes the risk of AEs compared to WM (RD −0.04, 95% CI −0.26 to 0.19, I<sup>2</sup> = 82%; 2 studies, 143 participants) with piracetam (<a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>) and donepizil (<a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>) in the control groups; very low quality of evidence due to serious study limitations, inconsistency and imprecision (<a href="./full#CD010284-tbl-0005">summary of findings Table 5</a>). </p> </li> <li> <p>NMT: we are very uncertain if NMT changes the risk of AEs compared to WM (RD 0.02, 95% CI −0.03 to 0.07, I<sup>2</sup> = 49%; 4 studies, 277 participants) with hydergine (<a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a>), piracetam (<a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>), and cerebroprotein hydrolysate (<a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a>) in the control groups; very low quality of evidence due to serious study limitations, inconsistency and imprecision (<a href="./full#CD010284-tbl-0006">summary of findings Table 6</a>). </p> </li> <li> <p>NXT probably makes little or no difference to the risk of AEs compared to WM (RD 0.00, 95% CI −0.03 to 0.02, I<sup>2</sup> = 0%; 7 studies, 515 participants) with nimodipine (<a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>), duxil (<a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a>), hydergine (<a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a>), donepezil and RT (<a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>), duxil and nimodipine (<a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a>), oxiracetam (<a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>) and aniracetam ( <a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a>) in the control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0007">summary of findings Table 7</a>). </p> </li> <li> <p>SFT may make little or no difference to the risk of AEs compared to WM (RD −0.01, 95% CI −0.05 to 0.04, I<sup>2</sup> = 0%; 2 studies, 166 participants) with piracetam (<a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>) and citicoline (<a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>) in the control groups; low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0009">summary of findings Table 9</a>). </p> </li> <li> <p>TXL may slightly decrease the risk of AEs compared to WM (RD −0.16, 95% CI −0.42 to 0.10, I<sup>2</sup> = 79%; 2 studies, 180 participants) with piracetam (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>) and huperzine A (<a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a>); low quality of evidence due to serious study limitations and imprecision (<a href="./full#CD010284-tbl-0010">summary of findings Table 10</a>). The 95% CI indicates that TXL might make little or no difference. </p> </li> </ul> </p> <p>Of the five TCHMs tested in single studies, all had a high overall risk of bias. Four studies reported no difference: DZHS (RD 0.00, 95% CI −0.08 to 0.08, 68 participants (<a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>)), QKL (RD 0.00, 95% CI −0.07 to 0.07, 60 participants (<a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>)), RML (RD 0.00, 95% CI −0.06 to 0.06, 60 participants (<a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>)), XNZZ (RD 0.00, 95% CI −0.08 to 0.08, 48 participants (<a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>)) and the remaining one reported a small effect in favour of control: NA (RD 0.03, 95% CI −0.05 to 0.12, 60 participants (<a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>)). </p> <p>There were four primary modes of action, three with multiple studies (<a href="./references#CD010284-fig-0026" title="">Analysis 4.5</a>): </p> <p> <ul id="CD010284-list-0031"> <li> <p>Diaphoretic or antipyretic or both (RD 0.00 95% CI −0.07 to 0.07; 1 study, 60 participants (<a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>)). The overall risk of bias was high and the result imprecise. </p> </li> <li> <p>Anti‐inflammatory (RD −0.01, 95% CI −0.05 to 0.04, I<sup>2</sup> = 0%; 2 studies,166 participants (<a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a>; <a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>)). The overall risk of bias was high in both studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The individual study effects were consistent. The pooled point estimate was not statistically significant and was imprecise. </p> </li> <li> <p>Anti‐thrombotic (RD 0.00, 95% CI −0.03 to 0.02, I<sup>2</sup> = 0%; 9 studies, 643 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Two individual study effects favoured TCHM and the rest showed no difference between the groups. The pooled point estimate was not statistically significant and was imprecise. </p> </li> <li> <p>Neuroprotective (RD −0.00, 95% CI −0.05 to 0.05, I<sup>2</sup> = 65%; 10 studies, 708 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). Three individual study effects favoured TCHM but the estimates were generally inconsistent. The pooled point estimate was not statistically significant and was imprecise. </p> </li> </ul> </p> <p>In conclusion, we are uncertain about the safety effect estimates, as the overall risk of bias was high in all 22 studies of the 10 TCHMs, and the GRADE quality of evidence ranged from moderate to very low. </p> </section> </section> <section id="CD010284-sec-0117"> <h5 class="title">Secondary outcomes</h5> <section id="CD010284-sec-0118"> <h6 class="title">4. Activities of Daily Living</h6> <p>Fourteen of 31 studies reported daily functioning; 13 used what we suspected was a Chinese version of the Activities of Daily Living Questionnaire (<a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>; <a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>; <a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>; <a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>; <a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>; <a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a>; <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>; <a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a>; <a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a>; <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>; <a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a>; <a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>; <a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>; <a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a>), but no details were given. The remaining study (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>) used the IADL Questionnaire, but the exact version (either five‐ or eight‐item) was not specified. Three TCHMs were tested in more than one study (FFHS, NXT, SFT). We summarise the results of the three TCHMs tested in more than one study below: </p> <p> <ul id="CD010284-list-0032"> <li> <p>FFHS: we are very uncertain if FFHS affects daily functioning compared to WM (MD 1.35, 95% CI −4.86 to 7.56, I<sup>2</sup> = 94%; 2 studies, 143 participants) with piracetam (<a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a>) and donepezil (<a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>) in the control groups; very low quality of evidence due to serious study limitations, inconsistency and imprecision (<a href="./full#CD010284-tbl-0005">summary of findings Table 5</a>). The pooled point estimate favoured WM but the 95% CI indicates that FFHS might make little or no difference. </p> </li> </ul> <ul id="CD010284-list-0033"> <li> <p>NXT probably improves daily functioning compared to WM (MD −4.72, 95% CI −5.85 to −3.58, I<sup>2</sup> = 23%; 3 studies, 227 participants) with nimodipine (<a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a>), donepezil and RT (<a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a>) and oxiracetam (<a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a>) in the control groups; moderate quality of evidence due to serious study limitations (<a href="./full#CD010284-tbl-0007">summary of findings Table 7</a>). The pooled estimate favoured TCHM and was consistent and precise. </p> </li> </ul> <ul id="CD010284-list-0034"> <li> <p>SFT: we are very uncertain if SFT improves daily functioning compared to WM (MD −10.16, 95% CI −16.61 to −3.71, I<sup>2</sup> = 88%; 2 studies, 189 participants) with citicoline and RT (<a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a>) and citicoline (<a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a>) in the control groups; very low quality of evidence due to serious study limitations, inconsistency and imprecision (<a href="./full#CD010284-tbl-0009">summary of findings Table 9</a>). The pooled estimate favoured TCHM but was inconsistent. </p> </li> </ul> </p> <p>Of the seven TCHMs tested in single studies, three reported potentially large effects, two in favour of TCHM: NA (MD −8.90, 95% CI −10.90 to −6.90, 60 participants (<a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a>)); XNZZ (MD −3.66, 95% CI −6.02 to −1.30, 48 participants (<a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a>)); and one in favour of control: QKL (MD 3.29, 95% CI 2.00 to 4.58, 60 participants (<a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>)). But all three had a high overall risk of bias. </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score negligibly changed the magnitude of the effects (<a href="#CD010284-tbl-0016">Table 6</a>). </p> <p>There were four primary modes of actions, three with multiple studies (<a href="./references#CD010284-fig-0027" title="">Analysis 4.6</a>): </p> <p> <ul id="CD010284-list-0035"> <li> <p>Diaphoretic or antipyretic or both (MD 1.27 95% CI 0.68 to 1.86; 1 study, 60 participants, <a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a>). The overall risk of bias was high. </p> </li> <li> <p>Anti‐inflammatory (MD ‐10.16, 95% CI ‐16.61 to ‐3.71, I<sup>2</sup> = 88%; 2 studies, 189 participants). The overall risk of bias was high in both studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The individual study effects were inconsistent. The pooled estimate was statistically significant but imprecise. </p> </li> <li> <p>Anti‐thrombotic (MD ‐4.26, 95% CI ‐5.63 to ‐2.90, I<sup>2</sup> = 46%; 5 studies, 355 participants). The overall risk of bias was high, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). All treatment effects favoured TCHM and were moderately inconsistent. The pooled estimate was statistically significant and precise. </p> </li> <li> <p>Neuroprotective (MD −2.54, 95% CI −5.19 to 0.11, I<sup>2</sup> = 94%; 6 studies, 411 participants). The overall risk of bias was high in all studies, mainly due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The pooled estimate favoured TCHM but the study effects were inconsistent. </p> </li> </ul> </p> <p>Sensitivity analyses using different values of the correlation coefficient for the estimation of the SD of the change score negligibly changed the magnitude of the effects (<a href="#CD010284-tbl-0017">Table 7</a>). Also there was minimal impact of using the RD effect measure (rather than the SMD) to pool the results of the single study that used the IADL Questionnaire (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a>) with the five others that used the Chinese ADL Questionnaire for the neuroprotective TCHMs. </p> <p>In conclusion, we are uncertain about the ADL effect estimates as the overall risk of bias was high in all 14 studies of the 10 TCHMs, and the GRADE quality of evidence ranged from moderate to very low. </p> </section> <section id="CD010284-sec-0119"> <h6 class="title">5. Behaviour</h6> <p>Only one study validly using TXL assessed behaviour (<a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006;</a><a href="./references#CD010284-fig-0021" title="">Analysis 3.7</a>, <a href="./references#CD010284-fig-0028" title="">Analysis 4.7</a>), using the Neuropsychiatric Inventory Scale, (MD −9.00, 95% CI −13.33 to −4.67; 100 participants). The overall risk of bias was high due to lack of blinding of participants (<a href="#CD010284-fig-0002">Figure 2</a>). The treatment effect favoured TCHM and was potentially large but we are uncertain about the behaviour effect estimate, as the overall risk of bias was high and the treatment estimate imprecise. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010284-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010284-sec-0120"></div> <p>Vascular dementia (VaD) is not a condition explicitly recognised in classical TCM theory, so there is no specific set of TCHM prescriptions for VaD. Here we identify potentially useful therapies from published clinical trials of TCHMs that were also listed in the <i>Chinese Pharmacopoeia</i> or the Chinese <i>National Essential Drug List</i>. </p> <p>We included 47 studies (3581 participants) of 18 TCHMs, of which (by primary mode of action) seven were anti‐thrombotic (CXQ, DZHS, FFDS, GGS, NXT, RML and YDXNT), eight were neuroprotective (DZXX, FFHS, NA, NMT, TXL, XNZZ, YXQN and ZZW); two were anti‐inflammatory (SFT and HQ) and one was diaphoretic/antipyretic (QKL). We did not find eligible studies for 11 TCHMs (CWJ, DS, HTZZ, KNS, LM, MLN, SM, SQFZ, TJTT, XNJ and XST). </p> <section id="CD010284-sec-0121"> <h3 class="title" id="CD010284-sec-0121">Summary of main results</h3> <section id="CD010284-sec-0122"> <h4 class="title">Effect of TCHM versus 'no treatment'</h4> <p>We addressed the effect of traditional Chinese herbal medicine (TCHM) versus 'no treatment' in four different ways (see Table 3). The studies of TCHM alone versus placebo directly estimate the effect of TCHM versus no treatment. The other three types of studies estimate that effect in the presence of an additional intervention common to both intervention groups; either Western medicine (WM), routine therapy (RT), or both. The overall risk of bias was high in 17 of the 18 studies and unclear in the remaining one. This was because of a lack of blinding of participants, caregivers and outcome assessors which threatened the validity of all the subjective outcome assessments. Only <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a> ensured blinding by using a placebo control. </p> <p>For the two primary efficacy outcomes (cognition, global performance), other than the problem of unblinded assessment, there were generally no issues with the incomplete data or selective reporting domains. The cognition treatment effects of the four TCHMs with multiple studies were consistently in favour of TCHM and clinically significant by at least one of the two criteria (MMSE), but we are very uncertain of the benefits for cognition because of the low GRADE quality of evidence (MMSE, HDS, ADAS‐Cog) and the small number of studies (HDS, ADAS‐Cog). For the two studies that measured global performance independent of cognition, we could not extract usable results from one study and we have very low certainty about the other study's result as it was imprecise. </p> <p>For the primary safety outcome (one or more adverse events (AEs)), we judged nine of 11 studies as having unclear or high risk of bias both for the incomplete outcome data and the selective reporting domains. For the three TCHMs with multiple studies, the point estimates were at or very close to no difference, but we have low certainty about these estimates because of the low GRADE quality of evidence. </p> <p>For the two secondary outcomes (activities of daily living (ADL), behaviour), we judged seven of 10 studies that reported ADL as having unclear or high risk of bias for the incomplete outcome data domain. There were no issues with the selective reporting domain. For the four TCHMs with multiple studies, although the treatment effect was in favour of TCHM, we are uncertain about the ADL estimates because the GRADE quality of evidence ranged from moderate to low. No studies assessed behaviour. </p> <p>When classified by primary mode of action, all the cognition effects were in favour of TCHM; antithrombotics appeared to have a slightly greater efficacy than neuroprotectives, but we are very uncertain about the effects. For the safety outcome, the estimate for antithrombotics is closer to no difference than for neuroprotectives (slightly in favour of control), but our certainty is low. For the ADL outcome, the effect is slightly in favour of TCHM, with antithrombotics slightly better than neuroprotectives, but our certainty is low. </p> <p>The table below summarises those TCHMs for which the reported results suggested either a clinically significant or a potentially large benefit compared to no treatment. </p> <p><b>Table of TCHMs with clinically significant or potentially large efficacy effects versus 'no treatment'</b> </p> <p> <div class="table" id="CD010284-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CXQ</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.10, 95% CI 4.47 to 7.73</p> <p>MD 5.40, 95% CI 3.91 to 6.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> <p>Cognition‐HDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.00, 95% CI −0.39 to 6.39</p> <p>MD −4.34, 95% CI −6.23 to −2.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> <p>Cognition‐ADAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0001">summary of findings Table for the main comparison</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFHS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.42, 95% CI 0.21 to 2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0002">summary of findings Table 2</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NXT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.29, 95% CI 2.66 to 5.93</p> <p>MD 5.50, 95% CI 4.20 to 6.80</p> <p>MD −6.18, 95% CI −7.02 to −5.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> <p>Cognition‐HDS</p> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0003">summary of findings Table 3</a> </p> <p><a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a> </p> <p><a href="./full#CD010284-tbl-0003">summary of findings Table 3</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TXL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.12, 95% CI 3.28 to 4.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>YDXNT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.61, 95% CI 0.74 to 2.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0004">summary of findings Table 4</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ZZW</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.00, 95% CI 4.71 to 7.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>The table below summarises those TCHMs for which the reported results suggest a 5% or more increased risk of AEs in favour of control. </p> <p><b>Table of TCHMs with greater than 5% increased risk of AEs versus 'no treatment'</b> </p> <p> <div class="table" id="CD010284-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NMT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.07, 95% CI −0.02 to 0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TXL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.37, 95% CI 0.19 to 0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD010284-sec-0123"> <h4 class="title">Effect of TCHM versus WM</h4> <p>We addressed the effect of TCHM versus WM in two different ways (see Table 3). The studies of TCHM alone versus WM directly estimate the effect of TCHM versus WM. The other type of study estimates the effect in the presence of additional RT common to both intervention groups. The overall risk of bias was high in all 31 studies. This was because of a lack of blinding of participants, caregivers and outcome assessors which threatened the validity of all the subjective outcome assessments. </p> <p>For the primary cognition outcome, we judged 10 of 31 studies as having unclear or high risk of bias for the incomplete outcome data domain and four of 31 studies as having unclear or high risk of bias for the selective reporting domain. For the five TCHMs with multiple studies, although the cognition treatment effects were consistently in favour of TCHM and clinically significant by at least one of the two criteria (MMSE), we are very uncertain about the MMSE effect estimates because the GRADE quality of evidence ranged from moderate to very low. </p> <p>For the primary global performance outcome, we judged two of 10 studies as having unclear or high risk of bias for the incomplete outcome data domain and none as having unclear or high risk of bias for the selective reporting domain. For the two TCHMs with multiple studies, although the treatment effects were consistently in favour of TCHM, we are uncertain of the global performance effect estimates because the GRADE quality of evidence ranged from moderate to low. </p> <p>For the primary safety outcome, we judged 16 of 31 studies as having unclear or high risk of bias for the incomplete outcome data domain, and 17 of 31 as having unclear or high risk of bias for the selective reporting domain. For the five TCHMs with multiple studies, the point estimates were at or very close to no difference (three TCHMs) or favoured TCHM (two TCHMs), but we have low confidence in these estimates because the GRADE quality of evidence ranged from moderate to very low. </p> <p>For the secondary outcomes (ADL, behaviour), we judged five of 14 studies that reported ADL as having unclear or high risk of bias for the incomplete outcome data domain, and two of 14 studies as having unclear or high risk of bias for the selective reporting domain. For three TCHMs with multiple studies, two favoured TCHM, but we have low certainty about these estimates because the GRADE quality of evidence ranged from moderate to very low. For the two studies that measured behaviour, we could not extract usable results from one study and we have low certainty about the other study's result which favoured TCHM as it was imprecise. </p> <p>When classified by primary mode of action, all the cognition effects were in favour of TCHM. Anti‐inflammatories appeared to have a slightly greater efficacy than antithrombotics and neuroprotectives, but we are very uncertain about the effects. For the safety outcome, all estimates are very close to no difference, but our certainty is low, especially for the neuroprotectives, because of inconsistency. For the ADL outcome, the effect is in favour of TCHM for anti‐inflammatories, antithrombotics and neuroprotectives, but not for diaphoretics/antipyretics (single study), but our certainty is low because of inconsistency. </p> <p>The table below summarises those TCHMs for which the reported results suggested either a clinically significant or a potentially large benefit compared to no treatment. Our definition of a 'potentially large' benefit was that the 95% CI lower bound for the MD of the HDS, ADAS‐Cog and ADL MD should be 2.0 or more, and for global performance the 95% CI lower bound of the RR should be 1.5 or more. </p> <p><b>Table of TCHMs with clinically significant or potentially large efficacy effects versus WM</b> </p> <p> <div class="table" id="CD010284-tblf-0019"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DZXX</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.19, 95% CI 3.13 to 5.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −8.90, 95% CI −10.90 to −6.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NMT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.08, 95% CI 2.27 to 3.89</p> <p>MD 7.58, 95% CI 5.15 to 10.01</p> <p>MD 2.19, 95% CI 2.11 to 2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> <p>Cognition‐HDS</p> <p>Cognition‐ADAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0006">summary of findings Table 6</a> </p> <p><a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a> </p> <p><a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NXT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.26, 95% CI 1.50 to 3.02</p> <p>MD −4.72, 95% CI −5.85 to −3.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0007">summary of findings Table 7</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QKL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.05, 95% CI 2.09 to 4.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SFT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.43, 95% CI 2.11 to 2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TXL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.58, 95% CI 1.54 to 3.62</p> <p>MD −9.00, 95% CI −13.33 to −4.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE</p> <p>Behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./full#CD010284-tbl-0010">summary of findings Table 10</a> </p> </td> </tr> </tbody> </table> </div> </p> <p>There were no TCHMs in which the risk of AEs was greater than 5% compared to the WM control. </p> </section> </section> <section id="CD010284-sec-0124"> <h3 class="title" id="CD010284-sec-0124">Overall completeness and applicability of evidence</h3> <section id="CD010284-sec-0125"> <h4 class="title">Trial setting</h4> <p>All 47 included studies were conducted in China between 1997 and 2015. Trials were conducted in either TCM (28%) or non‐TCM (72%) hospital settings. Most of the trials conducted in non‐TCM hospital settings were in Level III hospitals (with the highest capability). Nearly all trials recruited participants in tertiary care settings. </p> </section> <section id="CD010284-sec-0126"> <h4 class="title">Characteristics of randomised participants</h4> <p>In terms of gender and age distribution, men accounted for between 45% and 88% of participants across studies; the median age was approximately 67 years, with a range of 43 to 96 years. Participants were diagnosed according to one or a combination of the following criteria: DSM (versions III, III‐R, IV, IV‐R), ICD‐10, NINDS‐AIREN and Hachinski Ischaemic Score. Onset of treatment from stroke diagnosis was from 1 month to 30 years, with a median of 2.3 years. The duration of treatment was relatively short, between 2 and 24 weeks with a median of 12 weeks. </p> </section> <section id="CD010284-sec-0127"> <h4 class="title">Differences between trial protocol and routine practice</h4> <p>We could not ascertain whether the administration of the reviewed interventions differed in routine clinical practice (e.g. in formulation and bioavailability of TCHMs) or whether the control group used a less than optimal dose of what is recommended as best practice. </p> </section> <section id="CD010284-sec-0128"> <h4 class="title">Outcome measures and follow‐up</h4> <p>Almost all of the assessment tools used to assess cognition (e.g. MMSE, ADAS‐Cog, CDT, CCSE), daily function (ADL, IADL) and behaviour (NPI, BBS) were developed originally for native English speakers in North America or in Europe. The measurement properties (reliability, validity and responsiveness) of the Chinese versions of these scales are not well‐established. There was little information on the short‐term TCHM effect on behaviour and global performance. The results for the global performance outcome are also not likely to be generalisable outside of China, as TCM criteria are incorporated into its assessment. </p> <p>The safety results were incomplete due to partial or under‐reporting. Trials generally did not precisely report the number of participants who dropped out for treatment‐related reasons. Using the total dropout rate as an estimate, the group‐specific rates ranged from 1% to 13%, with a median of 4.4%. A number of trials also reported no "obvious" side effects, without qualifying the descriptor. Hence mild to moderate or non‐serious AEs may not have been reported. This low AE incidence rate may also be due to the belief that some AEs (e.g. diarrhoea) are part of the expected therapeutic response to treatment with TCHMs. </p> <p>Vascular dementia is a chronic disease. Given the short treatment period and short follow‐up time of the included studies (maximum treatment and follow‐up was 24 weeks), we can draw no conclusions on the long‐term effects of treatment on cognition, global performance, daily functioning, behaviour and safety. </p> </section> </section> <section id="CD010284-sec-0129"> <h3 class="title" id="CD010284-sec-0129">Quality of the evidence</h3> <p>Using the GRADE approach, the quality of evidence (certainty) rating for all outcomes ranged form moderate to very low. The principal reason for the moderate rating was because the overall 'Risk of bias' judgment was consistently rated high for most outcomes in all but two studies (<a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a>; <a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a>). This high rating was due to the consistent lack of participant and outcome assessor blinding, which we thought might affect the accuracy of all the five outcome assessments, all of which had a subjective dimension. There were also occasional additional issues with the incomplete data and selective reporting domains. Outcomes rated as low certainty were principally due to further imprecision or inconsistency. Outcomes rated as very low certainty were for both imprecision and inconsistency issues. </p> </section> <section id="CD010284-sec-0130"> <h3 class="title" id="CD010284-sec-0130">Potential biases in the review process</h3> <p>We were not successful in contacting authors to clarify aspects of RCT design that were partially reported, e.g. details of randomisation, completeness of the follow‐up by treatment arm, reasons for dropout or exclusion from analysis, scope of safety evaluation and safety outcomes as well as missing data for meta‐analyses. </p> <p>All but one of the included studies were reported in Chinese. Our 'Risk of bias' appraisal relied on the translations by our review team members who are native Chinese speakers. We were not able to test the reproducibility of the translations or the effect of multiple translators on the results of our appraisal. </p> </section> <section id="CD010284-sec-0131"> <h3 class="title" id="CD010284-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>We found four published systematic reviews on traditional Chinese Herbal Medicines on vascular dementia: <a href="./references#CD010284-bbs2-0150" title="ManSC , ChanKW , LuJH , DurairajanSS , LiuLF , LiM . hSystematic review on the efficacy and safety of Herbal medicines for vascular dementia. Evidence‐Based Complementary and Alternative Medicine2012;2012:426215. [DOI: 10.1155/2012/426215] ">Man 2012</a> (47 studies on 42 TCHMs, 3725 participants), <a href="./references#CD010284-bbs2-0161" title="QinXD , LiuY , WuYQ , WangS , WangDD , ZhuJQ , et al. A meta‐analysis of Chinese herbal medicines for vascular dementia. Neural Regeneration Research2013;8(18):1685‐92. ">Qin 2013</a> (31 studies on 29 TCHMs, 2868 participants), <a href="./references#CD010284-bbs2-0173" title="ZengLF , ZouYP , KongLS , WangNS , WangQ , WangL , et al. Can Chinese herbal medicine adjunctive therapy improve outcomes of senile vascular dementia? Systematic review with meta‐analysis of clinical trials. Phytotherapy Research2015;29(12):1843‐57. ">Zeng 2015</a> (27 studies on at least 15 TCHMs, 1961 participants) and <a href="./references#CD010284-bbs2-0172" title="XuQQ , ShanCS , WangY , ShiYH , ZhangQH , ZhengGQ . Chinese herbal medicine for vascular dementia: a systematic review and meta‐analysis of high‐quality randomized controlled trials. Journal of Alzheimers Disease2018;62(1):429‐56. [DOI: 10.3233/JAD‐170856] ">Xu 2018</a> (40 studies on 34 TCHMs, 3572 participants). </p> <p><a href="./references#CD010284-bbs2-0150" title="ManSC , ChanKW , LuJH , DurairajanSS , LiuLF , LiM . hSystematic review on the efficacy and safety of Herbal medicines for vascular dementia. Evidence‐Based Complementary and Alternative Medicine2012;2012:426215. [DOI: 10.1155/2012/426215] ">Man 2012</a> evaluated the efficacy and safety of Chinese herbal medicines as either monotherapy or in combination with WM versus placebo or WM in people with vascular dementia. The review examined the effect of 42 TCHMs on cognition as assessed by the MMSE and HDS, daily function as assessed by the Activities of Daily Living Scale and safety outcomes as assessed by the frequency of adverse events, number of withdrawals due to adverse events and biomarker events. All included studies were conducted in China and published in Chinese. The sample size ranged from 18 to 300 with a median of 68. Review authors rated the heterogeneity in clinical design of included studies as significant and decided to perform a narrative synthesis. Of 43 TCHM monotherapy studies, 37 reported TCHM to be better than WM or placebo, and six reported similar efficacy between TCHM and WM. The review concluded that the studies suggested that TCHM can be a safe and effective treatment for vascular dementia, either alone or in conjunction with WM. However, it also noted that methodological flaws in the design limited the extent to which results could be interpreted. For clinical recommendations to be made, the review authors stated the necessity of conducting multicentre trials with adequate power, high methodological quality and standardised TCHM ingredients. </p> <p><a href="./references#CD010284-bbs2-0161" title="QinXD , LiuY , WuYQ , WangS , WangDD , ZhuJQ , et al. A meta‐analysis of Chinese herbal medicines for vascular dementia. Neural Regeneration Research2013;8(18):1685‐92. ">Qin 2013</a> evaluated the efficacy of Chinese herbal medicines (mono‐ or polytherapy) against placebo or WM (mono‐ or polytherapy) in people with vascular dementia. The review examined the effect of 29 TCHMs on cognition, global performance (“effective” rate), and incidence of adverse events by estimating an overall TCHM effect. All included studies were conducted in China and published in Chinese. The sample size ranged from 40 to 300, with a median of 70. Treatment lasted from 4 (30 days) to 24 weeks (168 days). Pooled analyses indicated a statistically significant benefit of TCHM in cognition and global performance (“effective rate”), daily function and safety. They found that, compared to WM or placebo, TCHMs significantly improved the “effective rate” (RR 1.27, 95% CI 1.18 to 1.38), showed benefits in cognition as assessed by MMSE (SMD 2.83, 95% CI 2.55 to 3.12) and by the HDS (SMD 2.41, 95% CI 1.48 to 3.34) and resulted in fewer adverse events (RR 0.20, 95% CI 0.08 to 0.47). The review concluded that TCHMs appeared more effective and safer compared to placebo or WM in people with vascular dementia. However, review authors noted that the RCTs were generally of low quality, and recommended the conduct of well‐designed and high‐quality trials to provide stronger evidence to support claims of efficacy and safety of TCHMs for VaD. </p> <p><a href="./references#CD010284-bbs2-0173" title="ZengLF , ZouYP , KongLS , WangNS , WangQ , WangL , et al. Can Chinese herbal medicine adjunctive therapy improve outcomes of senile vascular dementia? Systematic review with meta‐analysis of clinical trials. Phytotherapy Research2015;29(12):1843‐57. ">Zeng 2015</a> evaluated the efficacy of Chinese herbal medicines as adjunctive therapy to routine pharmacotherapy (CHMAT) against routine pharmacotherapy (RP) alone in people with senile vascular dementia. The review examined the effect of at least 15 TCHMs on cognition, global performance (“effective” rate), daily function and safety parameters by estimating an overall TCHM effect in subgroups defined by treatment duration (4, 8, 12, 24 weeks from time of onset) and across all subgroups. All included studies were conducted in China and published in Chinese. The sample size ranged from 42 to 120, with a median of 63. Pooled analyses indicated a statistically significant additive benefit of CHMAT in cognition, response rate (“effective rate”), daily function, and significant improvements in various biomarkers, i.e. blood fat levels (TC, TG, HDL‐C, LDL‐C, Apo‐E), platelet aggregation rate (PAG1, PAG5, MPAG) and in some indices of blood rheology (WBV and HCT). They found that compared to RP alone, CHMAT significantly improved the “effective rate” (odds ratio (OR) 2.98, 95% CI 2.30 to 3.86) and showed benefits in cognition as assessed by changes in MMSE from time of onset to four weeks (SMD 3.01, 95% CI 2.15 to 3.87), to eight weeks (SMD 2.30, 95% CI 1.28 to 3.32), to 12 weeks (SMD 2.93, 95% CI 2.17 to 3.69) and to 24 weeks (SMD 3.25, 95% CI 2.61 to 3.88). It likewise showed benefits in daily function as assessed by the Activities of Daily Living Scale from time of onset to four weeks (SMD −4.64, 95% CI −6.12 to −3.17), to eight weeks (SMD −4.30, 95% CI −6.04 to −2.56), to 12 weeks (SMD −3.89, 95% CI −4.68 to −3.09) and 24 weeks (SMD −4.04, 95% CI −6.51 to −1.57). They saw similar beneficial effects in HDS, National Institutes of Health Stroke Scale, Clinical Dementia Rating and Montreal Cognitive Assessment Scores. On safety, trials did not report any serious or frequently‐occurring adverse events. The review concluded that CHMAT can improve cognitive impairment and enhance immediate response and quality of life in people with senile vascular dementia. However, noting serious limitations in the methodology of the included studies, the review authors assessed the GRADE quality of evidence as “very low”, and called for further research using well‐designed and well‐executed RCTs. </p> <p><a href="./references#CD010284-bbs2-0172" title="XuQQ , ShanCS , WangY , ShiYH , ZhangQH , ZhengGQ . Chinese herbal medicine for vascular dementia: a systematic review and meta‐analysis of high‐quality randomized controlled trials. Journal of Alzheimers Disease2018;62(1):429‐56. [DOI: 10.3233/JAD‐170856] ">Xu 2018</a> evaluated the efficacy of Chinese herbal medicines (CHM) as monotherapy versus placebo or WM and as an adjunct to WM against WM alone in people with vascular dementia. The review examined the effect of 34 TCHMs on cognition, daily function, behaviour, global performance ("effective" rate) and adverse events. They considered their review as an update of two earlier reviews (<a href="./references#CD010284-bbs2-0161" title="QinXD , LiuY , WuYQ , WangS , WangDD , ZhuJQ , et al. A meta‐analysis of Chinese herbal medicines for vascular dementia. Neural Regeneration Research2013;8(18):1685‐92. ">Qin 2013</a>; <a href="./references#CD010284-bbs2-0173" title="ZengLF , ZouYP , KongLS , WangNS , WangQ , WangL , et al. Can Chinese herbal medicine adjunctive therapy improve outcomes of senile vascular dementia? Systematic review with meta‐analysis of clinical trials. Phytotherapy Research2015;29(12):1843‐57. ">Zeng 2015</a>), but they only reviewed "high‐quality" studies by excluding "not‐so‐good" studies that failed to meet the requirement of at least a low risk of bias judgement in four of the seven Cochrane 'Risk of bias' domains. In spite of this, of the 40 included studies (42 comparisons) seven had unclear risk of bias for random sequence generation, 37 had high risk of bias for allocation concealment, 16 had high risk of bias for blinding of participants and personnel, and 34 had high risk of bias for blinding of outcome assessment. If the authors had further penalised the 28 studies that did not report adverse events, they would have only included 12 to at most 23 studies in their review. Thirty‐nine studies were conducted in China and one in Japan. The duration of treatment ranged from 21 days to three months, with sample sizes from 48 to 469. Thirty‐six comparisons were CHM versus WM, two compared CHM and WM versus WM alone, and four compared CHM versus placebo. Only three studies reported follow‐up beyond the duration of treatment (one to six months). They pooled effects across all CHMs and reported standardised mean differences for all continuous outcomes (MMSE, HDS, ADL, BBS), despite the measurements being on the same scale. Pooled analyses found CHMs more beneficial than placebo for MMSE (SMD 0.44, 95% CI 0.13 to 0.75) but not for behaviour. Analyses with WM controls showed benefit for CHMs for MMSE (SMD 0.27, 95% CI 0.19 to 0.35), HDS (SMD 0.38, 95% CI 0.12 to 0.63), ADL (SMD −0.40, 95% CI −0.53 to −0.27) and effective rate (RR 1.16, 95% CI 1.07 to 1.27). There was no advantage for behaviour. As an adjuvant to WM, they concluded that CHMs had an additive benefit (SMD 0.42, 95% CI 0.06 to 0.79). Adverse event risks were crudely summarised across all treatment arms (treatment group: 5.33% (40/751) versus control group: 15.13% (77/509)). Based on the most commonly occurring herbal components, they recommended the following seven for further development: ChuanXiong, DangGui, DanShen, HeShouWu, HuangQi, RenShen and ShiChangPu. </p> <p>The review questions investigated in <a href="./references#CD010284-bbs2-0173" title="ZengLF , ZouYP , KongLS , WangNS , WangQ , WangL , et al. Can Chinese herbal medicine adjunctive therapy improve outcomes of senile vascular dementia? Systematic review with meta‐analysis of clinical trials. Phytotherapy Research2015;29(12):1843‐57. ">Zeng 2015</a> and <a href="./references#CD010284-bbs2-0161" title="QinXD , LiuY , WuYQ , WangS , WangDD , ZhuJQ , et al. A meta‐analysis of Chinese herbal medicines for vascular dementia. Neural Regeneration Research2013;8(18):1685‐92. ">Qin 2013</a> are more restrictive compared to the review question addressed by <a href="./references#CD010284-bbs2-0172" title="XuQQ , ShanCS , WangY , ShiYH , ZhangQH , ZhengGQ . Chinese herbal medicine for vascular dementia: a systematic review and meta‐analysis of high‐quality randomized controlled trials. Journal of Alzheimers Disease2018;62(1):429‐56. [DOI: 10.3233/JAD‐170856] ">Xu 2018</a> and <a href="./references#CD010284-bbs2-0150" title="ManSC , ChanKW , LuJH , DurairajanSS , LiuLF , LiM . hSystematic review on the efficacy and safety of Herbal medicines for vascular dementia. Evidence‐Based Complementary and Alternative Medicine2012;2012:426215. [DOI: 10.1155/2012/426215] ">Man 2012</a>, which are more similar in scope to this review. In terms of eligibility criteria, our review differs from all previous systematic reviews in its explicit requirement that the TCHMs be listed or recognised in the <i>Chinese Pharmacopoeia</i> or the Chinese <i>National Essential Drug List</i> as some form of assurance of standardisation of TCHM components and manufacturing processes. Unlike <a href="./references#CD010284-bbs2-0172" title="XuQQ , ShanCS , WangY , ShiYH , ZhangQH , ZhengGQ . Chinese herbal medicine for vascular dementia: a systematic review and meta‐analysis of high‐quality randomized controlled trials. Journal of Alzheimers Disease2018;62(1):429‐56. [DOI: 10.3233/JAD‐170856] ">Xu 2018</a>, we did not exclude studies based on a cumulative risk of bias "score". This difference has resulted in a different set of TCHMs and studies reviewed. Our review also differs from the other reviews in that it synthesises effect sizes of individual TCHMs and does not estimate an overall 'TCHM' effect. It recognises that the question of the efficacy of TCHM versus 'no treatment' has been investigated using at least four different intervention‐control group comparisons: (1) TCHM alone versus placebo; (2) TCHM plus WM versus WM alone; (3) TCHM plus RT versus RT alone; (4) TCHM plus WM plus RT versus WM plus RT. If we assume there is no effect modification then all comparisons would estimate the TCHM versus no treatment effect. Similarly it recognises that the efficacy of TCHM versus WM has been investigated using at least two different intervention‐control group comparisons: (1) TCHM alone versus WM; (2) TCHM plus RT versus WM plus RT. If we assume there is no effect modification then all comparisons would estimate the TCHM versus WM effect. These six comparisons are separately synthesised. We also report a type of mechanistic class‐effect by pooling TCHMs with a common primary mode of action, i.e. diaphoretic/anti‐pyretic, anti‐inflammation, anti‐thrombosis and neuroprotection. Unlike the other reviews, we report the treatment effects on continuous outcomes (cognition, daily function, behaviour) as MDs instead of SMDs, which facilitates judgement about clinical significance. </p> <p>Despite these important differences, we found broad agreement in the following results and recommendations: </p> <p> <ol id="CD010284-list-0036"> <li> <p>Inadequate reporting for trials conducted after 2007, as assessed by compliance with the reporting standards recommended in the CONSORT extension statement for herbal interventions, published in 2007. Most of these trials did not explicitly mention methods of randomisation, of outcome assessment especially concerning safety, or of data analyses. Complete reporting of results was also lacking, particularly for safety, i.e. mild AEs and types of AEs. </p> </li> <li> <p>Poor methodological quality in the execution of RCTs: adequacy of randomisation by attainment of baseline balance of known prognostic factors was seldom demonstrated, ways to ensure blinded outcome assessments where outcomes were participant‐ or caregiver‐reported were poorly described or not undertaken, short follow‐up periods, and lack of long‐term follow‐up to ascertain the long‐term effects of TCHMs. </p> </li> <li> <p>Weak support for the finding of benefit of TCHMs (in both efficacy and safety) in view of the poor methodology that led to low confidence in the accuracy of the results and hence a consistent recommendation that further research with better‐designed and well‐executed trials are needed. </p> </li> <li> <p>The three TCHMs we propose for further research (see <a href="#CD010284-sec-0134">Implications for research</a>) have as their major active herbs, components also identified as promising by <a href="./references#CD010284-bbs2-0172" title="XuQQ , ShanCS , WangY , ShiYH , ZhangQH , ZhengGQ . Chinese herbal medicine for vascular dementia: a systematic review and meta‐analysis of high‐quality randomized controlled trials. Journal of Alzheimers Disease2018;62(1):429‐56. [DOI: 10.3233/JAD‐170856] ">Xu 2018</a>, i.e. DangGui, HuangQi, RenShen and ShiChangPu. </p> </li> </ol> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010284-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010284-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p> Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010284-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 1 Cognition‐MMSE." data-id="CD010284-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 1 Cognition‐MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 2 Cognition‐HDS." data-id="CD010284-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 2 Cognition‐HDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 3 Cognition‐ADAS‐Cog." data-id="CD010284-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 3 Cognition‐ADAS‐Cog. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 4 Global performance." data-id="CD010284-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 4 Global performance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 5 AEs." data-id="CD010284-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 5 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 6 Activities of Daily Living." data-id="CD010284-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators), Outcome 6 Activities of Daily Living. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 1 Cognition ‐ MMSE." data-id="CD010284-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 1 Cognition ‐ MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 2 Cognition ‐ HDS." data-id="CD010284-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 2 Cognition ‐ HDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 3 Cognition ‐ ADAS‐Cog." data-id="CD010284-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 3 Cognition ‐ ADAS‐Cog. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 4 Global performance." data-id="CD010284-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 4 Global performance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 5 AEs." data-id="CD010284-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 5 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 6 Activities of Daily Living." data-id="CD010284-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action), Outcome 6 Activities of Daily Living. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 1 Cognition‐MMSE." data-id="CD010284-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 1 Cognition‐MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 2 Cognition‐HDS." data-id="CD010284-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 2 Cognition‐HDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 3 Cognition‐ADAS‐Cog." data-id="CD010284-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 3 Cognition‐ADAS‐Cog. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 4 Global performance." data-id="CD010284-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 4 Global performance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 5 AEs." data-id="CD010284-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 5 AEs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 6 Activities of Daily Living." data-id="CD010284-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 6 Activities of Daily Living. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TCHM versus WM (Subgroup: common TCHMs), Outcome 7 Behaviour." data-id="CD010284-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 TCHM <i>v</i>ersus WM (Subgroup: common TCHMs), Outcome 7 Behaviour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 1 Cognition ‐ MMSE." data-id="CD010284-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 1 Cognition ‐ MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 2 Cognition ‐ HDS." data-id="CD010284-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 2 Cognition ‐ HDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 3 Cognition ‐ ADAS‐Cog." data-id="CD010284-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 3 Cognition ‐ ADAS‐Cog. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 4 Global performance." data-id="CD010284-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 4 Global performance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 5 AEs." data-id="CD010284-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 5 AEs.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 6 Activities of Daily Living." data-id="CD010284-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 6 Activities of Daily Living. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010284-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/urn:x-wiley:14651858:media:CD010284:CD010284-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_t/tCD010284-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 7 Behaviour." data-id="CD010284-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 TCHM versus WM (Subgroup: TCHM primary mode of action), Outcome 7 Behaviour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/media/CDSR/CD010284/image_n/nCD010284-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FuFangDanShen compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FFDS compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> FFDS<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><a href="#CD010284-tbl-0011">Table 1</a><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FFDS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ FFDS ranged from −0.83 to −0.52</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3 higher<br/> (0.39 lower to 6.39 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a, b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog<br/> assessed with: ADAS‐Cog<br/> Scale from: 0 to 70 (lower score better outcome) </p> <p>follow‐up: mean 24 weeks</p> <p>MD of change score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐ADAS‐Cog ‐ FFDS ranged from 0.22 to 2.80</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.34 lower<br/> (6.23 lower to 2.46 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>321<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0005" title="">Analysis 1.3</a> (subgroup 1.3.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more)<br/> follow‐up: mean 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD 0.02<br/> (−0.05 to 0.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>322<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.2) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version<br/> Scale from: 14 to 56 (lower score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from −0.55 to 1.13</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.33 lower<br/> (5.60 lower to 0.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Non‐overlapping 95% CIs, with high I<sup>2</sup> exceeding 75%.<br/> <sup>b</sup>95% CI is wide and not statistically significant.<br/> <sup>c</sup>Average control group risk of the included studies.<br/> <sup>d</sup>Point estimates differ in direction of effect. <br/> <sup>e</sup>Lowest control group risk of the included studies.<br/> <sup>f</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FuFangDanShen compared to 'no treatment'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FuFangHaiShe compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FFHS compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> FFHS<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FFHS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow up: mean 24 weeks<sup>a</sup> </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ FFHS ranged from 4.20 to 4.62</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.42 higher<br/> (0.21 higher to 2.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (AEs) (1 or more)<br/> follow‐up: mean 24 weeks<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RD 0.00<br/> (‐0.05 to 0.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>b, e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.3) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)</p> <p>follow‐up: mean 24 weeks<sup>a</sup> </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from −10.70 to −2.25</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.3 lower<br/> (4.98 lower to 0.39 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Follow‐up only reported by <a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a>.<br/> <sup>b</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria to be high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>c</sup>The 95% CI overlaps the threshold for a clinically significant difference.<br/> <sup>d</sup>Average control group risk of the included studies.<br/> <sup>e</sup>The effect is not statistically significant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FuFangHaiShe compared to 'no treatment'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NaoXinTong compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NXT compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> NXT<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NXT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 8 weeks to 12 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 1.9 to 3.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.29 higher<br/> (2.66 higher to 5.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0004" title="">Analysis 1.2</a> (subgroup 1.2.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global performance (improved) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0006" title="">Analysis 1.4</a> (subgroup 1.4.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (AEs) (one or more events) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.5) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow up: mean 12 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from ‐4.7 to ‐4.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.18 lower<br/> (7.02 lower to 5.33 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.5) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>RT:</b> routine therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria to be high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Non‐overlapping 95% CIs, with high I<sup>2</sup> exceeding 75%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NaoXinTong compared to 'no treatment'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">YinDanXingNaoTong compared to 'no treatment'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>YDXNT compared to no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> YDXNT<br/> <b>Comparison:</b> no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with YDXNT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ YDXNT ranged from 3.98 to 4.07</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.61 higher<br/> (0.74 higher to 2.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0003" title="">Analysis 1.1</a> (subgroup 1.1.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0004" title="">Analysis 1.2</a> (subgroup 1.2.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not‐ measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (AEs) (1 or more events)<br/> follow‐up: mean 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RD 0.00<br/> (−0.05 to 0.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>138<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD010284-fig-0007" title="">Analysis 1.5</a> (subgroup 1.5.7) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (−1 to 1) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in ADL ranged from −25.59 to −2.4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.59 lower<br/> (2.09 lower to 1.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0008" title="">Analysis 1.6</a> (subgroup 1.6.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria] to be high or unclear RoB.<br/> <sup>b</sup>The 95% CI overlaps the threshold for a clinically significant difference.<br/> <sup>c</sup>Average control group risk of the included studies.<br/> <sup>d</sup>95% CI is wide and not statistically significant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">YinDanXingNaoTong compared to 'no treatment'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">FuFangHaiShe compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FFHS compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> FFHS<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FFHS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 12 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 2.57 to 4.20</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.78 higher<br/> (3.05 lower to 4.60 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0017" title="">Analysis 3.3</a> (subgroup 3.3.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>AE (1 or more events)<br/> follow‐up: range 12 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RD −0.04<br/> (−0.26 to 0.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.2) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: range 12 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in activities of Daily Living (ADL) ranged from −10.7 to −4.29</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.35 higher<br/> (4.86 lower to 7.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.2) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Direction of the two treatment effects differ and the I<sup>2</sup> is large (&gt; 80%).<br/> <sup>c</sup>The 95% CI is wide and is not statistically significant.<br/> <sup>d</sup>Average control group risk of the included studies.<br/> <sup>e</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">FuFangHaiShe compared to Western medicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">NaoMaiTai compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NMT compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> NMT<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NMT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 12 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 2.87 to 4.24</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.08 higher<br/> (2.27 higher to 3.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.3) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0017" title="">Analysis 3.3</a> (subgroup 3.3.2) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more events)</p> <p>follow‐up: mean 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD 0.02<br/> (−0.03 to 0.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>277<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.4) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52.2 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies,we judged most of the RoB criteria as unclear or low RoB. But we judged the blinding of participants criteria as High RoB and as the outcome is calculated from participant‐reported information we judge the overall study limitation to be serious.<br/> <sup>b</sup>Lowest control group risk of the included studies.<br/> <sup>c</sup>In all studies, we rated most of the RoB criteria as high or unclear. <br/> <sup>d</sup>95% CI is wide and not statistically significant. <br/> <sup>e</sup>Very different point estimates and moderately high I<sup>2</sup>.<br/> <sup>f</sup>Median control group risk of the included studies. <br/> <sup>g</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">NaoMaiTai compared to Western medicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">NaoXinTong compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>NXT compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> NXT<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NXT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 8 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 1.58 to 6.89</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.26 higher<br/> (1.50 higher to 3.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS<br/> assessed with: HDS </p> <p>Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 12 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐HDS ‐ NXT ranged from 2.45 to 3.33</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.80 higher<br/> (0.31 higher to 3.30 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258<br/> (3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Global performance (improved)</p> <p>follow‐up: range 12 weeks to 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.43<br/> (1.15 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>168<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD010284-fig-0018" title="">Analysis 3.4</a> (subgroup 3.4.4) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>548 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>783 per 1000<br/> (630 to 975) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>816 per 1000<br/> (656 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more events)</p> <p>follow‐up: range 8 weeks to 24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD −0.00<br/> (−0.03 to 0.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>515<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.5) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: range 8 weeks to 24 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in ADL ranged from −6.5 to 0.0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.72 lower<br/> (5.85 lower to 3.58 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.4) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>RD:</b> Risk difference; <b>RT:</b> routine therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Very different point estimates, barely overlapping 95% CIs and high I<sup>2</sup> exceeding 75%.<br/> <sup>c</sup>Average control group risk of the included studies.<br/> <sup>d</sup>In all studies, most of the RoB criteria were judged as high or unclear RoB. <br/> <sup>e</sup>Median control group risk of the included studies.<br/> <sup>f</sup>Lowest control group risk of the included studies.<br/> <sup>g</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">NaoXinTong compared to Western medicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">QingKaiLing compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>QKL compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> QKL<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with QKL</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐MMSE ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.7) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS<br/> assessed with: HDS<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 4 weeks to 8 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐HDS ‐ QKL ranged from 2.38 to 3.2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.77 higher<br/> (1.11 higher to 4.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global performance (improved) ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (AEs) (one or more events) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activities of Daily Living (ADL) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RT:</b> routine therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria to be unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Very different point estimates and moderately high I<sup>2</sup> exceeding 50%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">QingKaiLing compared to Western medicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">ShenFuTang compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SFT compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> SFT<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with SFT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: range 3 weeks to 4 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ‐ SFT ranged from 0.88 to 1.98</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 3.63 higher<br/> (1.02 higher to 6.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>323<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.9) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global performance (improved) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events (AEs) (1 or more events)<br/> follow‐up: mean 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RD −0.01<br/> (−0.05 to 0.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>166<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.8) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities of Daily Living (ADL)</p> <p>assessed with: ADL Chinese version (lower score better outcome)<br/> follow‐up: range 3 weeks to 4 weeks </p> <p>MD of change score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in ADL ranged from −3.9 to −0.68</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10.16 lower<br/> (16.61 lower to 3.71 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.7) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behaviour ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> Risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria as unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Non‐overlapping 95% CIs, with high I<sup>2</sup> exceeding 75%.<br/> <sup>c</sup>The 95% CI overlaps the threshold for a clinically significant difference and is wide.<br/> <sup>d</sup>Average control group risk of the included studies.<br/> <sup>e</sup>95% CI is wide and not statistically significant. <br/> <sup>f</sup>Highest control group risk of the included studies.<br/> <sup>g</sup>Very different point estimates, barely overlapping 95% CIs and high I‐square exceeding 75%.<br/> <sup>h</sup>95% CI is wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">ShenFuTang compared to Western medicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010284-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">TongXingLuo compared to Western medicine</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>TXL compared to WM</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with vascular dementia<br/> <b>Setting:</b> Hospitals in mainland China<br/> <b>Intervention:</b> TXL<br/> <b>Comparison:</b> WM </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with WM</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with TXL</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐MMSE<br/> assessed with: MMSE<br/> Scale from: 0 to 30 (higher score better outcome)<br/> follow‐up: mean 24 weeks </p> <p>MD of change score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in cognition‐MMSE ranged from 1.97 to 2.56</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.58 higher<br/> (1.54 higher to 3.62 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0015" title="">Analysis 3.1</a> (subgroup 3.1.10) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐HDS ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0016" title="">Analysis 3.2</a> (subgroup 3.2.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognition‐ADAS‐Cog ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global performance (improved)<br/> follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.26<br/> (1.00 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010284-fig-0018" title="">Analysis 3.4</a> (subgroup 3.4.7) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>544 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>686 per 1000<br/> (544 to 871) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Adverse events (AEs) (1 or more)<br/> follow‐up: mean 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD −0.16<br/> (−042 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>180<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD010284-fig-0019" title="">Analysis 3.5</a> (subgroup 3.5.9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (40 to 205) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate<sup>f</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000<br/> (69 to 359) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (99 to 513) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Activities of Daily Living (ADL) ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0020" title="">Analysis 3.6</a> (subgroup 3.6.8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Behaviour ‐ only measured in one study</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010284-fig-0021" title="">Analysis 3.7</a> (subgroup 3.7.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RD:</b> risk difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>In all studies, we judged most of the RoB criteria as unclear or low RoB. But we judged the blinding of participants criteria as high RoB and as the outcome is calculated from participant‐reported information we judged the overall study limitation to be serious.<br/> <sup>b</sup>Average control group risk of the included studies.<br/> <sup>c</sup>Lower limit of 95% CI for the RR is 1.<br/> <sup>d</sup>Lowest control group risk of the included studies.<br/> <sup>e</sup>95% CI is wide and not statistically significant.<br/> <sup>f</sup>Median control group risk of the included studies. <br/> <sup>g</sup>Highest control group risk of the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">TongXingLuo compared to Western medicine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0011"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Traditional Chinese herbal medicines (TCHMs) to treat vascular dementia in the Chinese Pharmacopeia or National Essential Drug List </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abbreviation (Name)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary Mode of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Herbal components<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐herbal components</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CWJ (CiWuJia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CiWuiJia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CXQ<sup>a</sup>(ChuanXiongQin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChuanXiong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DS (DanShen)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanShen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DZHS<sup>a</sup> (DengZhanHuaSu, Breviscapine) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DengZhanXiXin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DZXX<sup>a</sup> (DengZhanXiXin) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DengZhanXiXin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FFDS<sup>a</sup> (FuFangDanShen) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian, <b>DanShen</b> , <b>SanQi</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FFHS<sup>a</sup> (FuFangHaiShe) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiChangPu, <b>YuanZhi</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HaiShe (sea snake), HaiShen (sea cucumber)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GGS<sup>a</sup> (GeGenSu) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GeGen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HQ<sup>a</sup> (HuangQi) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuangQi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HTZZ (HuaTuoZaiZao)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian, ChuanXiong, WuZhuYu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KNS (KangNaoShuai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao, DanShen, DangShen, GeGen, GouQi, HeShouWu, HuangQi, HuangQin, JuHua, MaiMenDong, Ren Shen, ShanYao, ShiChangPu, ShuDiHuang, SuanZaoRen, XiangFu, YuanZhi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fushen (Porea fungus sclerotium), LongGuFen (powdered animal bones)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LM (LeMai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiShao, <b>ChuanXiong</b> , DanShen, <b>HongHua</b>, MuXiang, ShanZha, XiangFu </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MLN (MaiLuoNing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JinYinHua, <b>NiuXi</b> , <b>ShiHu</b>, XuanShen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>a</sup> (NaoAn) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian, <b>ChuanXiong</b> , DangGui, <b>HongHua</b>, Ren Shen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NMT<sup>a</sup> (NaoMaiTai) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanShen, DangGui, GeGen, HeShouWu, HongHua, JiXueTeng, JuHua, <b>Ren Shen</b> , SanQi, ShanZha, <b>ShiChangPu</b>, ZhiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiJueMing (abalone shell)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NXT<sup>a</sup> (NaoXinTong) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiShao, ChuanXiong, DanShen, <b>DangGui</b> , GuiZhi, HongHua, <b>HuangQi</b> , JiXueTeng, <b>MoYao</b> , NiuXi, <b>RuXiang</b>, SangZhi, ShuiZhi, TaoRen, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DiLong (earthworm), QuanXie (scorpion)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QKL<sup>a</sup> (QingKaiLing) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diaphoretic and antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BanLanGen, HuangQin, <b>JinYinHua</b>, ZhiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NiuHuang (cattle gallstone), ShuiNiuJiao (water buffalo horn), ZhenZhuMu (mother of pearl, nacre) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RML<sup>a</sup> (RuanMaiLing) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao, ChuanXiong, DanShen, DangGui, GouQi, HeShouWu, HuaiNiuXi, HuangQi, ShuDiHuang, Ren Shen, WuWeiZi, YinYangHuo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SM (ShenMai)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MaiMenDong, <b>RenShen</b>, WuWeiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFT<sup>a</sup> (ShenFuTang) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FuZi</b> , <b>Ren Shen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SQFZ (ShenQiFuZheng)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DangShen</b> , <b>HuangQi</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TJTT (TaiJiTongTian)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiZhi, BoHe, ChaYe, ChiShao, <b>ChuanXiong</b>, FangFeng, GanCao, JuHua, QiangHuo, TianMa, XiXin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXL<sup>a</sup> (TongXinLuo) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RenShen</b>, TanXiang </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChanTui (cicada moult), QuanXie (scorpion), ShuiZhi (leech), TuBieChong (wingless cockroach), WuGong (centipede) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XNJ (XingNaoJing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diaphoretic and antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BingPian</b>, YuJin, ZhiZi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SheXiang (navel gland secretions of musk deer),</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XNZZ<sup>a</sup> (XingNaoZaiZao) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiFuZi, BaiShu, <b>BingPian</b> , ChiShao, ChuanXiong, DaHuang, DanNanXing, DangGui, GeGen, GouQi, HeShouWu, HongHua, HuangQi, JueMingZi, <b>RenShen</b> , SanQi, <b>ShiChangPu</b>, TaoRen, TianMa, XiXin, YinYangHuo, ZeXie, ZhuYaZao </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DiLong (earthworm), JiangCan (silkworm), ZhenZhu (pearl)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XST (XueSaiTong)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SanQi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YDXNT<sup>a</sup> (YinDanXinNaoTong) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AiPian, DaSuan, <b>DanShen</b> , DengZhanXiXin, JiaoGuLan, SanQi, ShanZha, <b>YinXingYe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YXQN<sup>a</sup> (YangXueQingNao) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao, ChuanXiong, DangGui, GouTeng, JiXueTeng, JueMingZi, ShuDiHuang, XiXin, XiaKuCao, YanHuSuo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZhenZhuMu (mother of pearl, nacre)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZZW<sup>a</sup> (25 Wei ZhenZhuWan) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CaoGuo, <b>DingXiang</b> , JiangXiang, <b>RouDouKou</b>, TanXiang, YuGanZi, ZangHongHua </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NiuHuang (cattle gallstone), ShiHuiHua (limestone powder) ShuiNiuJiao (water buffalo horn), ZhenZhu (pearl) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>The 18 TCHMS that were evaluated in the 47 included studies.<br/> <sup>b</sup>Scientific name, common name and part of plant used are given in <a href="#CD010284-tbl-0012">Table 2</a>. In TCHMs which contain a mixture of herbal components, those in <b>bold</b> are the major active herb/s according to TCM theory. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Traditional Chinese herbal medicines (TCHMs) to treat vascular dementia in the Chinese Pharmacopeia or National Essential Drug List </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0012"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scientific names of Traditional Chinese herbal medicine (TCHM) components in Table 1</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Herbal components (English common name(s)) [Mandarin]; Plant part used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scientific name (1) from www.plantlist.org; (2) from www.eflora.cn)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major active components (where known)<sup>b</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AiPian (Borneol crystal, Ngai camphor) [ 艾片 ]; leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Blumea balsamifera</i> (L.) DC. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiFuZi (Giant Typhonium) [ 白附子 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Typhonium giganteum</i> Engl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShao (White Peony) [ 白芍 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Paeonia lactiflora</i> Pall. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monoterpene glycosides e.g. paeoniflorin (&gt; 1.25%), ox‐paeonoflorin, benzoylpaeoniflorin, albiflorin R1, paeoniflorigenone, paeonilactones (A ‐ C) etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiShu (White Atractylodes) [ 白术 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1)<i>Atractylodes japonica</i> (Koidz. ex Kitam.) Kitag.; (2) Atractylodes macrocephala Koidz </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils e.g. α and β‐humulene, β‐elemol, atraction etc.</p> <p>Lactones e.g. atractylenolides I ‐ IV, atractylenolactam, beishulenolide A, etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BaiZhi (Dahurian Angelica) [ 白芷 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Angelica dahurica</i> (Hoffm.) Benth. &amp; Hook.f. ex Franch. &amp; Sav. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BanLanGen (Dyers Woad) [ 板蓝根 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Isatis tinctoria</i> L.; Isatis indigotica Fortune </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BingPian (Borneol flake) [ 冰片 ]; resin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dryobalanops aromatica</i> C.F.Gaertn, <i>Blumea balsamifera</i> (L.) DC. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BoHe (Field Mint, Mentha) [ 薄荷 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Mentha canadensis</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CaoGuo (Grass fruit, Tsaoko) [ 草果 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Amomum tsao‐ko</i> Crevost &amp; Lemarié </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChaYe (Tea leaves) [ 茶叶 ]; leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Camellia sinensis</i> (L.) Kuntze </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiShao (Red Peony) [ 赤芍 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Paeonia lactiflora</i> Pall. or <i>Paeonia veitchii</i> Lynch. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChuanXiong (Szechuan Lovage) [ 川芎 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Ligusticum striatum</i> DC.; (2) Ligusticum chuanxiong Hort. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CiWuJia (Manyprickle acanthopanax, Siberian Ginseng) [ 刺五加 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Eleutherococcus senticosus</i> (Rupr. &amp; Maxim.) Maxim.; (2) Acanthopanax senticosus (Rupr. et Maxim.) Harms </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DaHuang (Sorrel rhubarb) [ 大簧 ]; root and rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Rheum palmatum</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ahoursaquinone glycosides, tannins and analogues</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DaSuan (Garlic) [ 大蒜 ]; bulb</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Allium sativum</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanNanXing (Jack‐in‐the‐Pulpit, Bile Arisaema) [ 胆南星 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Arisaema heterophyllum</i> Blume </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DanShen (Red Sage, Salvia) [ 丹参 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Salvia miltiorhiza</i> Bunge, <i>Salvia miltiorhiza</i> var. <i>charbonnelii</i> (H. Lév.) C.Y. Wu </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanshinones: I, IIA, IIB, V, VI, cryptotanshinone, isotanshinones III, isocrptotanshinones I‐III etc. </p> <p>Acids: salvianolic acids A ‐ G, rosmarinic acid, lithospermic acid caffeic acid, isoferulic acid etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DangGui (Chinese Angelica) [ 当归 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Angelica sinensis</i> (Oliv.) Diels </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils: ligustilid, angelicone, n‐butylidene phthalide, carvacrol</p> <p>Acids: freulic acid, batanedioic acid, nicotinic acid, vanillic acid etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DangShen (Pilose Asiabell, Codonopsis) [ 党参 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Codonopsis pilosula</i> (Franch.) Nannf. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DengZhanXiXin (Erigerontis) [ 灯盏细辛 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Erigeron breviscapus</i> (Vaniot) Hand.‐Mazz. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flavonoids: scutellarin, apigenin‐β‐glucoside</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DingXiang (Clove) [ 丁香 ]; flower bud</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Syzygium aromaticum</i> (L.) Merr. &amp; L.M.Perry, <i>Eugenia caryophyllata</i> Thunb.; </p> <p>(2) Syringa oblata Lindl<i>.</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FangFeng (Ledebouriella, Divaricate Saposhnikovia) [ 防风 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Saposhnikovia divaricata</i> (Turcz.) Schischk. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FuZi (Common Monkshood, Aconite) [ 附子 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Aconitum carmichaelii</i> Debeaux </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GanCao (Ural licorice) [ 甘草 ]; rhizome and root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Glycyrrhiza uralensis</i> Fisch. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flavones: liquiritin, neoliquiritin, isoliquiritin, isoliquiritigenin.</p> <p>Glucuronic acid, glycyrrhetinic acid, glycrrhizin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GeGen (Kudzu root) [ 葛根 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Pueraria thunbergiana</i> (Siebold &amp; Zucc.) Benth.<i>,Pueraria lobata</i> (Willd.) Ohwi </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isolavones: puerarin (&gt; 2.4%), daidzein, daidzin etc.</p> <p>Saponins: sophoradiol, cantoniensistriol, soyasapogenols A ‐ B etc</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GouQi (Chinese Wofberry) [ 枸杞 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lycium chinense</i> Mill. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lycium barbarum (Lb) conjugates: LbGp1‐5</p> <p>Lb polysaccharides: LbP1a‐1,2,2a,3a‐1,3a‐2,3 etc.</p> <p>Alkaloids: betain</p> <p>Carotenoids: zeaxanthin, cryptosxanthin, zeaxanthin diplamitate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GouTeng (Gambir vine) [ 钩藤 ]; vine and branch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Uncaria rhynchophylla</i> (Miq.) Miq. ex Havil.,<i>Uncaria hirsuta</i> Havil.,<i>Uncaria sinensis</i> (Oliv.) Havil. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GuiZhi (Cassia, Cinnamon) [ 桂枝 ]; branch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cinnamomum cassia</i> (L.) J.Presl </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HeShouWu (Fleeceflower) [ 何首乌 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Polygonum multiflorum</i> Thunb.; (2) Fallopia multiflora (Thunb.) Harald. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anthraquinones: emodin, chrysophanol, physcion, rhein etc.</p> <p>Stilbenes: resveratrol, piceid, tetrahyroxystilbene glucoside etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HongHua (Safflower) [ 红花 ]; flower</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Carthamus tinctorius</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>31</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuaiNiuXi (Twotooth Achyranthes vine) [ 懷牛膝 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Achyranthes bidentata</i> Blume </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuangQi (Astragalus, Membranous Milkvetch) [ 黄芪 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Astragalus propinquus</i> Schischkin, <i>Astragalus mongholicus</i> Bunge; (2) Astragalus membranaceus (Fisch.) Bunge </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glucans: AG‐1 and 2 and heteroglycans 1 and 2.</p> <p>Polysaccharides: D‐glucose, D‐galactose, L‐araban.</p> <p>Flavonoids: dimercapto‐methoxyisoflavones, catycosin, kumatakenin, fomononetin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>33</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HuangQin (Bailkal Skullcap) [ 黄芩 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Scutellaria baicalensis</i> Georgi </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>34</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JiangXiang (Dalbergia, Odoriferous Rosewood) [ 降香 ]; heartwood</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dalbergia odorifera</i> T.C.Chen </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JiaoGuLan (Fiveleaf Gynostemma) [ 绞股蓝 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gynostemma pentaphyllum</i> (Thunb.) Makino </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JinYinHua (Honeysuckle), [ 金银花 ]; flower</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Lonicera japonica</i> Thunb. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorogenic acid and flavone derivatives</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JiXueTeng (Millettia vine, Spatholobus) [ 鸡血藤 ]; stem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Spatholobus suberectus</i> Dunn, <i>Millettia dielsiana</i> Harms </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flavonoids: formononetin, ononin, prunetin etc.</p> <p>Triterpenes: friedelinol, friedelin</p> <p>Sterol and glycosides: β‐sitosterol, daucosterol, anthemisol etc.</p> <p>Anthraquinones: aloe‐emodin, emodin‐3‐methyl‐ether</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JueMingZi (Cassia) [ 决明子 ]; seeds</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Senna tora</i> (L.) Roxb., <i>Senna obtusifolia</i> (L.) H.S.Irwin &amp; Barneby; (2) Cassia tora L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JuHua (Chrysanthemum) [ 菊花 ]; flower</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Chrysanthemum morifolium</i> Ramat.; <i>Chrysanthemum morifolium</i> Ramat.t.Dulce. var. <i>sinense</i> (Sabine) Makino </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils: borneol, chrysanthemon, camphor etc.</p> <p>Flavones: apigenin, acacetin, cosmosin, quercetin, luteolin etc.</p> <p>Sesquiterpenes: chrysanthediol‐A, chrysanthediacetates B ‐ C.</p> <p>Triterpenes: taraxasterol, faradiol, maniladiol etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MaiMenDong (Dwarf Lilyturf, Ophiopogon tuber) [ 麦门冬 ]; tuber</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ophiopogon japonicus</i> (Thunb.) Ker Gawl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MoYaoZi (Myrrh) [ 没药 ]; resin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Commiphora myrrha</i> (Nees) Engl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>42</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MuXiang (Common Aucklandia, Costus root) [ 木香 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Saussurea costus</i> (Falc.) Lipsch or <i>Dolomiaea souliei</i> (Franch.) C.Shih; Aucklandia costus Falc. or </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NiuXi (Twotooth Achryanthes root) [ 牛膝 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Achyranthes bidentata</i> Blume </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QiangHuo (Incised Notopterygium root) [ 羌活 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Notopterygium incisum</i> K.C.Ting ex H.T.Chang </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RenShen (Asian ginseng, Red Ginseng) [ 人参 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Panax ginseng</i> C.A.Mey. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saponins: ginsenosides Rg1, Rg2, Rc, Rd, Re, Rf, Rb1, Rb2, Rb0 etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RouDouKou (Nutmeg) [ 肉豆蔻 ], seed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Myristica fragrans</i> Houtt. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RuXiang (Franckincense) [ 乳香 ]; resin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Boswellia sacra</i> Flueck.; (2) Boswellia carteri Birdw. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SanQi (Notoginseng, Pseudoginseng) [ 三七 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Panax notoginseng</i> (Burkill) F.H.Chen; (2) Panax pseudo‐ginseng Wall. var. notoginseng (Burkill) Hoo &amp; Tseng </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saponins: notoginsenosides A ‐ E, G ‐ N, U, etc. ginsenosides Rb1, Rb2, Rd, Re etc.</p> <p>Favonosides and others: quercetin, sanchian A, denicichine, daucosterol, panaxydol etc. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>48</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SangZhi (Mulberry twig) [ 桑枝 ]; branch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Morus alba</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>49</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShanYao (Chinese Yam, Common Yam) [ 山药 ]; root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dioscorea oppositifolia</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mucopolysaccharides, diosgenin, allantoin, batatasin i, saponins, dopamine etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>50</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShanZha (Hawthorn) [ 山楂 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Crataegus pinnatifida</i> Bunge </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>51</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiChangPu (Grassleaf Sweetflag) [ 石菖蒲 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Acorus gramineus</i> Sol.; <i>Acorus gramineus</i> Soland. var. <i>crassispadix</i> Lingelsh. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>52</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShiHu (Dendrobium) [ 石斛 ]; whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Dendrobium nobile</i> Lindl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ShuDiHuang (Chinese Foxglove, Rehmannia) [ 熟地黄 ]; rootzanh</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Rehmannia glutinosa</i> (Gaertn.) DC. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acteoside (&gt; 0.02%), sterols, glycosides and polysaccharides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SuanZaoRen (Sour jujube, Spiney date) [ 酸枣仁 ]; seed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ziziphus jujuba</i> var. <i>spinosa</i> (Bunge) Hu ex H.F.Chow </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>55</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TanXiang (Sandalwood) [ 檀香 ]; heartwood</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Santalum album</i> L. (Santalaceae) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>56</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TaoRen (Peach) [ 桃仁 ]; seeds</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Prunis persica (L.) Stokes;</i> Amygdalus persica L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>57</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TianMa (Tall Gastrodia) [ 天麻 ]; tuber</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gastrodia elata</i> Bl. (Orchidaceae) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrodin (&gt; 0.2%), gastrodioside, vanillal alcohol, vanilline etc.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>58</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WuWeiZi (Chinese Magnoliavine, Schisandra) [ 五味子 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Schisandra chinensis</i> (Turcz.) Baill </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Volatile oils: sesquicarene, bisabolene, cahmigrene, ylangene.</p> <p>Organic acids: citric, malic, tartaric, succinic acids</p> <p>Lignans: schisandrin and derivatives, gomisins and derivatives</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>59</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WuZhuYu (Medicinal Evodia) [ 吴茱萸 ]; fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Evodia ruticarpa</i> (Juss.) Benth. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>60</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiaKuCao (Prunella, Selfheal Spike) [ 夏枯草 ]; spike or whole plant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Prunella vulgaris</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>61</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiangFu (Nutgrass Galingale) [ 香附 ]; rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyperus rotundus</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XiXin (Chinese/Manchurian Wildginger) [ 细辛 ], rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bei Xi Xin : <i>Asiarum heterothropoides</i> Fr. Schmidt/<i>Asarum heterotropoides</i> f. <i>mandshuricum</i> (Maxim.) Kitag. </p> <p>Hua Xi Xin : <i>Asarum sieboldii</i> Miq. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XuanShen (Ningpo Figwort) [ 玄参 ], root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Scrophularia ningpoensis</i> Hemsl. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YanHuSuo (Corydalis) [ 延胡索 ], rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Corydalis yanhusuo</i> (Y.H.Chou &amp; Chun C.Hsu) W.T.Wang ex Z.Y.Su &amp; C.Y.Wu </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>65</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YinXingYe (Gingko, Ginkgo) [ 銀杏叶 ], leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ginkgo biloba</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>66</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YinYangHuo (Longspur Epimedium) [ 淫羊藿 ], leaf</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Epimedium grandiflorum</i> C.Morren; (2) Epimedium brevicornu Maxim. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>67</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuGanZi (Emblic Leafflower) [ 于甘子 ], fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Phyllanthus emblica</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>68</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuJin (Common turmeric) [ 郁金 ], root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Curcuma longa</i> L.; (2) Curcuma aromatica Salisb. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>YuanZhi (Chinese Senega, Thinleaf Milkwort) [ 元志 ], root</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <i>Polygala tenuifolia</i> Willd., (2) Polygala sibirica L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>70</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZangHongHua (Saffron) [ 藏红花 ] ; stigma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Crocus sativus</i> L. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>71</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZeXie (Oriental Waterplantain) [ 泽泻 ], rhizome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Alisma plantago‐aquatica</i> subsp. <i>orientale</i> (Sam.) Sam. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZhiZi (Cape Jasmine, Gardenia) [ 栀子 ], fruit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gardenia jasminoides</i> J.Ellis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>73</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ZhuYaZao (Chinese Honeylocust) [ 猪牙皂 ], pod and seed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gleditsia sinensis</i> Lam. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Sources of information: (1) <a href="http://www.plantlist.org" target="_blank">www.plantlist.org</a> and (2) <a href="http://www.eflora.cn" target="_blank">www.eflora.cn</a> (Flora of China,中国植物志). Only one scientific name is given unless the two sources differ.<br/> <sup>b</sup>Source of information: (1) <a href="http://www.shen-nong.com" target="_blank">www.shen‐nong.com</a> and (2) TM‐MC database at <a href="http://informatics.kiom.re.kr/compound" target="_blank">informatics.kiom.re.kr/compound</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scientific names of Traditional Chinese herbal medicine (TCHM) components in Table 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0013"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Review outcome reporting status by study</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No.</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Review outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global performance</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADL</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Behaviour</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other trial outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0001" title="BaiWJ , TanJL , LiuYX . Clinical efficacy of DengZhanXiXin injection for 30 patients with vascular dementia [灯盏细辛注射液治疗血管性痴呆30例临床疗效观察]. Chinese Journal of Contemporary Neurology and Neurosurgery2006;6(3):216‐7. ">Baiweijie 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0002" title="ChenHH , WangJX , GuoMY . The efficacy of ShenFu injection in the treatment of elderly patients with vascular dementia on cognition function [参附注射液对老年血管性痴呆的治疗效果]. Medical Journal of Qilu2008;23(5):413‐5. ">Chenhonghua 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0003" title="DengGY . A follow‐up study of patients with vascular dementia after treating with compound Salvia tablet for 24 weeks [复方丹参片治疗血管性痴呆后的随访研究]. Thesis for Master of Chinese Medicine from Beijing University of Chinese Medicine2011. ">Dengguiying 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0004" title="DingY . Clinical observation on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗老年血管性痴呆临床观察]. Chinese Journal of Information on TCM2005;12(3):60. ">Dingyang 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0005" title="GaoL . Clinical analysis on NaoXinTong combined with nimodipine for the treatment of 45 patients with vascular dementia [脑心通联合尼莫地平治疗血管性痴呆45 例临床分析]. China Modern Medicine2012;19(25):92‐4. ">Gaoli 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>6</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0006" title="GuoQJ , ShiY . Therapeutic efficacy of NaoXinTong capsule on vascular dementia and effect of it on oxidative stress [脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察]. China Pharmacy2013;24(3):262‐4. ">Guoqingjun 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDA<sup>a</sup>; GSH<sup>a</sup>; SOD<sup>a</sup>; GSH‐PX<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>7</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0007" title="GuoWL , LiuSJ , LinWJ . Clinical efficacy observation on BuChang NaoXinTong capsule for the treatment of vascular dementia [步长脑心通胶囊治疗血管性痴呆疗效观察]. Journal of Emergency in Traditional Chinese Medicine2009;18(5):696,711. ">Guoweiling 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>whole blood viscosity<sup>a</sup>; plasma viscosity<sup>a</sup>; fibrinogen<sup>a</sup>; haematocrit<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0008" title="HanXG , SunKZ , ZhangRS , WangY . Clinical investigation of effect of NaoXinTong capsules on vascular dementia on 30 cases [脑心通胶囊治疗血管性痴呆30例临床观察]. Health Horizon · Medical Science Fascicule2007;4:6‐7. ">Hanxingguo 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS‐R<sup>a</sup>; </p> <p>brain CT scan<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0009" title="HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的临床研究]. China Medicine2010;5(8):715‐6. HanZC , WangC , QiaoSZ , LiuDL , HuiZL , TianLQ , WangL . Therapeutic efficacy and safety profile of NaoMaiTai capsul on vascular dementia: results of a randomized,double‐blind, placebo‐controlled, multicenter clinical trial [[脑脉泰胶囊治疗血管性痴呆(气虚血瘀兼痰浊阻窍证)有效性、安全性的随机、双盲、平行对照、多中心临床研究分中心报告]]. World Federation of Chinese Medicine Societies, International TCM Forum (Xi'an). 2010. ">Hanzucheng 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BBS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0010" title="HaoWP , YeFH , LiLZ . Clinical observations of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者临床观察]. Journal of Clinical Psychosomatic Diseases2006;12(6):424‐5. ">Haoweiping 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0011" title="HeYP , YangY , ZhangWP , LvHQ . Clinical efficacy observation on FuFangHaiShe capsule for the treatment of vascular dementia [复方海蛇胶囊治疗血管性痴呆的疗效观察]. Chinese Journal of Practical Nervous Diseases2006;9(2):66‐7. ">Heyuping 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0012" title="HuangCY , ZhangJJ , ZhangXQ . Clinical study on NaoXinTong for the treatment of 50 cases of vascular dementia [脑心通治疗血管性痴呆50例临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular DiseaseOctober 2014;2(10):610‐1. ">Huangchaoyun 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; HDS<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>13</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0013" title="HuangGX , LuJB . NaoXinTong capsule combined with Donepezil in treatment of 32 cases of vascular dementia [脑心通胶囊联合多奈哌齐治疗血管性痴呆32例]. Zhejiang Journal of Traditional Chinese Medicine2013;48(10):775‐6. ">Huanggenxian 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>14</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0014" title="JiangYY . BuChang NaoXinTong for the treatment of 30 cases of vascular dementia [步长脑心通治疗血管性痴呆30例]. Fujian Journal of TCM2006;37(5):7,9. ">Jiangyouyi 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>15</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0015" title="LiC , ZhongBW , HeMD . Clinical observation on XingNaoZaiZao capsule for the treatment of vascular dementia [醒脑再造胶囊治疗血管性痴呆临床观察]. Journal of TCM Univ. of Hunan2007;27(5):61‐2. ">Lican 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>whole blood viscosity<sup>a</sup>; plasma viscosity<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0016" title="LiFH . Clinical research of fleabane injection combined with piracetam on vascular dementia [灯盏细辛注射液联合吡拉西坦治疗血管性痴呆临床研究]. Chinese Journal of Practical Nervous Diseases2011;14(5):10‐3. ">Lifuhui 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>17</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0017" title="LiJY , HuangJS , ZhangZD , LinJ , ZhangWB , ZhengXM , et al. Clinical study on RuanMaiLing oral liquid in treatment of vascular dementia [软脉灵口服液治疗血管性痴呆的临床研究]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2009;7(9):1032‐4. ZhangZD . The clinical observation and the influence on SOD, VEGF, E2, T of RuanMaiLing koufuye on vascular dementia (Master's degree thesis) [软脉灵口服液治疗血管性痴呆的临床观察及其对SOD,VEGF,E2,T等的影响]. Fujian University of Traditional Chinese Medicine2007. ">Lijingyi 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hcy<sup>a</sup>; ET<sup>a</sup>; TXB<sub>2</sub><sup>a</sup>; TXA<sub>2</sub>/PGI<sub>2</sub><sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0018" title="LiuSJ , LiuJM . Clinical study of HuangQi with FuFangDanShen for 50 patients with vascular dementia [黄芪注射液加复方丹参注射液治疗早期血管性痴呆50 例临床研究]. Pharmacology &amp; Clinic of TCM2002;18(5):45‐6. ">Liushujuan 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDL<sup>b</sup>; LDL<sup>b</sup>; CHO<sup>b</sup>; TG<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>19</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0019" title="LiuYJ , TaiXF , HuangFH , XiaX . Clinical observation of DengZhanHuaSu for 35 patients with vascular dementia [灯盏花素片治疗老年痴呆35 例临床观察]. Liaoning Journal of Traditional Chinese Medicine1997;24(6):362. ">Liuyujin 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; HDS<sup>b</sup>; CCSE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAQ<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EEG<sup>b</sup>; rCBF<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0020" title="LuoHD , LuoHL . The clinical effect observation of NaoMaiTai capsule combined with Donepezil Hydrochloride in treatment of vascular dementia [脑脉泰胶囊联合盐酸多奈哌齐治疗血管性痴呆的临床疗效观察]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease2013;21(4):72‐3. ">Luohaidong 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>21</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0021" title="MaY , PanXQ , RenYQ , LiYL , ZhangJW . Clinical effect of NaoMaiTai capsule on vascular dementia patients [脑脉泰胶囊治疗血管性痴呆41例]. Chinese Journal of Experimental Traditional Medical Formulae2013;19(9):339‐41. ">Mayu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P300 latency<sup>a</sup>; P300 amplitude<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>22</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0022" title="PiaoZY , PiaoMA . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆的临床观察]. Acta Chinese Medicine and Pharmacology2005;33(6):47. ">Piaozhiyong 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0023" title="QianRY , SongQ . Clinical observation on QingKaiLing injection for the treatment of 40 cases of vascular dementia [清开灵注射液治疗血管性痴呆40例临床观察]. Chinese Journal of Traditional Medical Science and Technology1999;6(4):264‐5. ">Qianrenyi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>24</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0024" title="ShaoP , ZhengJ , ShaoP . Clinical efficacy observation on YinDanXinNaoTong capsule for the treatment of vascular dementia [银丹心脑通软胶囊治疗血管性痴呆的临床疗效观察]. For all Health2012;6(11):21‐2. ">Shaopeng 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>25</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0025" title="ShiLR . Clinical observation on ChuanXiongQin combined with Piracetam for the treatment of vascular dementia [川芎嗪联合吡啦西坦治疗血管性痴呆的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2010;10(5):22‐3. ">Shiliangrong 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological Function Defects Scale<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>26</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0026" title="TianJZ , ShiJ , WeiMQ , QinRA , ChenYP , WangYY . Efficacy and safety of FFDS tablets in people with mild‐to‐moderate vascular dementia: A 24‐week randomized, double‐blind, placebo, parallel‐controlled trial. Alzheimer's &amp; Dementia2013;4(9):P670‐1. ">Tianjinzhou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; ADAS‐Cog<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>27</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0027" title="WangH . Clinical study of ShenFu injection for vascular dementia [参附注射液治疗血管性痴呆的疗效观察]. Modern Journal of Integrated Traditional Chinese and Western Medicine2004;13(21):2486‐7. ">Wanghan 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0028" title="WangJM , LvXY , WangCH . Clinical study of Breviscapine treated the patients with vascular dementia [灯盏花素治疗血管性痴呆的临床研究]. Acta Academiae Medicinae Weifang2007;29(6):428‐30. ">Wangjingming 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>29</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0029" title="WangLL , YingPZ , WangXM . Clinical efficacy of TongXinLuo capsule in the treatment of vascular dementia [通心络胶囊治疗血管性痴呆患者的临床疗效观察]. Chinese Journal of Difficult and Complicated Cases2005;4(5):260‐2. ">Wanglinglin 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAQ<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>30</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0030" title="WangYH . Donepezil combined with FuFangHaiShe for the treatment of 68 patients with vascular dementia [多奈哌齐联合复方海蛇胶囊治疗血管性痴呆68例]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(7):488‐9. ">Wangyihu 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>31</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0031" title="WengYH . Clinical study of FuFangDanShen tablets on treatment of vascular dementia [复方丹参片治疗瘀血阻络型血管性痴呆的临床研究]. Thesis for Master of Internal Medicine in Chinese Medicine from Guangzhou University of Chinese Medicine2011. ">Wengyinghong 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>32</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0032" title="WuHB , XuHN , HeHG . Clinical observation of YangXueQingNao granula for 80 cases of vascular dementia [养血清脑颗粒治疗血管性痴呆病人临床观察]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2007;5(11):1069‐70. ">Wuhongbin 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DND<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>33</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0033" title="XuJQ , LuX . The efficacy of TongXinLuo capsule for senile vascular dementia [通心络胶囊治疗老年血管性痴呆疗效观察]. World Health Digest Medical Periodical2007;4(10):32‐3. ">Xujingqiang 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup>; CDT<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS‐R<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>34</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0034" title="XuK , WangKF . Impact of Donepezil Hydrochloride combined with YinDanXinNaoTong soft capsule on cognitive function in patients of vascular dementia [盐酸多奈哌齐联合银丹心脑通软胶囊对血管性痴呆患者认知功能的影响]. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease2011;9(10):1213‐5. ">Xuke 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>35</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0035" title="YanYX , LiangLZ , ZhouZL . Clinical study of combined treatment with compound Reinhartdt and sea cumber and Donepezil for vascular dementia [复方海蛇胶囊及盐酸多奈哌齐联合治疗血管性痴呆的临床研究]. Chinese Journal of Integrated Traditional and Western Medicine2007;27(10):887‐90. ">Yanyongxing 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSH<sup>a</sup>; TT<sub>3</sub><sup>a</sup>; TT<sub>4</sub><sup>a</sup>; FT<sub>3</sub><sup>a</sup>; FT<sub>4</sub><sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0036" title="YaoXS . Combined treatment of NaoXinTong with Nimodipine for vascular dementia [脑心通联合尼莫地平治疗血管性痴呆的临床研究]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong2011;40(4):490‐2. ">Yaoxinsheng 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vs<sup>a</sup>; Vm<sup>a</sup>; PI<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>37</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0037" title="YuDC , ZhangYY , LiuQL . Clinical study on NaoMaiTai capsule for the treatment of vascular dementia [脑脉泰胶囊治疗血管性痴呆的相关性研究]. China Clinical Practical Medicine2008;2(7):58‐9. ">Yudecai 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; ADAS‐Cog<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDR<sup>a</sup>; P300 latency<sup>a</sup>; P300 amplitude<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>38</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0038" title="ZhangJP , HuYT , ZhangXY . The rehabilitation effect of NaoMaiTai capsule on cognitive dysfunction of vascular dementia patients [脑脉泰胶囊对血管性痴呆患者认知功能障碍的康复作用]. China Medical Herald2006;3(29):141‐2. ">Zhangjianping 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P300 latency<sup>a</sup>; P300 amplitude<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0039" title="ZhangJS , ZhengLH . Clinical observation on ShenFu injection for the treatment of vascular dementia [参附注射液治疗血管性痴呆临床观察]. Journal of Emergency in Traditional Chinese Medicine2003;12(4):334‐5. ">Zhangjinsheng 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neurological Function Defects Scale<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>40</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0040" title="ZhangT , ZhangXQ , ZhuRH . GeGenSu with Citicoline for 36 patients with vascular dementia [葛根素配合胞二磷胆碱治疗血管性痴呆36例]. Journal of Shandong University of TCM2000;24(1):37‐8. ">Zhangtao 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TCD Vm<sup>a</sup>; TCD PI<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0041" title="ZhangYT . Effect of NaoXinTong capsule in treating vascular dementia [脑心通胶囊治疗血管性痴呆]. Journal of Liaoning University of TCM2012;14(6):174‐5. ">Zhangyoutai 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>b</sup>; HDS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>plasma viscosity<sup>a</sup>; fibrinogen<sup>a</sup>; whole blood viscosity<sup>a</sup>; haematocrit<sup>a</sup>; erythrocyte electrophoresis<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>42</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0042" title="ZhangYJ , ZhangWZ . The efficacy of NaoAn capsule for vascular dementia [脑安胶囊治疗脑血管性痴呆疗效观察]. Journal of Practical TCM2002;18(12):32. ">Zhangyujin 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>maximum platelet aggregation rate<sup>a</sup>; whole blood viscosity<sup>a</sup>; plasma viscosity<sup>a</sup>; haematocrit<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0043" title="ZhengTL , WangZ , LiuC , HeW . Clinical study of BuChang NaoXinTong capsule for the treatment of 85 cases of vascular dementia [步长脑心通胶囊治疗血管性痴呆85例临床研究]. Shanxi Medical Journal2014;43(2):205‐7. ">Zhengtaolin 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0044" title="ZhouLS , WangJX . The clinical observation of Donepezil Hydrochloride combined with NaoXinTong capsule in the treatment of vascular dementia after cerebral infarction [安理申联合脑心通胶囊治疗脑梗死后血管性痴呆临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2013;23(12):981‐2. ">Zhoulongshou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>45</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0045" title="ZhouQ , ZhuangYL . Clinical observations of 25 wei ZhenZhuWan in the treatment of vascular dementia [25味珍珠丸综合治疗血管性痴呆疗效观察]. Chinese Journal of Information on Traditional Chinese Medicine2003;10(10):55‐6. ">Zhouqiang 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>whole blood viscosity<sup>a</sup>; plasma contrast viscosity<sup>a</sup>; </p> <p>fibrinogen<sup>a</sup>; haematocrit<sup>a</sup>; erythrocyte sedimentation rate<sup>a</sup>; </p> <p>whole blood reduced viscosity<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>46</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0046" title="ZhouW , WuYB , XuXR . Clinical observation on NaoXinTong capsule for the treatment of vascular dementia [脑心通胶囊治疗血管性痴呆患者临床观察]. Shandong Medical Journal2009;49(8):99‐100. ">Zhouwei 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE<sup>a</sup>; HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy rate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FAQ<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010284-bbs2-0047" title="ZhuFM , SunGQ . The treatment of QingKaiLing injection for 46 patients with vascular dementia [清开灵注射液治疗血管性痴呆46例]. Clinical Focus2003;18(23):1352‐3. ">Zhufengmei 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Results fully reported<br/> <sup>b</sup>Results partially reported<br/> <sup>c</sup>Mentioned in Methods section, but no results reported<br/> N/A: Not assessed </p> <p>ADAS‐Cog: Alzheimer’s Disease Assessment Scale‐cognitive subscale; ADL: Activities of Daily Living; BBS: Blessed‐Roth Behaviour Scale; CDR: clinical dementia rating; CHO:cholestrol; CT: Computed Tomography; DND: delayed neuronal death; ECG: electrocardiogram; EEG: electroencephalogram; ET: endothelin; FAQ: Functional Activities Questionnaire; FT<sub>3</sub>: free triiodothyronine; FT<sub>4</sub>: free thyroxine; GSH: glutathione; GSH‐PX: Glutathione peroxidase; Hcy: homocysteine; HDL: High‐density lipoprotein; HDS: Hasegawa Dementia Scale; HDS‐R: Hasegawa Dementia Scale‐revised; LDL: Low‐density lipoprotein; MDA: Malondialdehyde; MMSE: Mini‐Mental State Examination; NPI: Neuropsychiatric Inventory; PGI<sub>2</sub>: prostaglandin I<sub>2</sub>; PI: pulsatility index; rCBF: regional cerebral blood flow; SOD: Superoxide Dismutase; TCD: Transcranial Doppler; TG: Triglyceride; TSH: thyroid stimulating hormone; TT<sub>3</sub>: Total‐triiodothyronine; TT<sub>4</sub>: total thyroxine; TXA<sub>2</sub>: thromboxane A<sub>2</sub>; TXB<sub>2</sub>: thromboxane B<sub>2</sub>; Vm: mean velocity; Vs: systolic velocity; WMS: Wechsler memory scale; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Review outcome reporting status by study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0014"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis ‐ common TCHM ‐ vs no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.57 to 6.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.49 to 6.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.39 to 6.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.66 to 3.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.29 to 3.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 to 2.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53 to 5.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58 to 5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66 to 5.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>YDXNT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 to 2.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 to 2.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 to 2.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognition_ADAS‐COG (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.1 to −2.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.14 to −2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.23 to −2.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADL (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.84 to −0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.89 to −0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.98 to −0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.66 to 0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.82 to 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.13 to 0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.78 to −0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.09 to −1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.68 to −1.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>YDXNT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.34 to 0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.34 to 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.33 to 0.73</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis ‐ common TCHM ‐ vs no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0015"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis ‐ primary mode of action ‐ vs no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.03 to 5.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.12 to 5.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.25 to 4.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 to 1.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 to 1.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 to 1.90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ HDS (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.18 to 6.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 to 5.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.83 to 5.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.30 to 5.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.32 to 5.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34 to 5.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ ADAS‐COG (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.10 to −2.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.14 to −2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.23 to −2.46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.71 to −1.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.87 to −1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.95 to −1.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.87 to 1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.86 to 1.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.85 to 1.12</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis ‐ primary mode of action ‐ vs no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0016"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ common TCHM ‐ vs WM</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.77 to 4.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.92 to 4.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3.05 to 4.60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71 to 4.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96 to 4.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27 to 3.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 to 3.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 to 3.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 to 3.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 to 6.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 to 6.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 to 6.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 to 4.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 to 3.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 to 3.62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_HDS (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 to 3.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25 to 3.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 to 3.30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QKL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 to 4.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 to 4.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 to 4.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FFHS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.99 to 7.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.93 to 7.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.86 to 7.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NXT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.25 to −3.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.99 to −3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.85 to −3.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SFT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−16.88 to −4.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−16.75 to −3.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−16.61 to −3.71</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ common TCHM ‐ vs WM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010284-tbl-0017"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analysis ‐ primary mode of action ‐ vs WM</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>No of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Summary statistics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TCHM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.25</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.50</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>rho = 0.75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_MMSE (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 to 6.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 to 6.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 to 6.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 to 2.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55 to 2.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 to 2.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71 to 3.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 to 3.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.77 to 3.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ HDS (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diaphoretics and antipyretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 to 4.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 to 4.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 to 4.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 to 3.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 to 3.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 to 3.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition_ ADAS‐COG (MD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06 to 2.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08 to 2.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.11 to 2.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADL (SMD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.36 to −0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.66 to −0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2.35 to −0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anti‐thrombotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.85 to −0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.01 to −0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.36 to −0.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroprotection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.43 to −0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.43 to −0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.44 to −0.01</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's disease assessment scale: cognition subscale; ADL: activities of daily living; MD: mean difference; MMSE: Mini mental state examination; TCHM: traditional Chinese herbal medicine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analysis ‐ primary mode of action ‐ vs WM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/full#CD010284-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010284-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cognition‐MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CXQ + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [4.47, 7.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 DZXX + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [‐0.26, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 FFDS versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [‐0.39, 6.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 FFHS + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.21, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NMT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.21, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NXT + WM +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.29 [2.66, 5.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 YDXNT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.74, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognition‐HDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CXQ + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 GGS + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 NMT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 NXT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 TXL + RT versus RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 YDXNT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 ZZW + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognition‐ADAS‐Cog <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 FFDS versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.34 [‐6.23, ‐2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 FFHS + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐6.02, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global performance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 NXT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 CXQ + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 FFDS versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 FFHS + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 NMT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.02, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 NXT + WM + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.22, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 TXL + RT versus RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.19, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 YDXNT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Activities of Daily Living <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 DZXX + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.39, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 FFDS versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.33 [‐5.60, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 FFHS + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐4.98, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 NMT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.51 [‐4.19, ‐0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 NXT + WM +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.18 [‐7.02, ‐5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 YDXNT + WM versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐2.09, ‐1.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TCHM versus 'no treatment' (Subgroup: specific TCHM and comparators)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010284-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cognition ‐ MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [2.25, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.54, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognition ‐ HDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.29 [2.83, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [2.34, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognition ‐ ADAS‐Cog <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.34 [‐6.23, ‐2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐6.02, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global performance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.04, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.02, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.06, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Activities of Daily Living <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐5.95, ‐1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.37 [‐3.85, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TCHM versus 'no treatment' (Subgroup: TCHM primary mode of action)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010284-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">TCHM versus WM (Subgroup: common TCHMs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cognition‐MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 DZHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.36, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 DZXX + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.19 [3.13, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 FFHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [‐3.05, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 NA versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.78, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 NMT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [2.27, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 NXT +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.50, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 QKL + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [2.09, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 RML + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.50, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 SFT +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [1.02, 6.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 TXL versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.54, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 XNZZ versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.69, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 YXQN versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [‐0.09, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognition‐HDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 DZHSversus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [‐2.13, 7.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 HQ+DS + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.40, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 NMT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.58 [5.15, 10.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 NXT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.31, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 QKL +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.11, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 SFT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [2.11, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 TXL versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.33, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 XNZZ versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [1.11, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognition‐ADAS‐Cog <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 FFHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 NMT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global performance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 DZHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.06, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 NA versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [1.07, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NMT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.92, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 NXT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.15, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 RML + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 SFT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.07, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 TXL versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.00, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 XNZZ versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.4 [0.99, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 DZHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.08, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 FFHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.26, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 NA versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.05, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 NMT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 NXT +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 QKL + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.07, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 RML + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.06, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 SFT versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 TXL versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.42, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 XNZZ versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.08, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Activities of Daily Living <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 DZHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.65 [‐8.52, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 FFHS versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [‐4.86, 7.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 NA versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.90 [‐10.90, ‐6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 NXT +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.72 [‐5.85, ‐3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 QKL + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [2.00, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 RML + RT versus WM + RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐4.17, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 SFT +/‐ RT versus WM +/‐ RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.16 [‐16.61, ‐3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 TXL versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐1.96, ‐0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 XNZZ versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.66 [‐6.02, ‐1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 YXQN versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.92 [‐6.42, ‐1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 TXL versus WM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">TCHM versus WM (Subgroup: common TCHMs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010284-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">TCHM versus WM (Subgroup: TCHM primary mode of action)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cognition ‐ MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Diaphoretic and/or antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [2.09, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [1.02, 6.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.53, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.77, 3.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cognition ‐ HDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Diaphoretic and/or antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.11, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [2.13, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.89, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.21 [1.55, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognition ‐ ADAS‐Cog <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [2.11, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global performance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.07, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.03, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.15, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Diaphoretic and/or antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.07, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Activities of Daily Living <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Diaphoretic and/or antipyretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [2.00, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Anti‐inflammatory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.16 [‐16.61, ‐3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Anti‐thrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.26 [‐5.63, ‐2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.54 [‐5.19, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Neuroprotective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐12.46, ‐5.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">TCHM versus WM (Subgroup: TCHM primary mode of action)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010284.pub2/references#CD010284-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010284.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010284-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010284-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010284-note-0030">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD010284-note-0006">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD010284-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010284-note-0007">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010284-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD010284-note-0004">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010284-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010284-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010284\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010284\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010284\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010284\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010284\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010284.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010284.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010284.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010284.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010284.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720371280"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010284.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720371284"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010284.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dff83a8159377',t:'MTc0MDcyMDM3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 